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1. General introduction 
Tables and figures in the introduction are based on these reviews:   
1. Grassmann F, Heid IM & Weber BHF (2014) Genetic risk models in age-related 
macular degeneration. Adv. Exp. Med. Biol. 801: 291–300  
2. Grassmann F, Fauser S & Weber BHF (2015) The genetics of age-related macular 
degeneration (AMD) and its usability for designing treatment options Eur J Pharm 
Biopharm. invited review. in revision 
 
1.1 Clinical features of age-related macular degeneration (AMD) 
According to a recent survey, the majority of people in different ethnic groups agree that 
“good eye health is important to overall health” [1]. In fact, severe visual impairment and 
blindness are among the most-feared health conditions, after cancer and cardiovascular 
disease, mostly due to the loss of independence that comes with it [1].  
Age-related macular degeneration is a common, multifactorial, late-onset human disease [2] 
characterized in its final stages by neurodegeneration of cells in the outer retina, leading to 
pronounced visual loss and eventually to complete blindness. The affected cell types and 
functional entities mainly include but are not limited to: (i) the photoreceptors, which are the 
main sensory cells in the eye, (ii) the retinal pigment epithelium cells (RPE), which among 
many other functions phagocytose shed photoreceptor outer segments, are responsible for the 
recycling of metabolites reqired for the visual cylce and provide nurtrients to the 
photoreceptors [3], (iii) the Bruch’s membrane, a five-layered extracellular matrix embedded 
between the RPE and the choroid, responsible for the regulation of metabolit transport from 
and to the RPE [4–6] and finally (iv) the choriocapillaris, which delivers oxygen and nutrients 
to support retinal metabolism [5].  
AMD is an age-related disease and thus its phenotype has to be differentiated from age 
specific changes in the retina and choroid. For example, with increasing age, the RPE cells 
accumulate (auto)fluorescent material, thus increasing autofluoresence of RPE cells [7–9]. 
The number of RPE cells and photoreceptor cells, however, remains stable throughout this 
process [10]. In addition, Bruch’s membrane thickens, leading to decreased permeability 
[5,11], potentially aggravating further accumulation of fluorescent material in the RPE. 
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Finally, thickness of the choriocapillaris decreases with age, further reducing oxygen and 
nutrition supply to the eye and thus increasing susceptibility to degenerative processes [5,12]. 
The diseased retina due to AMD is categorized into two main stages including early AMD 
and late stage AMD. Early AMD is a heterogenous manifestion, clinically defined by 
extracellular depositions between Bruch’s membrane and the RPE (so-called drusen) and 
pigmentary changes of the RPE (either hyper- or hypopigmentation). These pathological 
changes usually do not significantly influence retinal function and thus do not lead to visual 
impairment, although dark adaptation is delayed in eyes with early AMD [13]. In contrast, 
late stage AMD can result in severe and irreversible vision loss. Late stage AMD can manifest 
in two forms, namely as an atrophic, non-exudative (“dry”) condition and a neovascular, 
exudative (“wet”) complication. In the neovascular form (NV), growth of blood vessels into 
the outer retina is stimulated by the release of vascular endothelial growth factor (VEGF) 
from the RPE [14]. These new vessels extend through Bruch’s membrane and can result in 
profound bleeding, extracellular fluid accumulation and subsequent scarring of the outer 
retina, thus leading to rapid (within days or weeks) and severe vision loss [15]. The late stage 
of the non-exudative form is characterized by geographic atrophy (GA) of choriocapillaris, 
RPE cells and photoreceptors, leading to a slow (within years) but steady progression of 
vision loss. While neovascular AMD can be treated by anti-VEGF drugs, there is no treatment 
availble for GA  at present [16] . 
 
1.2 Epidemiology of AMD 
Per definition, the prevalence of an age-related disease increases with age. The prevalence for 
late stage AMD in Western societies increases from less than 1% at 55 years of age to more 
than 15% in individuals aged 85 years and above [17], while the overall prevalence of all 
AMD types is estimated to be 8.7% [18]. The proportion of GA in late stage AMD is 
approximately 35-40% [19,20]. While the overall incidence of the neovascular form is more 
frequent, GA occurs more commonly in individuals over 85 years of age [20]. Conservative 
estimates project the worldwide number of people with AMD in 2020 to 196 million and in 
2040 to 288 million [18]. In the near future, this will dramatically increase the individual as 
well as the socioeconomic burden of the disease. This greatly emphasizes the impact of late 
stage AMD on aging populations, and underscores the need for effective treatments to 
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prevent, slow or cure the disease. To identify potential treatment options, knowledge on 
genetic and non-genetic factors involved in disease risk and progression are crucial. 
 
1.3 Risk factors associated with AMD 
1.3.1 Environmental, life-style and clinical risk factors 
Several environmental or life-style factors, like diet, sunlight exposure or allergies [21] have 
been associated with early and late stage AMD, although only smoking has consistently been 
found to increase the risk for both stages of AMD [22]. In addition, recent reports indicate a 
protective effect of nutritional fish oil based fatty acid supplementation (DHA and EPA) [23–
25], promising a possible intervention for a delayed disease progression.   
Many features of early AMD in the outer retina are indicators for progression to late stage 
AMD and are thus considered to be clinical and in principle, non-modifiable risk factors. In 
particular, the presence of large, confluent (soft) drusen and defective dark adaptation are 
associated with a high risk for progression to late stage AMD [13]. In contrast, pigmentary 
changes in the RPE and presence of small and non-confluent (hard) drusen are not associated 
with late stage AMD progression [26,27]. Furthermore, the presence of a late stage form of 
the disease in one eye is a strong risk factor for the progression of the fellow eye to late stage 
AMD. 
1.3.2 Genetic risk factors associated with late stage AMD 
Among the two stages of the disease, early and late, the genetics of late stage AMD has been 
more extensively studied and is currently better understood. In most genetic association 
studies, both late stage forms (neovascular and atrophic AMD) are analyzed jointly and the 
reported genetic variants are risk factors for both forms. The first findings for a genetic 
contribution to the disease were reported in 1997 by implicating variations in the ATP binding 
cassette, subfamily A, member 4 (ABCA4) gene to be associated with AMD (Figure 1) [28]. 
This association, however, remained controversial since several attempts at replication failed 
[29,30]. Only recently, it was shown that mono-allelic changes in ABCA4 are indeed 
associated with a rare subtype of geographic atrophy, namely fine granular pattern with 
peripheral punctate spots (GPS) [31]. In 1998, Klaver et al. reported a significant association 
of variations in the apolipoprotein E (APOE) with late stage AMD [32].  
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Figure 1. Gene loci associated with AMD. The first genetic locus associated with AMD was ABCA4 
and was implicated in 1997. Since then, the number of associated loci has risen exponentially and as 
of today comprises 34 independent loci. Included in this count are 16 novel loci to be reported by the 
International AMD Genomics Consortium (IAMDGC) in 2015. Green squares represent the date of 
discovery of novel risk loci. Red diamonds represent the odds ratio of the identified top variant in the 
respective locus and error bars the respective 95% confidence intervals (data based on effect sizes 
obtained from Fritsche et al. 2013 [33]). Figure taken from Grassmann et al. 2015, Eur J Pharm 
Biopharm. invited review. in revision 
 
These findings were later replicated in several studies, implicating the contribution of lipid 
pathways to disease etiology. By conducting the first ever genome-wide association study 
(GWAS) for a human disease, Klein et al. identified in 2005 a common missense mutation 
(CFH p.Y402H) in the complement factor H gene to be strongly associated with AMD [34]. 
Later, a similarly strong association was observed in the ARMS2/HTRA1 locus on 10q26 
[35,36]. In the following years, candidate gene studies identified non-synonymous risk 
variants in other complement genes, e.g. the complement component 3 (C3), complement 
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component 2 (C2) and complement factor B (CFB) [37,38]. Currently, more than 19 disease 
associated loci have been implicated with a genome-wide significant p-value below 0.5 * 10
-8
 
(Figure 1) [39,40]. 
 
1.3.3 Genetic risk factors associated with early AMD 
In contrast to our extensive knowledge on the genetics of late stage AMD, only little is known 
about the genetic basis of early AMD. The heritability of early AMD has been estimated to be 
between 35% and 55% and thus slightly lower than the estimate for late stage AMD [41]. 
Recently, Holliday et al. reported a meta-analysis of five genome-wide association studies in 
early AMD and implicated both, the ARMS2/HTRA1 as well as the CFH locus to be 
significantly (on a genome-wide level) associated with early AMD. Notably, although late 
stage AMD risk increasing alleles were also found to be risk increasing alleles for the early 
stage of the disease, the estimated effect sizes (i.e. the observed odds ratios) for the risk alleles 
in the ARMS2/HTRA1 as well as the CFH locus were strikingly lower. In the same study, no 
other variants reached a genome-wide significant p-value threshold. 
 
1.4 (Genetic) Risk models for AMD 
AMD is unique among complex diseases as several common variants show strong association 
with late stage AMD with large effect sizes. This unique feature has led to efforts to predict 
the risk for AMD based on genetic factors with or without including non-genetic risk factors 
(Table 1). While pure genetic risk models perform reasonably well with area under the 
receiver operating characteristics curve (AUC) values reported around 0.80, they still fall 
short of the recommended AUC value of 0.99 needed for presymptomatic DNA testing in the 
general population [42]. The number of associated variants with average effect sizes 
necessary to increase the AUC to 0.99 and above will probably range in the hundreds [42,43]. 
These models have, nevertheless, comparable accuracies to other risk models, e.g. risk models 
for the prediction of cardiovascular diseases [44] or for the prediction of prostate cancer [45]. 
However, the validity of AMD risk models in a clinical setting has yet to be shown. 
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Table 1. Risk models for age-related macular degeneration (from: Grassmann et al. 2014 Adv. Exp. Med. Biol. 801: 291–300) 
 
1 LR= logistic regression, CR= cox regression, DT= decision tree  
² Risk score calculated 
3 methods used to avoid inflation of risk: “independent samples” (IS) means independent samples were used to test the models and to obtain AUC values; CV=cross validation  
4 the number in parentheses states the number of risk variants in that locus used in the best performing model. No number indicates only one SNP at given locus 
5 study was used to discover novel variants which were also used in model 
6 non genetic factors are coded: s= smoking, e=education, a=age, b=body mass index, v=vitamins, g=gender, t= AREDS treatment assignment, ** family history of late stage AMD 
* ARED study samples 
Publication Year Genetic factors
4
 
Non-genetic 
factors
6
 Clinical factors 
Study design  
(sample size) Method
1
 
Risk 
Score
2
 disc
5
 
Valida
tion
3
 
Reported 
AUC 
Maller et al* [46] 2006 CFH(2), CFB, ARMS2 no no case-control (2172) LR no yes - - 
Gold et al [47] 2006 CFH(2), CFB(3) no no case-control (~1500) DT no yes IS - 
Hughes et al [48] 2007 CFH(4), ARMS2 s no case-control (667) LR yes yes - - 
Jakobsdottir et al [49] 2008 CFH, ARMS2, C2 no no case-control (675) LR NA yes - - 
Jakobsdottir et al [42] 2009 CFH, ARMS2, C2 no no case-control (675) LR yes yes - 0.79 
Seddon et al* [50] 2009 CFH(2), ARMS2, C2, 
CFB, C3 
a, g, e, s, t, b no longitudinal (1446) LR yes no - 0.83 
Farwick et al [51] 2009 CFH, ARMS2(2), C2, 
CFB 
s no longitudinal (913) LR NA no - 0.81 
Gibson et al [52] 2010 CFH(3), ARMS2, C3, 
SERPING 
a, g, s no case-control (940) LR yes yes - 0.83 
Chen et al* [53] 2011 CFH(3), C2, CFB, 
ARMS2(2), C3 
s, a, g, b no case-control (1844) LR yes no - 0.82 
Hageman et al [54] 2011 CFH(4), CFHR4/5(3), 
FI3B(2), C2, CFB, 
ARMS2, C3 
s no case-control (3182) LR yes yes IS 0.80 
Klein et al* [55] 2011 CFH, ARMS2 a, e, s, ** AREDS Score; late 
stage AMD 
longitudinal (2962) CR no no IS 0.87 
Seddon et al* [26] 2011 CFH(2), ARMS2, C3, C2, 
CFB 
e, s, b, v drusen size, late 
stage AMD 
longitudinal (2937) CR no no CV 0.92 
Spencer et al [56] 2011 CFH, ARMS2, CFB, C3 a, s no case-control (~900) LR yes no IS 0.84 
McCarthy et al* [57] 2012 CFH, ARMS2 a, g, e, s, b, v AREDS Score, late 
stage AMD 
longitudinal (2011) LR yes no IS 0.89 
Grassmann et al [58] 2012 CFH(3), ARMS2, CFB, 
C3, C2, APOE(2), CFI, 
LIPC(2), TIMP3 
no no case-control (1782) LR yes no CV 0.82 
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Of note, several risk models report high AUC values around 0.90 [26,55,57]. These models 
include clinical findings from fundus pictures, e.g. soft drusen area, presence of geographic 
atrophy in the fellow eye or the AREDS severity score [59] as predictive factors. While these 
models outperform genetic risk models in their prediction accuracy, these models are aimed at 
predicting late stage AMD later in life, especially in the case where an individual already has 
symptoms of (early) AMD. In contrast, genetic risk models predict disease risk at birth and 
could therefore proof more useful for long term interventions, long before an onset of 
symptoms. 
 
1.5 Improving genetic risk models and further applications of the genetic risk score 
Several venues are currently explored in order to improve existing risk models and to foster 
our understanding of the genetic basis of the disease: 
(1) Identification of novel genetic variants associated with AMD. This is primarily achieved 
by increasing the sample size of case-control studies by combining these studies in large 
consortia (see also Perspectives). However, due to substantial differences in the composition 
of case control studies in these consortia, candidate gene studies in single centers are still a 
promising option to identify novel genetic variations associated with the disease. 
Furthermore, GWA studies can not readily assess complex variations, which are not easily 
queried by chip genotyping, e.g. copy number variations or variations in repeat regions. These 
variations can be assessed with non-highthroughput methods like multiplex ligation-
dependent probe amplification (MLPA) and can therefore, at present, only be detected in 
candidate gene or candidate variant studies. 
(2) Complementing known (common) variants with rare variants by exome sequencing or 
custom-made variant arrays. It is estimated that a large proportion of the genetic risk is 
attributed to rare variants with moderate to high impact on disease risk [60]. However, studies 
need to be sufficiently large to detect these associations since only few individuals will carry a 
risk increasing allele, thus decreasing the power to detect the association. This is especially 
true if such variants are identified in a genome-wide approach since an association signal 
needs to reach p-values below 0.5 * 10
-8
 to adjust for multiple testing/comparisons. Currently, 
the International AMD Genomics Consortium (IAMDGC) is conducting a genome-wide 
association study on a custom genotyping platform. This platform specifically includes more 
than 150,000 coding variants, effectively capturing around 70% of the known coding variants 
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in the exome. Most of these coding variants are rare and found in less than 1% of the general 
population. 
(3) Identification of a biomarker for early and late stage AMD. Although genetic variants can 
also be considered a “biomarker”, true biomarker studies usually aim to find small molecules 
or cells in the blood/serum of patients and controls (e.g. modified/unmodified proteins 
[61,62], immune active cells [63], lipids [64], sugars, ribonucleic acids, complement 
components [65]), that can be used as a diagnostic tool to allow discrimination between 
affected und unaffected individuals. In addition, those biomarkers can potentially be used as 
prognostic markers predicting the onset or progression of a disease and levels of a biomarker 
can correlate with disease severity. Therefore, biomarkers are especially valuable for clinical 
trials to monitor and evaluate treatment success, especially if they can be analyzed in a non-
invasive and inexpensive manner. 
 
The genetic risk score does not only allow to discriminate between cases and controls. It 
efficiently sums up the known genetic risk for late stage AMD of an individual. There are 
additional, as of yet unexplored possibilities to further use this information: 
(1) Improving the design for future case-control association studies. Genotyping patients with 
arrays or sequencing of specific areas in the genome of patients is still a costly endeavour. 
Therefore, an algorithm to prioritize samples for such association studies is warranted. Cases 
with a high genetic risk score are not likely to carry additional (unknown) disease associated 
variants and thus can be excluded from further studies. The same is true for controls with a 
very low genetic risk score, since these samples will most likely not carry additional 
(unknown) protective alleles. In order to identify novel associated variants, cases in the lower 
risk groups and controls in the higher risk groups as well as samples with an average risk 
score should be included in future studies. 
 (2) AMD risk and influence on monogenic diseasse. The AMD genetic risk score could also 
influence disease risk in ocular (monogenic) diseases. For instance,  up to 35% of patients 
affected with autosomal recessive Stargardt disease, a monogenic disease caused by 
homozygous or compound heterozygous mutations in the ABCA4 gene, none or only a single 
disease associated mutation in the ABCA4 gene could be found [66]. Other genetic variants or 
environmental factors must therefore play a role in this Mendelian disease. Since Stargardt 
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disease shows striking similarities with GA AMD, a high risk for AMD might help to explain 
the observed findings. 
 
1.6 Aims and structure of this thesis 
The overall aim of the thesis was to identify and characterize genetic and non-genetic markers 
involved in AMD risk, progression and severity by analysing a diverse set of epidemiological 
studies. In addition, I aimed to evaluate the influence of several AMD associated markers on 
cells and tissues in vitro. 
Specifically, we wanted to generate a genetic risk model for late stage AMD by calculating a 
genetic risk score for AMD patients and controls from the Lower Frankonian AMD case-
control study recruited at the University of Würzburg [35,58]. We calculated the risk score 
based on 13 common (previously published) variants and then evaluated its impact on disease 
risk. In addition, we used the genetic risk score to investigate differences in the genetic 
architechture of the disease in different age-groups, in men and women and in different late 
stage forms of the disease (e.g. GA or NV AMD). 
A second specific aim was to evaluate circulating microRNAs (cmiRNAs) as potential novel 
biomarkers for AMD. To this end, we recruited AMD cases and AMD-free controls from the 
eye clinic Regensburg. To validate candidate cmiRNAs in an independent, population based 
(cross-sectional) study, we analyzed serum samples of patients and controls from the 
EUGENDA study [21] recruited in Cologne in collaboration with Prof. Dr. Fauser from the 
Department of Ophthalmology at the University Hospital of Cologne. The influence of 
significantly associated cmiRNAs on neovascularization was assessed in vitro with a so called 
tube formation assay. 
The third specific goal was to investigate a potential correlation of common, AMD risk 
associated variants as well as clinical factors with the growth rate of geographic atrophy 
lesions. Patients in the initial study were recruited as part of the prospective Fundus 
Autofluorescence Imaging in Age-related Macular Degeneration Study (FAM) [67] at the 
Department of Ophthalmology at the University of Bonn. In addition, we used GA 
progression data from the prospective Age-Related Eye Disease Study (AREDS) [22] 
recruited by the National Institute of Health (NIH) to replicate our findings. 
The final objective of this thesis was to find additional common genetic variants associated 
with AMD in a candidate gene approach in a large collection of cases and controls from 
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several studies. The initial study consisted of individuals from the Southern Germany case-
control study recruited at the University Hospitals in Würzburg, München and Tübingen [33]. 
The samples of the replication study were recruited at the Centre for Public Health at the 
Queen's University of Belfast, the
 
Department of Ophthalmology at the Columbia University 
and the Department of Ophthalmology at the University Hospital of Cologne.  
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2. Modelling the genetic risk in age-related macular degeneration 
 
This chapter is identical to the following publication: 
Grassmann F, Fritsche LG, Keilhauer CN, Heid IM & Weber BHF (2012). Modelling the 
genetic risk in age-related macular degeneration. PLoS One 7: e37979 
 
Abstract 
Late-stage age-related macular degeneration (AMD) is a common sight-threatening disease of 
the central retina affecting approximately 1 in 30 Caucasians. Besides age and smoking, 
genetic variants from several gene loci have reproducibly been associated with this condition 
and likely explain a large proportion of disease. Here, we developed a genetic risk score 
(GRS) for AMD based on 13 risk variants from eight gene loci. The model exhibited good 
discriminative accuracy (area-under-curve (AUC) of the receiver-operating characteristic of 
0.820), which was confirmed in a cross-validation approach. Noteworthy, younger AMD 
patients with an age below 75 years had a significantly higher mean GRS (1.87, 95% CI: 
1.69-2.05) than patients aged 75 and above (1.45, 95% CI: 1.36-1.54). Based on five equally 
sized GRS intervals, we present a risk classification with a relative AMD risk of 64.0 (95% 
CI: 14.11-1131.96) for individuals in the highest category (GRS 3.44-5.18, 0.5% of the 
general population) compared to subjects with the most common genetic background (GRS -
0.05-1.70, 40.2% of general population). The highest GRS category identifies AMD patients 
with a sensitivity of 7.9% and a specificity of 99.9% when compared to the four lower 
categories. Modeling a general population around 85 years of age, 87.4% of individuals in the 
highest GRS category would be expected to develop AMD by that age. In contrast, only 2.2% 
of individuals in the two lowest GRS categories which represent almost 50% of the general 
population are expected to manifest AMD. Our findings underscore the large proportion of 
AMD cases explained by genetics particularly for younger AMD patients. The five-category 
risk classification could be useful for therapeutic stratification or for diagnostic testing 
purposes once preventive treatment is available. 
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2.1 Introduction 
Age-related macular degeneration (AMD) is a common degenerative disease of the central 
retina and a leading cause of severe vision impairment in Western societies [2]. Advanced 
forms of AMD (late-stage AMD) are known as geographic atrophy (GA) of the retinal 
pigment epithelium (RPE) or neovascular (NV) complications with RPE detachment, scar 
formation, and subretinal hemorrhage [68,69]. To date, effective therapeutic intervention is 
available for active NV, while GA still remains untreatable [70,71]. 
 
AMD is a complex disease influenced by genetic and environmental factors with estimates of 
heritability varying from 45% to 71% [72]. So far, several AMD susceptibility loci have been 
identified. Two loci are accounting for an estimated 50% of AMD cases: complement factor 
H (CFH) on 1q32 and age-related maculopathy susceptibility 2 (ARMS2) / HtrA serine 
peptidase 1 (HTRA1) on 10q26 [34,73]. Fine-mapping studies and functional analyses at the 
CFH locus indicate at least three independent risk variants [34,37,74–77]. At the 
ARMS2/HTRA1 region, a single risk haplotype was found to fully explain the observed 
association [35]. 
 
A crucial role of the complement system in AMD pathogenesis was further supported by 
subsequent candidate gene studies. These studies identified risk-associated variants in or near 
three additional complement genes including the complement component 2 (C2) / 
complement factor B (CFB)[47], complement component 3 (C3) [78,79] and complement 
factor I (CFI) [80]. In addition, variants in genes involved in the cholesterol and lipid 
metabolism were also implicated in AMD susceptibility [81,82]. Strongest signals peaked 
near the hepatic lipase gene (LIPC) on chromosome 15q22 [81,82], the cholesterylester 
transfer protein (CETP) and the lipoprotein lipase precursor (LPL) genes [81]. Also, among 
the most replicated AMD risk variants are two coding SNPs in the apolipoprotein E (APOE) 
gene [32,83]. A recent genome wide association study established a significant association of 
AMD with rs9621532, a variant intronic to synapsin III (SYN3) and approximately 100kb 
upstream of the tissue inhibitor of metalloproteinases-3 gene (TIMP3) [81]. Finally, common 
variations near VEGFA and FRK/COL10A1 were associated with AMD, further implicating 
angiogenesis as well as extracellular matrix metabolism in AMD pathogenesis [84]. 
 
To predict the genetic risk in complex diseases, testing of single susceptibility variants is 
generally of limited value [85]. In contrast, genotyping and evaluating a series of independent 
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disease associated variants, a process also known as genetic profiling, may be more 
appropriate [85]. This can be facilitated by a genetic risk score (GRS) which could simply 
represent the sum of risk associated variants found in each individual. However, such an 
approach may not be particularly effective in the presence of greatly differing effect sizes of 
the respective variants [86]. Therefore, an extension to this model weighs each additional risk 
allele by its effect size. For example, Seddon et al. (2009) calculated a risk score for AMD 
based on 6 known genetic risk variants and additional environmental factors. Their model 
revealed good discriminatory power with a reported area-under-curve (AUC) of the receiver-
operating characteristic of 0.82 [50]. Other studies reporting a GRS [81,82,84] primarily 
aimed at identifying novel variants without using independent data or a cross-validation 
approach and are thus likely biased to overestimate the effect of these variants. The 
quantification of the genetic risk based on frequently replicated AMD loci in a single study 
which is independent from locus identification is still lacking.  
 
Here, we present a genetic risk model for AMD, specifically the late-stage forms of AMD, 
based on a large and well characterized AMD case-control study group including 986 cases 
and 796 controls. We selected 13 genetic variants from eight gene loci that have repeatedly 
been shown to be associated with AMD and computed a genetic risk score. This was used to 
establish a classification system that allows for discriminating subjects at high and low 
genetic risk. Environmental variables such as smoking or diet were not included in the model 
building. 
 
2.2 Results 
SNP selection based on published data and linkage disequilibrium structure 
Eight loci (CFH, ARMS2/HTRA1, CFI, CFB, C3, APOE, LIPC and TIMP3) with 13 SNPs 
and established association with AMD were included into our genetic risk score modeling 
(Supplementary Table S1). There were three further SNPs with reportedly established 
association, which we did not select for the model: (i) at the CFH locus, an association of four 
variants with AMD is known (rs1410996, rs800292, rs1061170, rs6677604); however, 
rs1410996 is present on two distinct haplotypes, each of which is tagged by rs800292 
(correlation r²=0.473 to rs1410996[87] ) or rs6677604 (r² =0.283 to rs1410996[87]), 
respectively [77], while rs800292 and rs667604 are uncorrelated (r²=0.008 [87]), (ii) among 
the three highly correlated ARMS/HTRA variants (rs10490924, rs11200638, and 
c.del443ins54; pairwise r²=1), rs10490924 was reported to fully capture the disease risk at this 
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locus [88]. We therefore selected rs1061170, rs800292 and rs667604 at CFH and rs10490924 
at the ARMS2/HTRA1 locus yielding the 13 SNPs for model building. 
 
Genotyping of SNPs in the Lower Frankonian AMD case-control study 
We genotyped the selected 13 SNPs as well as the three highly correlated SNPs (to validate 
the correlations) in 986 cases and 796 controls from the Lower Frankonian AMD case-control 
study (Table 2). 
 
Table 2.Summary characteristics of the case-control study 
 
 
 
 
 
1
 Geographic atrophy 
2 
Neovascular AMD  
3
 Mixed GA+NV: GA and NV in the same eye or GA in one and NV in the second eye 
4
 Smoking was defined as ever smoked more than 20 pack years 
5 
This variable was surveyed incompletely in cases and controls and thus was not further considered in 
the analysis 
 
All variants showed high genotyping quality with an average call rate > 99.5%. With the 
exception of rs1061170 at CFH, all genotypes were in Hardy-Weinberg equilibrium in 
controls (HWE, p>0.04). The variant rs1061170 was genotyped twice with two independent 
assays yielding identical genotypes and therefore persistent HWE violation in controls (p= 
0.002) [89]. There were no missing genotypes at the 13 variants for any individual in the 
study. 
 
Association of the selected 13 SNPs with AMD 
For each SNP, association with AMD was computed using a logistic regression model, 
unadjusted for age or gender (Table 3). Sensitivity analysis additionally adjusting for age and 
gender yielded similar results. Odds ratio (OR) estimates per AMD risk increasing variant 
ranged from 1.14 [95% CI: 1.00-1.30] for rs2285714 to 3.13 [95% CI: 2.68-3.68] for 
rs10490924 and were significantly different from unity for all 13 variants demonstrating 
 Cases Controls Total 
Subjects 986 796 1782 
GA
1
 229 -  
NV
2
 581 -  
Mixed GA+NV
3
 176 -  
Mean Age (S.D.) [in years] 78.7 (6.5) 78.3 (5.1) 78.5 (5.9) 
Men [%] 34.1 39.3 36.4 
Fraction smoker [%]
4,5
 15.9 14.3  
  
15 
 
sufficient statistical power in our study (Table 3). In a subgroup analysis, AMD cases with 
GA (n=229) or NV (n=581) or mixed GA+NV in one or both eyes (n=176) were compared to 
controls using logistic regression for each variant separately (Supplementary Figure S1). 
  
Computing the genetic risk score 
Based on the data from the 13 SNPs, we fit a multiple logistic regression model (Figure 2). 
The odds ratios in this model ranged from 1.070 to 4.063. This is, to our knowledge, the first 
study to report these 13 variants together in one multiple logistic regression accounting for 
other AMD risk variants. We computed a GRS for each individual as the sum of AMD risk 
increasing alleles weighted by the relative effect size of each SNP from the logistic model. 
We added the alpha estimate of -10.13 to center the GRS on zero for our study (see Methods). 
Cases had a significantly higher mean GRS (1.61, 95% CI: 1.53-1.69) compared to controls (-
0.03, 95% CI: -0.12-0.06, p <0.01). The relative risk of AMD per GRS unit approximated by 
the OR was 2.72 (95% CI: 
2.46-3.01). The mean GRS 
of our controls was slightly 
lower than the one for the 
HapMap data representing 
a general population (0.00, 
95% CI: -0.14-0.14), which 
is in-line with our controls 
being selected for having 
no AMD.  
Figure 2. Risk estimates for each of thirteen AMD risk variants 
from eight gene loci. Odds ratios (OR) per risk allele were derived 
from multiple logistic regression models. Horizontal lines indicate 95% 
confidence intervals. 
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Table 3. Association results for the 13 known AMD associated variants in the lower Frankonian case-control study (986 cases, 796 
controls) using single logistic regression 
 
1
 CI = confidence interval 
2
 P-values were derived from a logistic regression model with one SNP as covariate. 
3
 Risk allele is the allele that is associated with increased risk of AMD 
4
 AUC = area-under-curve of the receiver-operating characteristic 
5
 r² values representing the correlation with the first SNP in each gene/locus based on 1000 genomes data (build 1) or HapMap release 22 [87] 
         Frequency of risk allele in   
Nearby 
gene(s) 
Marker ID Impact/effect of variant Odds ratio 95% CI1 P-value2 
Non risk 
allele 
Risk 
allele3 
Controls 
(N=796) 
Cases (N=986) 
AUC4 of 
variant 
correlation 5 
CFH rs1061170 1 p.Y402H 2.74 2.36-3.18 1.66E-45 T C 0.365 0.600 0.676  
 rs800292 2 p.I62V 2.43 2.02-2.92 6.95E-23 A G 0.761 0.888 0.606 0.150 
 rs6677604 3 proxy for ∆CFHR3/CFHR1 2.19 1.82-2.64 1.42E-17 A G 0.777 0.884 0.590 0.203 
ARMS2 rs10490924 4 p.A69S 3.13 2.68-3.68 7.97E-54 G T 0.189 0.441 0.684  
CFB rs4151667 5 p.L9H 2.82 1.90-4.28 1.41E-07 A T 0.951 0.982 0.530  
 rs438999 6 proxy for rs641153 (p.R32Q) 2.31 1.73-3.11 5.75E-09 C T 0.915 0.962 0.542 0.01 
C3 rs2230199 7 p.R102G 1.52 1.29-1.80 4.71E-07 G C 0.175 0.245 0.556  
APOE rs7412 8 p.R158C 1.41 1.12-1.80 0.003613 C T 0.079 0.107 0.526  
 rs429358 9 p.C112R 1.35 1.09-1.69 0.006812 C T 0.881 0.908 0.528 0.783 
PLA2G12A rs2285714 10 synonymous exonic, unknown 1.14 1.00-1.30 0.04839 C T 0.409 0.443 0.523  
LIPC rs493258 11 intergenic (36kb upstream) 1.18 1.04-1.35 0.01277 T C 0.538 0.580 0.531  
 rs10468017 12 intergenic (46kb upstream) 1.26 1.08-1.46 0.002992 T C 0.707 0.751 0.536 0.367 
SYN3/TIMP3 rs9621532 13 intronic, unknown 1.58 1.09-2.30 0.01246 C A 0.96 0.974 0.512  
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Good discriminative ability of the GRS 
Computing the area-under-the-curve (AUC) of the receiver-operating characteristic for the 
13-SNP GRS, we observed good ability to correctly classify those with and without the 
disease (AUC=0.820, Figure 3). We also computed the AUC per locus demonstrating that the 
impact by gene varied substantially, as expected. The three SNPs at the CFH locus alone 
(rs800292, rs1061170, rs6677604) showed the highest classification efficiency (AUC=0.710), 
followed by rs10490924 at ARMS2/HTRA1 (AUC=0.684), and the remaining variants (AUC 
from 0.512 to 0.571) (Figure 3).  
 
Although we specifically avoided selecting the SNPs based on association in our own data set 
but rather from the literature, 
there could be a potential 
overestimation of the AUC. We 
estimated the effect sizes per 
variant from our data and used 
these as weights for the GRS.  
 
To evaluate this potential over-
estimation, we performed a 
sensitivity analysis via a cross-
validation approach by repeated 
(i=2000) random sub-sampling 
with 2/3rd of the data for model 
building and 1/3rd for testing. 
The cross validated AUC of 
0.813 (95% CI: 0.813-0.814) is 
close to the one described in our 
initial study (AUC=0.820).  
 
Developing a parsimonious genetic risk score model 
We evaluated whether a parsimonious model based on our data could be developed. We thus 
explored several models by subsequently excluding the loci with the weakest AUC and found 
a model restricted to 10 variants with equally discriminatory ability (AUC 0.820) and equal 
model fit (R²=0.247) (Table 4). This model could be of value for translational studies 
minimizing the genotyping burden. Whether this is specific to our data set or holds true for 
Figure 3. Area-under-the-curve of the receiver 
operating characteristic for the 13-SNP genetic risk 
score and by gene locus. Observed AUC was 0.820 and 
the locus-specific AUCs were 0.513, 0.524, 0.536, 0.547, 
0.555, 0.571, 0.686 and 0.710 from bottom to top. 
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other study populations needs to be evaluated further. It should be noted that all further 
analyses are based on the 13-SNPs-GRS.  
 
Table 4. Model fit and discriminative accuracy of parsimonious models 
Model
1
 Variants
2
 R² AUC 
13-SNP model 1,2,3,4,5,6,7,8,9,10,11,12,13 0.2475 0.820 
    - TIMP3 1,2,3,4,5,6,7,8,9,10,11,12 0.2475 0.820 
    - PLA2G12A 1,2,3,4,5,6,7,8,9,11,12 0.2454 0.819 
    - APOE 1,2,3,4,5,6,7,10,11,12 0.2411 0.816 
    - LIPC
3
 1,2,3,4,5,6,7,8,9,10 0.2457 0.820 
 
1
 SNPs from one additional locus at a time were omitted from the 13-SNP model by starting with the 
locus with the smallest risk  
2
 Numbering corresponds to IDs in Table 3 
³ This model contained the least number of SNPs without compromising R² or AUC values 
 
 
Distribution of the genetic risk score 
The distribution of GRS for cases and controls as observed in our study is given in Figure 
4A. To provide a more realistic view of the GRS distribution, the proportion of cases were 
weighted to reflect a general distribution. For this modeling, an AMD prevalence of 15% was 
assumed as reported for the general population aged >85 years [17,19,90] (Figure 4B). The 
derived GRS is comparable to the distribution estimated from individual HapMap data 
(Figure 4B).  
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Figure 4. Genetic risk score distribution in the study population and in a modeled population. 
AMD cases are shown in red, controls in blue, while overlapping bars are shaded blue/red. (A) 
Genetic risk score distribution for cases (N=986) and controls (N=796) in the present study. (B) 
Counts of cases in (A) were scaled to represent 15% of the total population (assumed as AMD 
prevalence of the 85-90 year old general population). The density curve represents the risk score 
distribution in 381 European ancestry samples available through the 1000 Genomes Project (Release 
20110521). 
 
Genetic risk score by age groups, gender and AMD subtype 
We further investigated differences of the GRS between age-groups (below or older than 75 
years), men and women, or types of AMD (GA, NV, or mixed GA+NV) using a significance 
level of 0.05/3 to account for the three subgroup tests performed. 
 
Significant differences in mean GRS were found between younger (1.87, 95% CI: 1.69-2.05) 
and older (1.45, 95% CI: 1.36-1.54) AMD cases (p=8.7x10
-5
), but there was no difference 
between the age-groups among controls (p= 0.18). The OR per GRS unit was 3.06 (95%CI: 
2.64-3.59) for younger and 2.71 (95% CI: 2.44-3.05) for older individuals. We also found that 
the AUC restricted to the younger subjects (cases and controls) was higher (0.852) than when 
only older subjects (cases and controls) were included in the calculations (0.809). 
 
Cases with mixed GA+NV had a significantly higher mean GRS (1.87, 95% CI: 1.69-2.04) 
compared to NV cases (1.44, 95% CI: 1.34-1.55, p=6.6x10
-5
). It was also higher when 
compared to GA cases (1.65, 95% CI: 1.48-1.83, p=0.03), although the latter was statistically 
not significant when applying a conservative Bonferroni-adjusted significance level of 0.05/3. 
The OR per GRS unit was also higher for mixed GA+NV cases (OR=3.79, 95% CI: 3.13-
4.67) than for NV cases (OR=3.79, 95% CI: 3.13-4.67) or for GA cases (OR=2.84, 95% CI: 
2.44-3.33). This effect appeared to be independent of age, since mean age in GA (78.8 years, 
95% CI: 77.9-79.6), NV (78.5 years, 95% CI: 77.9-79.0) and mixed GA+NV (79.4 years, 
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95% CI: 78.4-80.3) was similar. There was no significant difference in the GRS means 
between men and women neither among cases nor among controls.  
 
These subgroup analyses demonstrate a higher genetic risk of the younger AMD patients 
compared to the older patients as well as a higher genetic risk for those with mixed late-stage 
manifestations (GA+NV) when compared to NV or GA alone. 
 
Genetic risk groups and relative risk estimates 
To establish a classification scheme, we formed five equally sized intervals for the GRS 
spectrum (≤-1.79, (-1.79)-(-0.05), (-0.05)-1.70, 1.60-3.44, and >3.44; Table 5). The highest 
GRS category (no. 5) contained 7.92% of AMD cases, but only 0.13% of controls. In contrast, 
the two lowest GRS categories (nos. 1+2) jointly contained only 9.8% of cases, but 48.7% of 
controls. According to the HapMap data reflecting a general population, the proportion of 
subjects in the two lowest risk groups combined was 48.9% and 0.5% in the highest risk 
group. This is consistent with the general population being a mixture of mostly controls and 
only few cases. The relative risks were approximated as ORs for each GRS category using the 
middle category (no. 3) as reference (Table 5). It can be seen that the OR is dramatically 
increased for category four (OR=5.44, 95% CI=4.03 – 7.46) and even more for category five 
(OR=64.00, 95% CI=14.11 – 1132.96). The odds ratios are substantially decreased for 
categories two and one (OR=0.22, CI=0.17-0.29 and OR=0.12, 95% CI=0.05-0.24) compared 
to the reference. Thus, these GRS categories can effectively describe genetic risk groups for 
AMD.  
 
Due to the substantial differences found in mean GRS for younger compared to older cases 
(see above), we derived these ORs also separately by age-group. To avoid scarce data, risk 
group one and two as well as four and five were combined to a low and a high risk group, 
respectively (Table 5). This highlights the higher genetic relative risk for AMD when 
restricting the analysis to the younger (OR =12.66, 95% CI: 6.76-25.65) compared to the 
older (OR=5.18, 95% CI: 3.70-7.38) subjects. Although the 95% confidence intervals overlap 
slightly, we observed a significant difference (p=0.0194). 
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Modeled absolute risk for late-stage AMD 
To reflect the anticipated situation in the general population and to compute the absolute risk 
of AMD per GRS group, we computed the fraction of late-stage AMD cases per GRS 
category by (i) utilizing the fraction of cases and controls as observed in each GRS category 
(Table 5) and (ii) weighting the fraction of cases assuming various AMD prevalences (1%-
15%). The fraction of cases and the fraction of subjects of the modeled general population 
(also for comparison in the HapMap sample) by GRS category are shown in Table 6. The 
fraction of late-stage AMD in the highest GRS group (absolute AMD risk) ranged from 38.6-
91.7% depending on the assumed AMD prevalence which were chosen to correspond to the 
various age-groups as reported [17,19,90]. For example, in a general population with an AMD 
prevalence of 10% approximately 90% of the persons in the highest GRS group are expected 
to be affected by late-stage AMD. Consequently, the genetic relative risk for subjects in the 
highest GRS group (compared to the middle GRS group) is higher for younger compared to 
the older AMD cases. However, the absolute risk of AMD among subjects in the highest GRS 
group is higher for the older population due to the higher AMD prevalence among the older 
persons.  
We again adopted the same cross-validation approach to compute absolute risks since the 
effect sizes of the variants in the GRS model, on which the absolute risk estimates are based, 
were estimated from our study data. This approach yielded overall similar estimates 
(Supplementary Table S2). 
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Table 5. Five genetic risk groups and relative risk of AMD (ORs and 95% confidence intervals) 
 
 
 
 
 
 
 
 
 
 
 
 
 
1  
Fraction of individuals in 1000 Genome Project European Ancestry Samples residing in risk groups 
 Genetic risk groups 
GRS category 1 2 3 4 5 
Sample size N=63 N=417 N=761 N=450 N=79 
GRS interval ≤-1.79 ]-1.79,-0.05] ]-0.05,1.70] ]1.70,3.44] >3.44 
Cases [%] 0.81 9.00 42.5 39.7 7.92 
Cases <75 years [%] 1.70 6.20 34.0 42.3 15.8 
Cases >75 years [%] 0.54 9.96 45.2 38.9 5.38 
Controls [%] 6.99 41.7 43.6 7.50 0.13 
Frequency in HapMap
1
 8.92 40.2 41.2 9.18 0.53 
OR (95% CI) 0.12 (0.05-0.24) 0.22 (0.17-0.29) reference 5.44 (4.02-7.46) 64.00 (14.11-1131.96) 
    
GRS categories low (1+2) 3 high (4+5) 
Sample size N=480 N=761 N=529 
GRS interval ≤-0.05 ]-0.05,1.70] >1.70 
OR (95% CI) 0.21 (0.16-0.27) reference 6.41 (4.76-8.76) 
<75 years: OR (95% CI) 0.19 (0.10-0.33) reference 12.66 (6.76-25.65) 
>=75 years: OR (95% CI) 0.22 (0.16-0.29) reference 5.18 (3.70-7.38) 
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Table 6.Absolute risks for AMD by modeling a general population for various prevalences of AMD (reflecting various age-groups) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
 Approximate age-groups corresponding to the modeled prevalences for 65 and 79 years [17,19] and for those above 80 years [90].  
2  
see Table 5. 
 Modeled 
prevalence (age-
group [yrs])
1
 
Absolute risk of AMD by genetic risk group [%] 
  1 (low) 2 3 4 5 (high) 
GRS interval  ≤-1.79 ]-1.79,-0.05] ]-0.05,1.70] ]1.70,3.44] >3.44 
% cases, modeled general population       
 1% (65-69) 0.12 0.22 0.97 5.08 38.6 
 2.5% (70-74) 0.30 0.55 2.44 12.0 61.5 
 5% (75-79) 0.61 1.13 4.87 21.8 76.6 
 10% (80-84) 1.30 2.40 9.80 37.0 87.4 
 15% (>85) 2.00 3.70 14.7 48.3 91.7 
% subjects, modeled general population       
 1% 6.84 40.9 43.6 8.31 0.32 
 2.5% 6.68 40.1 43.8 8.50 0.34 
 5% 6.69 40.1 43.6 9.12 0.52 
 10% 6.38 38.5 43.5 10.7 0.91 
 15% 6.10 36.8 43.5 12.3 1.30 
% subjects, HapMap population2  8.92 40.2 41.2 9.18 0.53 
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2.3 Discussion 
Based on a genetic risk score including 13 reported SNPs from eight established AMD gene 
loci, we propose a five-category classification system that effectively differentiates subjects 
with high or low genetic risk. With this, we extend on earlier efforts to predict the genetic risk 
for late-stage AMD [42,50,52,56]. Seddon et al. described a risk score model for six genetic 
variants in four loci also including environmental factors like BMI, smoking, age and diet 
(sample size was 1.446 individuals of which 279 progressed to AMD) [50]. Similarly, a study 
from Gibson et al. included 470 cases and 470 controls and reported an AUC of 0.83 (95% CI 
0.81 to 0.86) using six SNPs in four loci and two environmental factors [52]. A study by 
Spencer et al. investigated one variant in each of four loci as well as age and smoking as 
environmental factors and found an AUC of 0.84 (95% CI: 0.81-0.88) [56]. Jakobsdottir et al. 
reported an AUC of 0.79 based on one SNP in each of three loci [42]. This study consisted of 
around 1.000 family-based cases and 429 controls as well as a case-control study with 187 
cases and 168 controls. We evaluated 13 SNPs from 8 AMD loci in a well characterized and 
well powered case-control study and observed an AUC of 0.820, which is sufficient to 
classify AMD patients and controls into high risk and low risk groups [85]. Our study has not 
contributed to the identification of any of the 13 SNPs as AMD risk-increasing variants and 
would thus not be subject to winner’s curse regarding the effect size. To our knowledge, this 
is a first study to include most of the currently known genetic loci for their value to predict 
late-stage AMD risk in a study that is independent of the identification of any of these loci.  
 
Interestingly, we find a higher relative risk of the CFB SNP rs4151667 compared to CFH and 
ARMS2/HTRA1 risk-increasing SNPs particularly in the multivariable logistic regression 
model. This can also be seen in a previously published study (Seddon et al., Table 4) [26], 
although it needs to be noted that the models used in our and the published study differ in the 
sense that ours considers exclusively genetic factors while the other work largely focused on 
non-genetic factors. The smaller allele frequency of the CFB SNP (1.8% in our cases, 6.7% in 
the European ancestry 1000G individuals) compared to SNP frequencies in CFH and 
ARMS2/HTRA1 results in a reduced power to detect association and may explain why CFB 
SNP rs4151667 was not among those detected first by AMD GWAS.  
 
As expected, the mean GRS was significantly higher in cases when compared to controls. 
Importantly, patients with late-stage AMD diagnosed at an earlier age had a significantly 
higher mean GRS than individuals that developed AMD later in life. This strongly suggests 
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that genetic predisposition influences disease onset, which is also reflected in the higher 
relative AMD risk for younger subjects with an OR of 12.66 (95% CI: 6.76-25.65) when 
compared to older individuals with an OR of 5.18 (95% CI: 3.70-7.38). The mean genetic risk 
score in our control group was slightly lower but similar to the mean score in the HapMap 
sample (including a total of 381 European subjects from CEU, GBR, IBS, TSI and FIN, 1000 
Genomes Project (Release 20110521, http://www.1000genomes.org, accessed 2 May 2012).). 
The slight discrepancy would be in-line with the fact that our controls were specifically 
selected to reveal no signs of early or late-stage AMD.  
 
Limitations of our study for risk prediction should be acknowledged. First, the analysis was 
based on a case-control study, which has no element of a prospective study or a nested case-
control study. The controls were often spouses of AMD patients and thus non-genetic risk 
factors could not be studied due to the known similarities among spouses regarding life style 
factors. However, our AMD patients were virtually incident AMD cases and thus the age at 
study entry is likely the age-at-diagnosis and the best possible proxy for age-of-onset 
(allowing for a delay of about 1-2 years between onset and diagnosis). In a case-control 
setting, absolute risk or positive/negative predictive values cannot be derived without making 
assumptions on the overall AMD prevalence, which a prospective cohort study could estimate 
directly. Thus, the predictive ability of the risk score groups greatly depends on those 
assumptions. Second, it might be considered a limitation but also a strength that our study 
included exclusively late-stage AMD with NV or GA in one or both eyes as well as highly-
matched controls with no signs of early or late-stage AMD in any eye. A strength as our data 
might exhibit less disease misclassification than other studies, but a limitation as the genetic 
relative risk could be overestimated if the genetic risk is larger for subjects with both eyes 
affected than for those with only one affected eye. Third, we had no independent and equally 
well characterized data set available to separate model building from testing although this is 
also the case for all other studies published on AMD risk score model building [42,50,52]. 
Only one study [56] reported a small replication study. We avoided selecting SNPs for our 
model based on association signals in our own data but rather selected SNPs from the 
literature. However, the SNP-specific effect sizes utilized as weights in the genetic risk score 
computation were still estimated in our data set. Thus, estimations of AUC or absolute risk in 
the same data could lead to a slight over-estimation of risk. We therefore adopted a cross-
validation approach as sensitivity analysis, which did not provide evidence of remarkable 
over-estimation.  
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The highest genetic risk group of our proposed five-category classification scheme can 
effectively identify subjects at high risk for AMD. The specificity in this risk group was 
99.9% (95% CI: 99.3%-100%). For example, our data and model suggest that 87.4% of 
subjects testing positive at some time in life for a high genetic risk are likely to develop AMD 
in their mid-eighties (positive predictive value). Thus, this group of individuals could greatly 
profit from a sight-saving prevention or early intervention program while only 13% of (false-
positive) subjects would be alarmed and treated unnecessarily. However, still a large number 
of cases would be missed if this was established as a screening method (sensitivity 8.0% (95% 
CI: 6.5%-9.9%), i.e. 92% of all AMD cases would not be found in the highest risk group). 
Also individuals in the second highest risk group could possibly profit from early 
intervention, which would increase sensitivity to 47.6% and decrease specificity to 91.2%. 
However, this would only be acceptable, if the prevention/intervention is not harmful to the 
59.9% of subjects treated and alarmed unnecessarily (40.1% positive predictive value). These 
numbers are well in the range of established screening tests, e.g. for prostate cancer by 
prostate specific antigen (PSA) (positive predictive value = 25.1%, sensitivity = 72.1%, 
specificity = 93.2%, [91]), albeit with a higher predictive value at the cost of reduced 
sensitivity. Abnormal levels of PSA are detected in about 10% of the male population, which 
is comparable to the coverage of high risk group four and five [91]. Offering an effective 
prevention program to individuals in the highest AMD risk group (approximately 400,000 
individuals in Germany alone), almost 10% of incident late-stage AMD could be avoided. If 
individuals in risk groups four and five are included (about 10% of the general population), up 
to 50% of future AMD patients could be addressed. 
 
So far, only the progression of the neovascular complications in AMD can be slowed by 
treatment [92]. If disease progression to an advanced neovascular form is detected early in 
high risk patients, immediate intervention might prove essential to sustain full vision for a 
more extended time. Accordingly, high risk individuals could be advised to seek clinical 
follow-ups more frequently and could also benefit from dietary recommendations, including 
the intake of antioxidants [22] or omega-3 fatty acids [93,94]. Identification of individuals at 
high risk for developing AMD may also help to include defined candidates in clinical AMD 
trials and thus may allow a better assessment of therapeutic effects.  
 
In conclusion, our study provides a genetic risk score for late-stage AMD from a well 
characterized case-control study emphasizing the large proportion of disease explained by 
genetic markers particularly for younger subjects. We propose a classification scheme to 
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identify subjects at high or low genetic risk that might be suitable for risk stratification in 
therapy studies or genetic screening once preventive treatment is available. 
  
2.4 Materials and Methods 
Ethics statement 
This study followed the tenets of the declaration of Helsinki and was approved by the Ethics 
Review Board at the University of Würzburg, Germany. Informed written consent was 
obtained from each patient after explanation of the nature and possible consequences of the 
study. 
 
The study subjects 
The case-control sample includes 986 AMD patients and 796 controls recruited from the 
Lower Frankonian area at the University Eye Clinic of Würzburg, Germany [35]. Controls 
were often unaffected spouses or nonrelated acquaintances of cases of similar age as the 
patient. All patients and controls were examined by a trained ophthalmologist (CNK). Stereo 
fundus photographs were graded according to standardized classification systems as described 
previously [37,95,96]. Only patients with severe forms of AMD (GA or NV) in at least one 
eye and signs of early AMD (e.g. large soft drusen) in the other eye were included. The 
patients were divided into three subgroups according to their type of late-stage AMD: patients 
with GA in the severe eye, patients with NV in the severe eye and patients that had either GA 
in one eye and NV in the other eye or that showed both late-stage forms in the same eye 
(mixed GA+NV). Mean age in cases was 78.7 (±6.5) years and 78.3 (±5.1) in controls. A total 
of 34.1% of cases and 39.1% of controls were male. Study characteristics are summarized in 
Table 2.  
 
Genotyping 
Genomic DNA was extracted from peripheral blood leukocytes according to established 
protocols. Genotyping of SNPs was achieved by direct sequencing, restriction enzyme 
digestion of PCR products, TaqMan SNP Genotyping (Applied Biosystems, Foster City, 
USA) or primer extension of multiplex PCR products with detection of the allele-specific 
extension products by the matrix-assisted laser desorption/ionization time of flight (MALDI-
TOF) mass spectrometry method (Sequenom, San Diego, USA) (Supplementary Table S3). 
Direct sequencing was performed with the Big Dye Terminator Cycle Sequencing Kit Version 
1.1 (Applied Biosystems, Foster City, USA) according to the manufacturer’s instructions. 
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Reactions were analyzed with an ABI Prism Model 3130xl Sequencer (Applied Biosystems). 
TaqMan Pre-Designed SNP Genotyping Assays (Applied Biosystems) were performed 
according to the manufacturer’s instructions. Additionally, some variants were genotyped by 
PCR followed by restriction enzyme digestion (New England Biolabs, Ipswich, USA) and 
subsequent restriction fragment length analysis. The c.del443ins54 variant in the 3’-region of 
the ARMS2 locus was genotyped by a single PCR with oligonucleotide primers 5’-
ACTCATCACGTCATCACCAAT-3’ and 5’-CTCTCTGCAGCCCTCATTTG-3’ resulting in 
distinct fragment sizes due to the presence or absence of the deletion/insertion polymorphism. 
 
Estimating genetic risk and model fit 
Genotypes were coded as the number of AMD risk increasing alleles (0, 1, and 2). Logistic 
regression analyses were carried out using the R software [97]. Odds ratios (OR) per risk 
allele and 95% confidence intervals (95% CI) were calculated from the estimated beta-
coefficients to derive an approximate relative risk. The goodness-of-fit of each model was 
assessed by calculating McFaddens pseudo R
2 
[98], which however, does not reflect the 
variance explained by the model [99].  
 
Computing the genetic risk score 
Based on the intercept “a” and the single-SNP beta-coefficients estimated using the logistic 
regression model including all SNPs at once, the genetic risk score (GRS) was calculated as 
 
 (1) 
 
with k being the number of SNPs in the model and xi the genotype of the ith SNP. Here, “a” 
denotes a constant that centers the risk score distribution around zero and bi relates to the ith 
variant. The odds ratio of the effect of the ith variant is thus given by exp(bi) [50,81,84]. The 
mean GRS by age-group, sex, or AMD subtype were compared based on the independent 
samples t test using the R software [97] and differences were considered as significant, if P< 
0.05/3 accounting for the three comparisons performed.  
 
Assessing the discriminative ability 
To estimate the ability of a potential genetic screening test to discriminate between AMD 
cases and healthy subjects, we computed the receiver-operating-characteristic (ROC) curve. 
This involves ranking all subjects according to their GRS starting with the smallest, 
computing sensitivity and specificity at each possible GRS cut-off, and plotting sensitivity 
ix
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versus 1-specificity. The area-under-the-curve (AUC) is a measure of how well the GRS cut-
offs can separate AMD cases from controls. We used the package EPICALC [100] for AUC 
computations and forest plots were generated with RMETA [101].  
 
Internal validation by cross-validation 
Although we have not selected the SNPs into the model based on their association in our data 
set but rather with information from the literature, there is a potential overestimation of the 
AUC due to the fact that we used the SNP effect sizes to weigh the risk alleles when 
computing the GRS. Thus, we conducted a sensitivity analysis using a cross-validation 
approach to derive AUC estimates that are not subject to this bias to compare with the original 
data AUC. We randomly assigned 2/3
rd
 of the data to the model building (to compute the 
effect sizes and thus establish the GRS model) and 1/3
rd
 of the data to testing (to compute the 
AUC and positive predictive values) [102,103]. We repeated this 2000 times and computed 
the average AUC as an unbiased estimate.  
 
Modeling of the absolute risk by GRS group 
In order to derive the fraction of cases in the five GRS categories as expected in the general 
population (corresponding to the absolute AMD risk) from the number of cases 
(N_cases=986) and controls (N_controls=796) in our case-control study, we weighted the 
number of AMD cases in our study by  
 
 (2) 
 
 
where prevalence denotes the fraction of AMD cases in the general population, that we chose 
to reflect previously reported prevalences of AMD in the various age groups (65-69 years: 
1%, 70-74 years: 2.5%, 75-79 years: 5%, 80-84 years: 10% and >85 years: 15%) [17,19,90]. 
These were also used to compute positive and negative predictive value for the highest GRS 
category as a screening test for AMD. The cross-validation approach described above was 
also adopted for a sensitivity analysis to compute unbiased absolute risk. 
  
cases*N
controls*N
_)prevalence-(1
_prevalence
weight 
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3. A circulating microRNA profile is associated with late-stage neovascular 
age-related macular degeneration 
 
This chapter is identical to the following publication: 
Grassmann F, Schoenberger PGA, Brandl C, Schick T, Hasler D, Meister G, Fleckenstein M, 
Lindner M, Helbig H, Fauser S, Weber BHF (2014). A Circulating MicroRNA Profile Is 
Associated with Late-Stage Neovascular Age-Related Macular Degeneration. PLoS One 
9: e107461 
 
Abstract 
Age-related macular degeneration (AMD) is the leading cause of severe vision impairment in 
Western populations over 55 years. A growing number of gene variants have been identified 
which are strongly associated with an altered risk to develop AMD. Nevertheless, gene-based 
biomarkers which could be dysregulated at defined stages of AMD may point toward key 
processes in disease mechanism and thus may support efforts to design novel treatment 
regimens for this blinding disorder. Circulating microRNAs (cmiRNAs) which are carried by 
nano‑sized exosomes or microvesicles in blood plasma or serum, have been recognized as 
valuable indicators for various age-related diseases. We therefore aimed to elucidate the role 
of cmiRNAs in AMD by genome-wide miRNA expression profiling and replication analyses 
in 147 controls and 129 neovascular AMD patients. We identified three microRNAs 
differentially secreted in neovascular (NV) AMD (hsa-mir-301a-3p, pcorrected = 5.6*10
-5
, hsa-
mir-361-5p, pcorrected = 8.0*10
-4
 and hsa-mir-424-5p, pcorrected = 9.6*10
-3
). A combined profile 
of the three miRNAs revealed an area under the curve (AUC) value of 0.727 and was highly 
associated with NV AMD (p = 1.2*10
-8
). To evaluate subtype-specificity, an additional 59 
AMD cases with pure unilateral or bilateral geographic atrophy (GA) were analyzed for 
microRNAs hsa-mir-301a-3p, hsa-mir-361-5p, and hsa-mir-424-5p. While we found no 
significant differences between GA AMD and controls neither individually nor for a 
combined microRNAs profile, hsa-mir-424-5p levels remained significantly higher in GA 
AMD when compared to NV (pcorrected < 0.005). Pathway enrichment analysis on genes 
predicted to be regulated by microRNAs hsa-mir-301a-3p, hsa-mir-361-5p, and hsa-mir-424-
5p, suggests canonical TGFβ, mTOR and related pathways to be involved in NV AMD. In 
addition, knockdown of hsa-mir-361-5p resulted in increased neovascularization in an in vitro 
angiogenesis assay. 
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3.1 Introduction 
Age-related macular degeneration (AMD) is a highly prevalent cause of severe vision 
impairment among people aged 55 years and older [104]. It is a degenerative disorder of the 
central retina involving predominantly the rod photoreceptors, the retinal pigment epithelium 
(RPE), Bruchs membrane and the underlying choriocapillaris [40]. The disease aetiology is 
complex and is influenced by a combination of multiple genetic susceptibility factors and 
environmental components.  
 
An early sign of AMD is the appearance of drusen, yellowish extracellular deposits of protein 
and lipid material within and beneath the RPE. Advanced AMD manifests essentially as two 
distinct late-stage lesions – geographic atrophy (GA) and neovascular (NV) AMD. GA occurs 
in up to 50% of cases and is clinically defined as a discrete area of RPE atrophy with visible 
choroidal vessels in the absence of neovascularization in the same eye [2-5]. It may or may 
not involve the fovea. NV AMD describes the development of new blood vessels beneath and 
within the retina and is characterized by serous or hemorrhagic detachment of either the RPE 
or the sensory retina, the presence of subretinal fibrous tissue and eventually widespread RPE 
atrophy. Progression to visual loss can be rapid in NV AMD [104].  
 
The precise aetiology of AMD is still not fully understood, although risk factors such as age, 
smoking, and genetic components are known to strongly contribute to disease development 
[40]. In Western societies, AMD reveals an age-dependent prevalence of almost 1 in 5 people 
aged 85 and above [17,90,105]. Across a number of epidemiological studies, smoking has 
consistently been associated with increased risk of developing advanced AMD with an 
estimated odds ratio of approximately 2 [106]. The exact mechanism, however, by which 
smoking affects the retina is unknown. Twin studies and familial aggregation studies 
suggested a significant genetic contribution of up to 70% in disease risk [72]. Subsequently, 
several genes have been implicated in AMD pathology by candidate gene studies as well as 
genome wide association studies. Genetic variants in complement factor H (CFH) and 
ARMS2/HtrA Serine Protease 1 (HTRA1) were found to be strongly associated with odds 
ratios over 2.5 per risk allele. In addition, multiple medium to low effect size gene variants 
were discovered in a large number of loci across the genome. A recent meta-analysis of 
genome wide association studies found a total of 19 independently associated loci by 
comparing over 17,000 cases and 60,000 controls [33].  
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The combined effect of the major risk variants on AMD was estimated by modelling risk 
scores [58]. The multiple logistic regression model was found to have an area under the curve 
(AUC) of about 82%, which is suitable for classifying individuals in high and low risk 
groups. Accordingly, roughly 50% of AMD cases and 50% of healthy controls can now 
reliably be predicted. However, a large proportion of AMD cases do not have the expected 
genetic risk profile despite their given disease status. Consequently, other components, 
genetic or environmental, may influence disease development. This makes it crucial to 
identify these components possibly by defining disease biomarkers correlating with the 
underlying genetic or environmental factors and eventually reflecting a defined disease stage.  
 
Recently, circulating microRNAs (cmiRNAs) were found in blood plasma or blood serum 
where they are carried by nano‑sized exosomes or microvesicles [107,108]. Origin and 
effects of these cmiRNAs are unclear although some studies suggested functional 
involvement in cell-to-cell signalling [109]. In general, cmiRNAs are potential biomarkers 
which can be used for diagnostics and prognostics of human diseases [110]. Additionally, 
synthetic microRNAs in artificial exsosomes could be applicable for therapeutic approaches 
by modulating cmiRNA levels.  
 
In this study, we aimed to elucidate the role of cmiRNAs in AMD and performed a genome-
wide expression profiling in patients affected by late stage neovascular manifestation. Such 
analyses provide a promising approach to define biomarkers for AMD which could be helpful 
to identify as of yet unknown gene targets involved in defined aspects of AMD pathology. 
Such biomarkers could also serve as the long sought-after variable needed to monitor 
treatment effects in future clinical trials for AMD.   
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3.2 Results 
Study design 
We applied a three stage design to identify significantly associated cmiRNAs. First, RNASeq 
was performed to screen for miRNA candidates in 9 cases and 9 controls from the 
Regensburg study. The cmiRNAs with a nominal significance of p > 0.1 were then validated 
in an unrelated set of 45 NV cases and 68 controls from the Regensburg study (Table 7). 
Finally, candidate cmiRNAs with a nominal significant association (p < 0.05, adjusted or 
unadjusted for glaucoma) and an odds ratio above 2 or below 0.5 were then replicated in a 
population based study (Cologne study, Table 7) consisting of 75 NV cases and 70 controls. 
In total, the combined study included 129 patients with NV AMD and 147 AMD-free controls 
(Table 7). Additionally, 59 AMD patients with pure GA were assessed for candidate 
cmiRNAs to test for specificity of the findings in NV AMD. 
 
Table 7. Summary characteristics of the study 
 
Regensburg  Bonn Cologne  
Study type Case/Control Case/Control Population based 
Number of individuals 131 18 186 
Controls 77 0 70 
Cases 54 18 116 
Geographic atrophy 0 18 41 
Neovascular AMD 54 0 75 
Mean age cases (S.D.) [years] 75.15 (6.75) 74.60 (8.70) 80.22 (9.24) 
Mean age controls (S.D.) [years] 73.26 (8.00) - 78.44 (8.76) 
Female cases [%] 59.3 61.1 56.9 
Female controls [%] 54.5 - 55.7 
Glaucoma in cases [%] 11.1 5.5 NA 
Glaucoma in controls[%] 83.1 - NA 
 
Identification of cmiRNAs in NV AMD (discovery study) 
To search for candidate cmiRNAs, we first performed next-generation sequencing of 
cmiRNAs extracted from plasma of 9 AMD NV cases and 9 matched controls. Overall, in the 
18 samples we identified 203 different cmiRNA species. Of these, 10 cmiRNAs were 
significantly associated with late-stage NV AMD (puncorrected < 0.1) (Table 8). 
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Table 8.Association of circulating microRNAs with AMD in the Regensburg discovery 
study (9 NV cases and 9 controls) 
microRNA 
uncorrected 
 p-value 
mean cases 
 (95%CI)* 
mean controls 
 (95%CI)* 
hsa-miR-142-5p 0.012 1.21  (1.14-1.28) 1.00  (0.93-1.07) 
hsa-miR-192-5p 0.010 1.29  (1.20-1.38) 1.00  (0.91-1.09) 
hsa-miR-194-5p 0.028 1.28  (1.19-1.38) 1.00  (0.89-1.11) 
hsa-miR-26a-5p 0.082 0.90  (0.83-0.96) 1.00  (0.94-1.06) 
hsa-miR-301a-3p 0.084 0.83  (0.72-0.93) 1.00  (0.90-1.10) 
hsa-miR-335-5p 0.094 1.34  (1.17-1.50) 1.00  (0.84-1.16) 
hsa-miR-361-5p 0.056 0.74  (0.56-0.91) 1.00  (0.85-1.15) 
hsa-miR-424-5p 0.028 0.52  (0.30-0.73) 1.00  (0.84-1.16) 
hsa-miR-4732-5p 0.086 1.24  (1.12-1.36) 1.00  (0.88-1.12) 
hsa-miR-505-5p 0.048 1.29  (1.13-1.44) 1.00  (0.85-1.15) 
 
*95% confidence intervals 
Circulating miRNAs associated with NV AMD (replication study) 
To replicate the initial findings, qRT-PCR was performed for the significant 10 cmiRNAs in 
113 samples consisting of 45 NV AMD cases and 68 controls. Three cmiRNAs were 
identified (hsa-mir-301-3p, hsa-mir-361-5p, and hsa-mir-451a-5p) which showed (1) an 
association signal in the same direction as in the discovery study, (2) an odds ratio over 2 or 
under 0.5 and (3) an uncorrected (one-sided) p-value below 0.1. These three cmiRNAs 
showed reduced levels in the serum of CNV cases compared to AMD free controls. The 
association was robust also when adjusting for covariates such as age, gender, smoking 
(measured in packyears), genetic risk score (GRS) or levels of the housekeeping cmiRNA 
hsa-mir-451a-5p (Table 9). Of note, two cmiRNAs (hsa-mir-301-3p and hsa-mir-361-5p) 
were strongly confounded by glaucoma disease status and showed stronger association signals 
when adjusting for glaucoma.  
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Table 9. Sensitivity analysis in the Regensburg study by multiple logistic regression 
models 
covariate hsa-miR-301a-3p hsa-miR-361-5p hsa-miR-424-5p 
none 0.31 (0.10-0.86)* 0.50 (0.19-1.27) 0.28 (0.12-0.59)* 
age [years] 0.33 (0.13-0.92)* 0.49 (0.19-1.26) 0.27 (0.12-0.59)* 
packyears [years] 0.31 (0.10-0.86)* 0.50 (0.19-1.27) 0.27 (0.12-0.59)* 
gender 0.29 (0.09-0.82)* 0.48 (0.18-1.23) 0.28 (0.12-0.59)* 
genetic risk score 0.38 (0.10-1.33) 0.53 (0.13-2.12) 0.21 (0.07-0.56)* 
glaucoma 0.15 (0.04-0.54)*
1
 0.23 (0.06-0.78)*
1
 0.24 (0.08-0.65)* 
hsa-mir-451a-5p 0.38 (0.12-1.08) 0.68 (0.24-1.85) 0.35 (0.14-0.78)* 
 
1
 strong increase in association signal by adjusting for glaucoma as a covariate 
* statistically significant association (p < 0.05) 
 
 
Circulating miRNAs hsa-mir-301-3p, hsa-mir-361-5p, and hsa-mir-424-5p were then 
analyzed by qRT-PCR in an additional replication study (Cologne study) consisting of 75 NV 
cases and 70 controls. In concordance with the Regensburg study, we also found reduced 
levels of those three cmiRNAs in NV cases compared to controls in the Cologne study. The 
results of the two replications were pooled and jointly analyzed (Figure 5, Supplementary 
Table S4). We found raw (one-sided) p-values of 2.78x10
-7
, 4.09x10
-6
, and 4.75x10
-5
 for hsa-
mir-301-3p, hsa-mir-361-5p, and hsa-mir-424-5p, respectively. The p-values were adjusted by 
a conservative Bonferroni correction, assuming 203 statistical tests based on the number of 
microRNAs detected in the serum of cases and controls. After correction, the p-values for 
hsa-mir-301-3p, hsa-mir-361-5p, and hsa-mir-424-5p were 5.63 x 10
-5
, 8.03 x 10
-4
, and 9.64 x 
10
-3
, respectively. A cmiRNA profile including hsa-mir-301-3p, hsa-mir-361-5p, and hsa-mir-
424-5p was significantly associated with AMD in the combined study (129 NV AMD versus 
147 controls, p = 1.17*10
-8
) as well as in the Cologne study alone (75 NV cases and 70 
controls, p = 2.43*10
-5
). 
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Figure 5. Expression analysis of three cmiRNAs (hsa-mir-301a-3p, hsa-mir-361-5p and hsa-mir-
424-5p) in 129 NV AMD cases, 59 GA AMD cases and 147 healthy controls. Expression values for 
all samples were normalized by the median expression value in controls. Broad horizontal bars 
represent the mean value in each group (NV cases, GA cases or controls) for each cmiRNA. Smaller 
horizontal bars represent the 95% confidence intervals for each mean (see  Supplementary Table 
S4). Significant differences between means are indicated by asterix. * = pcorrected< 0.05; ** = pcorrected< 
0.005; *** = pcorrected< 0.0005 
 
Testing of cmiRNAs specificity in NV and GA AMD 
The expression of hsa-mir-301-3p, hsa-mir-361-5p, and hsa-mir-424-5p was analyzed by 
qRT-PCR in the serum of 59 GA AMD patients from the Cologne and Bonn study and 
compared to all controls (Figure 5, Supplementary Table S4). There was no statistically 
significant association of cmiRNA levels with GA compared to controls (pcorrected> 0.05). We 
also found no significant association of the cmiRNA profile including hsa-mir-301-3p, hsa-
mir-361-5p, and hsa-mir-424-5p with GA AMD versus controls (p = 0.084).  
Circulating miRNA hsa-mir-424-5p showed significantly higher levels in GA compared to 
NV (pcorrected< 0.005), while hsa-mir-301-3p and hsa-mir-361-5p were not significant 
(pcorrected>0.05). 
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Pathway analysis 
Pathway enrichment analysis was performed for 3,516 genes predicted by microT-CDS to be 
regulated by either hsa-mir-301-3p, hsa-mir-361-5p, or hsa-mir-424-5p. A total of 410 genes 
was predicted to be regulated by at least two of the three cmiRNAs and 35 genes were 
regulated by the three cmiRNAs jointly (Supplementary Figure S2). Evaluation with 
miRSystem implicated the canonical TGF-β and mTOR pathways as well as related pathways 
such as WNT signaling, focal adhesion, neutrophin signaling and insulin metabolism as the 
top regulated pathways. This is in agreement with the results of mirPATH v2.0, which 
implicated mTOR (KEGG ID: hsa04150, p < 10
-13
) and TGF-β pathways (KEGG ID: 
hsa04350, p < 10
-14
) as top regulated pathways (Table 10).  
 
Table 10. Pathway enrichment analysis performed with miRSystem and mirPATH2 
 genes observed / 
genes in pathway 
genetic association 
reported
1
 
Canonical pathway (ID²) miRSystem mirPATH2  
TGF-β signaling (hsa04350) 25/84 35/80 TGFBR1   [33] 
mTOR signaling (hsa04150) 16/52 33/60 VEGFA     [84] 
Neutrophin signaling (hsa04722) 38/127 - - 
WNT signaling (hsa04310) 48/150 -  
Focal adhesion (hsa04510) 43/199 - VEGFA     [84] 
Insulin signaling (hsa04910) 35/137 -  
Melanogenesis (hsa04916) 28/101 -  
 
1
 genetic associations were reported in or near genes in this pathway by genome wide association 
studies 
² KEGG pathway ID (http://www.genome.jp/kegg/) 
 
Functional characterization of candidate miRNAs in human endothelial cells 
MicroRNA hsa-mir-361-5p was shown earlier to influence the expression level of VEGFA 
[111] and thus should also influence angiogenesis. In order to test this hypothesis in vitro, we 
designed antisense oligoribonucleotides against hsa-mir-361-5p but also against hsa-mir-
301a-3p and hsa-mir-424-5p and performed tube formation assays with human umbilical vein 
endothelial cells (HUVEC). We show that a knockdown of hsa-mir-361-5p significantly alters 
tube formation in vitro (pcorrected< 0.05, Figure 6, Supplementary Figure S3 and 
Supplementary Figure S4). Knockdown of hsa-mir-301a-3p and hsa-mir-424-5p also 
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showed elevated average tube lengths, however, this was not statistically significant after 
adjustment for multiple testing (pcorrected> 0.05). 
 
 
 
Figure 6. In vitro tube formation assays in human endothelial cells. HUVEC cells were transfected 
with antagomirs for hsa-mir-301a-3p, hsa-mir-361-5p or hsa-mir-424-5p or with control antagomirs 
(see Supplementary Figure S3) and seeded on Geltrex/Matrigel. Cumulative tube length was 
quantified with Angiogenesis Analyzer implemented in ImageJ. Each measurement point indicates one 
independent transfection. Low Serum Growth Supplements (Life) were used as a positive inducer 
control. Representative images are shown in Supplementary Figure S4. Significant differences 
between means are indicated by asterix. * = pcorrected< 0.05; *** = pcorrected< 0.0005. 
 
Classification 
The raw AUC value for the cmiRNA profile was 0.727 for NV AMD and controls from the 
Regensburg study and 0.802 when restricting the analysis to NV AMD and controls from the 
Cologne study. Additionally, we used the weights obtained from the Regensburg study of 
each cmiRNA in the profile to predict the outcome (case or no case) in the Cologne study and 
found an AUC value of 0.722. To estimate non-parametric confidence intervals, we 
performed a 2,000 fold bootstrap analysis in the pooled study. The bootstrapped AUC value 
for the profile was 0.730 (95%CI: 0.544-0.877) indicating a good classification accuracy.  
 
 39 
 
3.3 Discussion 
To our knowledge, this is the first study to evaluate the relative abundance of cmiRNAs in the 
serum of late stage AMD patients. We identified three cmiRNAs (hsa-mir-301a-3p, hsa-mir-
361-5p, and hsa-mir-424-5p) which were significantly altered in NV AMD patients compared 
to AMD-free controls. Even when conditioned on covariates such as age, gender, smoking or 
genetic risk scores computed from known AMD-associated variants, the three cmiRNAs 
showed little alteration in their association strength, indicating a true association with late 
stage NV AMD. In contrast, there was no association of cmiRNAshsa-mir-301a-3p, hsa-mir-
361-5p, or hsa-mir-424-5p with GA AMD, suggesting subtype-specific cmiRNA profiles for 
late stage AMD. A global screening strategy similar to the one applied in this study may be 
suited to eventually characterize a GA AMD specific cmiRNA profile. 
Our initial discovery study comprised 9 NV AMD cases and 9 matched controls and 
identified several cmiRNA candidates with altered expression levels although none reached 
statistical significance after adjustment for multiple testing (n = 203 equivalent to the 
discovery of 203 cmiRNAs). A recent study compared cmiRNA levels in long-surviving 
versus short-surviving patients with lung cancer and found fold changes of significantly 
altered cmiRNAs between 1.60 and 7.15 [112] and Cohen’s effect sizes between 0.92 and 
1.54 which are considered to be large [113]. Given the number of samples in our discovery 
study, we calculated the power to detect comparable effect sizes after adjustment for multiple 
testing between 4.2% and 33.2%. This would imply a power to identify between 4 and 33 
cmiRNAs out of 100 in our discovery study at the assumed effect size or higher. To 
compensate for lower effect sizes, we increased our sample size to 276 individuals (129 NV 
cases and 147 AMD-free controls) in the replication and retested individually the top 10 
cmiRNAs hits from discovery. This uncovered a statistically significant association of NV 
AMD with cmiRNAshsa-mir-301a-3p, hsa-mir-361-5p, and hsa-mir-424-5p. 
Bioinformatical pathway analysis for genes suggested to be regulated by the NV AMD 
associated cmiRNAs were performed with two independent programs including the 
miRSystem and mirPATH v2.0. Both revealed concurring results and implicated the TGF-β 
and mTOR pathways in neovascular AMD pathology. Interestingly, this is in agreement with 
a recently published GWAS which also implicated the TGF-β and the mTOR pathways in late 
stage AMD by identifying risk associated genetic variants near or within the genes encoding 
the transforming growth factor, beta receptor 1 (TGFBR1) and the vascular endothelial growth 
factor A (VEGFA)[33,84]. The TGF-β as well as the mTOR pathway are involved in cellular 
responses to stress and injury and also regulate angiogenesis. Consequently, we performed in 
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vitro tube formation assays and reduced the levels of hsa-mir-424-5p, hsa-mir-301a-3p, and 
hsa-mir-361-5p by antisense oligoribonucleotides to evaluate the impact of decreased miRNA 
levels on angiogenesis. Knockdown efficiency reduced microRNA levels in the test system on 
average by about two-fold. Antisense treatment of hsa-mir-361-5p lead to a significant 
increase in tube formation and, thus, angiogenesis in vitro. Results for hsa-mir-424-5p and 
hsa-mir-301a-3p revealed a similar direction of effect but were not statistically significant due 
to correction for multiple testing. Together, the data are promising and support our 
bioinformatical analyses. 
Additionally, pathways closely related to the mTOR pathway were implicated by our analysis 
including WNT signaling, focal adhesion, neutrophin signaling and the insulin pathway. 
These pathways are involved in (neural) cell survival and therefore are reasonable candidate 
pathways for the pathogenesis of AMD. However, so far no genetic association with late stage 
AMD was observed for any genes associated with these signaling pathways. In this context, it 
should be noted that until now only few studies evaluated a genetic association for 
progression and severity of AMD [114,115]. These studies mainly focused on strong (and 
known) signals associated with increased risk for AMD and therefore may have missed 
possible existing associations. The present study has now identified cmiRNAshsa-mir-301a-
3p, hsa-mir-361-5p, and hsa-mir-424-5p as new biomarkers for late stage neovascular AMD. 
Furthermore, our data show that these biomarkersare not associated with GA AMD implying 
that different biomarkers and thus different biological pathways are likely involved in 
subtype-specific manifestations of late stage AMD. If confirmed, this could have major 
implications for designing treatment regiments for AMD.  
A recent study investigated a treatment option for patients with stroke by increasing a disease-
related reduction in plasma levels of hsa-mir-424-5p [116]. In an inducible mouse model of 
acute stroke which also revealed a down-regulation of hsa-mir-424-5p in plasma as well as in 
brain, lentiviral overexpression of hsa-mir-424-5p in the murine brain prior to induction of 
ischemic stroke significantly lowered the infarct volume as well as the brain edema levels 
[116]. A similar approach could be envisioned for treating AMD lesions. The identification of 
cmiRNAs that are dysregulated in NV AMD patients, now offers a number of novel starting 
points for therapeutic regimens. For example, such targets could be the genes that are 
regulated by the cmiRNAs or, alternatively, could directly address the dysregulated cmiRNAs 
itself. Specifically, the latter approach would initially entail prescreening of patients for 
altered cmiRNAs levels. Reduced expression of a diagnostic cmiRNA (as pre-microRNA or 
mature microRNA) could be supplemented by lentiviral transduction, nano-particle aided 
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transfection or by delivery of the dysregulated cmiRNA via synthetic microRNAs in artificial 
exsosomes. Therapies to modify up- or down-regulated genes are also conceivable. This could 
be done by using small molecules to influence gene activity [117], protein activity and 
stability [118] or by targeting proteins or interacting proteins with specific antibodies [119]. 
 
In summary, this study has identified three cmiRNAs with a significantly altered expression 
profile in the serum of NV AMD patients when compared to AMD-free control individuals. 
This finding opens up a number of new avenues in understanding disease mechanisms and 
designing targeted treatment options. Another important aspect of our finding pertains to 
monitoring treatment effects in clinical trial settings. Although proof of concept is still 
waranted, measuring drug responses as a means of measuring changes in the cmiRNA profil 
from blood samples of AMD patients may proof a direct and little invasive approach in the 
future.  
 
3.4 Materials and Methods 
Ethics statement 
This study followed the tenets of the declaration of Helsinki and was approved by the Ethics 
Review Board at the University of Regensburg, Germany (ID: 12-101-0241), University of 
Bonn, Germany and University of Cologne, Germany. Informed written consent was obtained 
from each proband after explanation of the nature and possible consequences of the study. 
 
Recruitment of AMD cases and control individuals 
The case-control sample included 54 individuals with seemingly non-familial NV AMD and 
77 age- and gender-matched AMD-free controls from the Regensburg study, 116 cases and 70 
controls from the Cologne study, and 18 GA AMD cases from the Bonn Eye Clinic (Table 7). 
Inclusion and exclusion criteria have been described elsewhere [33,65,67,120]. 
 
Genotyping of samples 
Genotyping was carried out as described elsewhere [58]. Briefly, genomic DNA was 
extracted from peripheral blood leukocytes. Ten single nucleotide polymorphisms (SNPs, 
Supplementary Table S5) were genotyped either by direct sequencing, restriction enzyme 
digestion of PCR products (RFLP) or TaqMan SNP Genotyping (Applied Biosystems, Foster 
City, USA).  
  
 42 
 
Isolation of cmiRNAs from stabilized blood samples and serum 
To reduce degradation of microRNAs and other RNA species [121], for the Regensburg and 
Bonn samples peripheral venous blood was drawn in PAXgene Blood RNA tubes 
(PreAnalytiX GmbH, Hombrechtikon, CH) and immediately stored at -80°C. To isolate RNA, 
tubes were thawed at room temperature on a rocker and centrifuged for 5 minutes at 1500 rcf 
at 4°C. The RNA isolation was carried out with the mirVANA microRNA isolation kit 
(Ambion, Austin, TX, USA) as described elsewhere [122]. Briefly, 300 µl of the supernatant 
were mixed with 600 µl of binding/lysis buffer. Then, 90µl of microRNA homogenate 
additive was added, thoroughly mixed for 30s and incubated on ice for 10 minutes. An equal 
amount of acid/phenol/chloroform (Ambion) was then added to each aliquot and vortexed for 
1 minute at maximum setting. The solution was spun for 10 minutes at 10,000g at room 
temperature. The resulting aqueous (upper) phase was mixed with 1.25 volumes of 100% 
ACS grade ethanol and passed through a mirVANA column in sequential 700µl steps. The 
columns were then washed according to the manufactures protocol and the RNA was eluted 
with 50µl nuclease-free water (preheated to 95°C). 
For the Cologne samples, RNA isolation from blood serum was carried out with the 
miRNeasy Serum/Plasma kit (Qiagen) according to the manufacturer’s recommendations. 
Typically, we used 200 ul of serum and eluted the RNA in 24ul of nuclease-free water. 
 
Sequencing of cmiRNAs and data analysis (discovery study) 
cDNA libraries were constructed using the Ion Total RNA-Seq v2 kit (Life Technologies) 
according to the manufacturers recommendations for 9 NV AMD cases and 9 control 
samples. The resulting cDNA libraries were purified by AMPure beads (Beckman Coulter), 
and their concentrations and sizes distribution were determined on an Agilent BioAnalyzer 
DNA high-sensitivity Chip (Agilent Technologies). Emulsion PCR and enrichment of cDNA 
conjugated particles were performed with an Ion OneTouch 200 Template Kit v2 DL (Life 
Technologies) according to the manufacturer's instructions. The final particles were loaded on 
an Ion 316 chip and sequenced on a Personal Genome Machine with 200bp read length (Life 
Technologies).  
The data obtained were analyzed with the mirDEEP2 package [123]. Briefly, all reads were 
mapped to the human genome. Reads that failed to align were excluded. Remaining reads 
were then mapped to the pre-microRNA and microRNA sequences obtained from mirbase.org 
(Release 19, August 2012) and quantified. Reads per microRNA were normalized to the 
overall number of reads and normalized to 100,000 reads. The data were transformed with the 
natural logarithm to obtain a normal distribution of expression values. In order to account for 
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batch effects in the data, we employed an empirical Bayesian batch effect correction 
algorithm known as ComBat [124]. For each microRNA, mean values of cases were 
compared to mean values of controls via t-test. Nominal significant associations with a (two-
sided) p-value < 0.1 were considered for replication.  
 
Quantitative (q)RT-PCR and data analysis (replication study) 
Circulating miRNA was extracted from blood as described above and reverse transcription 
followed by qRT-PCR was performed according to Hurteau et al. [125]. Briefly, 10µl of 
purified cmiRNA solution were modified by E. coli Poly (A) Polymerase I (E-PAP) by the 
addition of a polyA tail (Ambion, Austin, TX, USA). Reverse transcription was performed 
with Superscript III reverse transcriptase (Invitrogen Carlsbad, CA) and a Universal RT 
oligonucleotide primer, which contains a polyT stretch of DNA that binds to the newly 
synthesized polyA tail (Supplementary Table S6). The RT solution was diluted 1:50, of 
which 4µl were used per qRT-PCR reaction. Each qRT-PCR master mix was prepared 
according to the protocol of the Power SYBR Green Master Mix (Applied Biosystems, 
Foster, CA, USA) and run on an ABI Viia-7 (Applied Biosystems, Paisley, UK). Each 
microRNA was assayed in triplicates. Primers that performed poorly (<50% qRT-PCR 
efficiency) were excluded from further analysis. We further excluded measurements with a 
standard deviation greater than 0.4 Ct values in the triplicates. In order to normalize the Ct-
values according to the amount of isolated RNA and reverse transcription efficiency, we used 
hsa-mir-451-5p as a housekeeping cmiRNA. This microRNA showed the least variance 
between cases and controls and within each group in our discovery study and was therefore 
regarded suitable as a housekeeper. The normalized Ct values of each individual were then 
normalized versus the median of the Ct values of the controls. We considered associated 
cmiRNAs with an odds ratio greater than 2 or lower than 0.5 for further replication. 
The standard student’s t-tests was applied to evaluate a statistically significant association as 
implemented in R [97]. In the final dataset, we adjusted the observed raw p-values (puncorrected) 
by a conservative Bonferroni correction (pcorrected). Adjusted p-values below 0.05 were 
considered significant. Sensitivity analysis was carried out by fitting logistic regression 
models adjusted for possible confounding variables. 
 
Target prediction for cmiRNAs 
We used miRSystem[126] and DIANA mirPATH v2.0 [127] to identify canonical pathways 
involved in AMD pathogenesis based on differentially regulated microRNAs. We used the 
default settings in miRSystem to identify target genes and to find canonical KEGG pathways. 
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With mirPATH v2.0, targets predicted by microT-CDS were selected with a threshold of 0.7. 
The intersection of pathways which showed an involvement of all investigated microRNAs 
(p-value threshold: 0.005, with Conservative Stats) was considered. We excluded KEGG 
pathways with more than 200 genes to increase specificity and to exclude pathways 
considered to be too general. Furthermore, we excluded validated cmiRNA targets as well as 
cancer pathways such as prostate cancer (hsa05215) or glioma (hsa05214), as the majority of 
the cmiRNA work has been in the field of oncology and thus cancer pathways are expected by 
design to be among the top findings. 
 
Classification of cases and controls 
Area under the curve (AUC) measurements were carried out with the function lroc from the 
package “epicalc” [100]. We used a bootstrap (n=2000) approach to calculate robust mean 
and confidence interval estimates for the AUC measurements by randomly selecting half of 
the cases and half of the controls (with replacement) and calculating the risk model with this 
sub-sample (training data). A randomly selected sample of half of the cases and half of the 
controls (with replacement) was then used to calculated the AUC (test data). 
 
In vitro angiogenesis assay 
Pooled human umbilical vein endothelial cells (HUVECs) were purchased from Life 
Technologies and cultured in Medium 200PRF with Low Serum Growth Supplement and 
Gentamicin/Amphotericin Solution (Life Technologies). Transfection of HUVECs was 
carried out as described in Bonauer et al. 2009 [128]. Briefly, cells were subcultured to 
passage 3 and grown until 70% confluent. 2`O-methyl antisense oligoribonucleotides against 
hsa-mir-424-5p (5’-UUCAAAACAUGAAUUGCUGCUG-3`), hsa-mir-301a-3p (5’-
GCUUUGACAAUACUAUUGCACUG-3’) or hsa-mir-361-5p (5’-
ACAGGCCGGGACAAGUGCAAUA-3’) or GFP (5’-
AAGGCAAGCUGACCCUGAAGUU-3`) were synthesized by VBC Biotech and 50 nM 
were transfected with GeneTrans II (MoBiTec) according to the manufacturer’s protocol. 
After 24h the medium was changed to full growth medium with supplements and antibiotics. 
48h after transfection, 3.5x10
4
 HUVECs of each transfection were sown onto one well of a 24 
well plate coated with 150μl Geltrex (Life Technologies). As a positive inducer control, cells 
were cultured in full growth medium with supplements. Total tube length was quantified after 
24 hours by measuring the cumulative tube length in four random fields (area in each field: 
2.25 mm²) using the Angiogenesis Analyzer in ImageJ [129]. In total, we performed between 
5 and 14 independent transfections for each knockdown or control experiment. In order to 
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assess the transfection efficiency, miRNAs were isolated with the mirVANA microRNA 
isolation kit (Ambion, Austin, TX, USA) according to the manufacturer’s protocol. cDNA 
synthesis and qRT-PCR was carried out as described above. 
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4. Clinical and genetic factors associated with progression of geographic 
atrophy lesions in age-related macular degeneration. 
 
This chapter is identical to the following publication currently in revision: 
Grassmann F, Fleckenstein M, Chew EY, Strunz T, Schmitz-Valckenberg S, Göbel AP, Klein 
ML, Ratnapriya R, Swaroop A, Holz FG, Weber BHF (2015) Clinical and genetic factors 
associated with progression of geographic atrophy lesions in age-related macular 
degeneration. PLoS One in revision 
 
Abstract 
Worldwide, age-related macular degeneration (AMD) is a serious threat to vision loss in 
individuals over 50 years of age with a pooled prevalence of approximately 9 %. For 2020, 
the number of people afflicted with this condition is estimated to reach 200 million. While 
AMD lesions presenting as geographic atrophy (GA) show high inter-individual variability, 
only little is known about prognostic factors. Here, we aimed to elucidate the contribution of 
clinical, demographic and genetic factors on GA progression. Analyzing the currently largest 
dataset on GA lesion growth (N = 388), our findings suggest a significant and independent 
contribution of three factors on GA lesion growth including at least two genetic factors 
(ARMS2_rs10490924 [P < 0.00088] and C3_rs2230199 [P < 0.00015]) as well as one clinical 
component (presence of GA in the fellow eye [P < 0.00023]). These correlations jointly 
explain up to 7.2% of the observed inter-individual variance in GA lesion progression and 
should be considered in strategy planning of interventional clinical trials aimed at evaluating 
novel treatment options in advanced GA due to AMD. 
 
4.1 Introduction 
Age-related macular degeneration (AMD) is a common cause of blindness in Western 
societies with an estimated prevalence for all forms of the disease to reach almost 8.7 % and 
prevalence rates higher in Europeans than Asians or Africans [18]. Well-founded estimates 
project the worldwide number of people with AMD in 2020 to 196 million and in 2040 to 288 
million [18]. In the near future, this will dramatically increase the individual as well as the 
socioeconomic burden of the disease.  
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AMD can progress in a succession of stages from an early to an intermediate and finally to a 
late form, where atrophic and neovascular subtypes are distinguished [130]. The early form is 
characterized by abnormalities at the level of the retinal pigment epithelium (RPE) and 
depositions of extracellular material located predominantly between Bruch’s membrane and 
the RPE [131]. As this material accumulates, it becomes recognized clinically as individual 
drusen deposits. When drusen progress in size to greater than 125 microns in diameter, they 
are designated as large drusen and the eye is classified as having intermediate AMD. Drusen 
may become confluent and be associated with RPE hyper- and hypopigmentation. The 
presence of large drusen is a strong indicator of increased risk to develop a late form of the 
disease [132] which can manifest as geographic atrophy (GA), involving a gradual 
degeneration and disappearance of RPE, photoreceptor cells and the choriocapillaris layer of 
the choroid in the central retina. Another form of late stage manifestation is the exudative or 
neovascular phenotype, which is accompanied by choroidal neovascularisation (CNV) with 
subpigmentepithelial, subretinal and/or intraretinal extracellular fluid accumulation evolving 
to retinal scarring if left untreated [133]. Both late stage disease manifestations can exist at the 
same time in the same eye or mixed with neovascular AMD in one eye and GA in the fellow 
eye. While CNV development may be associated with rapid functional impairment, GA 
typically progresses slowly and eventually may extend beyond the macular area of the retina 
[133]. While intravitreal administration of anti-vascular endothelial growth factor agents are 
beneficial for the treatment of neovascular AMD [134], there is no proven therapy for GA. 
 
The proportion of GA in late stage AMD is approximately 35-40% [19,20]. While the overall 
incidence of the neovascular form is more frequent, GA occurs more common in individuals 
over 85 years of age [20]. This further emphasizes the impact of GA on ageing populations, 
and underscores the need of effective treatment to prevent, slow or cure the disease.  
 
GA lesions usually expand with an average growth rate of about 1.3 to 2.6 mm² per year 
[115,135–137] and may ultimately result in severe central vision loss [138]. While meta-
analysis of genome-wide association studies for advanced stage AMD has identified at least 
19 loci [33] and biological pathways underlying AMD are slowly getting recognized [40], 
limited information is available about the influence of genetic, demographic and clinical 
factors on GA growth. One study reported a significant contribution of a common, AMD risk 
associated haplotype in 10q26 (ARMS2/HTRA1 locus) on GA progression as measured by 
lesion size [115], although this correlation was not replicated in two subsequent studies of 
similar sample size [139,140]. This inconsistency can be ascribed to a number of specifics in 
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the respective studies, e.g. related to imaging (color fundus photographs vs fundus 
autofluorescence), correction for initial lesion size [141] or different summarization of 
obtained growth rates [67]. Also, the effect of the presence of GA in the fellow eye was found 
to be a significant modulator of GA growth [137].  
 
Design and evaluation of state-of-the-art clinical trials in GA require knowledge on factors 
that contribute to the progression of atrophic lesions. To validate previous findings [115,137] 
and to identify novel factors correlated with GA lesion growth, we analyzed the currently 
largest dataset on GA and GA lesion growth by combining two available studies: (i) the 
Fundus Autofluorescence in Age-related Macular Degeneration Study (FAM) [142], a 
multicenter study conducted in Germany and (ii) the Age-Related Eye Disease Study 
(AREDS) conducted in the United States [135]. We validated earlier findings for variant 
ARMS2_rs10490924 and for the presence of bilateral GA. We also expanded the analysis and 
searched for novel genetic and demographic factors correlated with GA lesion growth. Taken 
together, our data provide evidence for significant correlations between GA lesion growth and 
ARMS2_rs10490924, C3_rs2230199 and the presence of GA in the fellow eye, respectively. 
These correlations are independent of each other and jointly explain up to 7.2% of the 
observed inter-individual variance of GA growth.  
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4.2 Results 
Study design 
Overall, we investigated the effect of five clinical/demographic variables as well as ten 
genetic factors on GA lesion growth in 529 eyes from 388 individuals in a three stage study 
design (Table 11). Each area measurement was root transformed to eliminate the dependence 
of the growth rate on the initial lesion size [141]. A single growth rate per individual was 
calculated by taking the means of all calculated growth rates for each individual. In a first 
step, we aimed to replicated the findings from an earlier study for risk haplotype on 10q26 
(ARMS2/HTRA1 locus) [115]. This study showed that the risk increasing allele at 
ARMS2_rs10490924 increased GA lesion growth rate. We then searched for significant 
correlations between GA growth and novel clinical and genetic factors in a discovery study 
including 86 randomly selected individuals (FAM study – discovery) and considered factors 
which showed a nominally significant correlation (Praw< 0.05) for further replication. 
Significant findings were replicated in two additional studies (FAM study – replication and 
AREDS – replication, N=302 individuals) and a meta-analysis was conducted to combine the 
effect sizes and standard errors from each individual study assuming a random effects model. 
The final P-values were adjusted by a conservative Bonferroni correction assuming 16 
independent statistical tests and corrected P-values (Pcorrected) below 0.05 were considered 
significant. Lastly, we fitted a multivariate linear regression model to evaluate the 
independence of significantly correlated factors. 
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Table 11. Summary characteristics of participating study populations 
  FAM - discovery FAM - replication ARED replication combined 
Imaging technique FAF FAF color fundus mixed 
Number of individuals 86 48 254 388 
Mean follow-up time (S.D.) [years] 3.19 (1.97) 2.77 (1.66) 5.21 (3.00) 4.46 (2.85) 
Mean interval between examinations  (S.D.) [years] 1.37 (0.86) 1.56 (1.22) 1.13 (0.37) 1.24 (0.68) 
Mean number of examinations (S.D.) 3.95 (2.86) 2.85 (1.61) 4.72 (2.83) 4.31 (2.78) 
Mean age (S.D.) [years] 75.47 (7.37) 76.77 (5.90) 70.27 (5.07) 72.22 (6.36) 
Mean growth [mm²/year] (S.D.) 1.62 (0.96) 1.34 (0.92) 1.55 (1.74) 1.54 (1.51) 
Mean √growth [mm/year] (S.D.) 0.28 (0.14) 0.28 (0.14) 0.32 (0.30) 0.30 (0.25) 
Mean ln (√growth [mm/year]) (S.D.) -1.40 (0.60) -1.43 (0.58) -1.54 (1.03) -1.50 (0.91) 
Patients with bilateral GA [%] 67.4 64.6 29.1 40.72 
Mean initial size (S.D.) [mm²] 6.53 (4.4) 5.03 (5.02) 2.96 (4.24) 4.01 (4.62) 
Fraction male [ %] 39.5 31.3 43.3 41.0 
 
FAF = fundus autofluorescence 
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Table 12. Correlation between genetic, clinical and demographic factors and GA growth 
 
 
1 
GRS computed with reduced (10 SNPs) set according to Grassmann et al. 2012 
2 
95% confidence intervals     
3 
P value from linear regression model without covariates  
4
 P value adjusted for multiple testing (Bonferroni correction) assuming 16 tests performed 
5
 P value for evidence of heterogeneity from random effects model 
6
 previously been shown to influence GA growth. We used the FAM study to replicate this finding  
 
FAM - discovery FAM - replication AREDS - replication Combined (random effects model) 
 
Effect 
size 
95% CI 2 P 3 
Effect 
size 
95% CI 2 P 3 
Effect 
size 
95% CI 2 P 3 
Effect 
size 
95% CI 2 P 3 Pcorr4 Pheter 5 
Gender 0,036 -0.228 - 0.300 0,788 - - - - - - - - - - - 
Age [years] 0,001 -0.016 - 0.019 0,866 - - - - - - - - - - - 
Initial size [mm²] 0,015 -0.015 - 0.044 0,325 - - - - - - - - - - - 
Genetic Risk Score1 0,037 -0.057 - 0.132 0,434 - - - - - - - - - - - 
CFH_rs1061170 -0,042 -0.233 - 0.148 0,660 - - - - - - - - - - - 
CFH_rs6677604 -0,181 -0.551 - 0.189 0,334 - - - - - - - - - - - 
CFH_rs800292 0,243 -0.048 - 0.534 0,100 - - - - - - - - - - - 
C3_rs2230199 -0,262 -0.455 - -0.070 0,008 -0,358 -0.635 - -0.081 0,012 -0,141 -0.340 - 0.057 0,162 -0,24 -0.358 - -0.114 1,50E-04 0,0024 0,4186 
ARMS2_rs104909246 0,149 -0.019 - 0.317 0,082 0,193 -0.016 - 0.402 0,069 0,194 0.017 - 0.370 0,032 0,176 0.072-0.280 8,80E-04 0,0141 0,919 
CFB_rs438999 0,054 -0.452 - 0.561 0,832 - - - - - - - - - - - 
CFB_rs4151667 0,113 -0.743 - 0.969 0,793 - - - - - - - - - - - 
APOE_rs7412 -0,195 -0.500 - 0.111 0,209 - - - - - - - - - - - 
APOE_rs429358 0,086 -0.216 - 0.388 0,574 - - - - - - - - - - - 
CFI_rs2285714 -0,146 -0.354 - 0.062 0,167 - - - - - - - - - - - 
bilateral GA 0,322 0.054 - 0.590 0,019 0,278 -0.09 - 0.647 0,135 0,333 0.055 - 0.611 0,019 0.317 0.148 - 0.485 2,30E-04 0,0037 0,9704 
No. of exams 0,006 -0.051 - 0.039 0,796 - - - - - - - - - - - 
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Influence of ARMS2_rs10490924 risk allele on GA growth 
Klein et al. [115] found a significant contribution of the ARMS2_rs10490924 risk allele on 
GA lesion growth in 114 individuals from AREDS. We expanded these analyses by 
calculating the correlation of the number of risk alleles at this variant with GA growth in an 
extended AREDS panel of 254 patients (Table 12). We found a nominally significant 
correlation (P = 0.032) and a positive slope (0.194, 95% CI: 0.017 - 0.370) consistent with the 
previous study [115]. The findings were replicated in both FAM studies (FAM - discovery and 
FAM - replication) and the obtained slopes and standard errors were pooled using a random 
effects model. The combined slope was 0.176 (95CI: 0.072-0.280) with a raw P-value of 
0.00088 (Table 12 and Figure 7). This correlation remained statistically significant after 
correction for multiple testing (Pcorrected = 0.0141) and no evidence for heterogeneity between 
the studies was found (Phet = 0.919). The correlation was visualized for the combined study (N 
= 388) by stratifying the patients according to their genotype (homozygous non-risk, 
heterozygous risk and homozygous risk) and plotting the growth rate for each individual 
(Figure 8). 
 
 
 
 
Figure 7. Forestplot representations of univariate linear regression models. Univariate linear 
regression models were fitted for variables ARMS2_rs10490924, C3_rs2230199 and bilateral GA for 
each study separately. Slope and standard errors obtained from the models of each study were 
combined by performing a meta-analysis assuming a random effects model. The combined estimates 
for slope and 95% confidence intervals (CI) were computed from the random effects model. In all 
analyses, no evidence was found for heterogeneity (Pheterogeneity> 0.05). 
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Figure 8. GA lesion growth rates for each individual in the combined study. The measured area of 
GA was square-root transformed. From the transformed area the growth rate was calculated per year in 
[mm/year]. Growth rates from each individual were then obtained by calculating the mean of all 
growth rates of the individual. If both eyes were affected, the mean of both eyes were calculated 
resulting in a single growth variable per individual. These individual growth rates were further 
transformed by the natural logarithm (ln) and were stratified either by A the genotype at 
ARMS2_rs10490924 or B the genotype at C3_rs2230199 or C the presence or absence of bilateral 
GA. 
 
Correlation of genetic factors with GA growth 
To estimate the contribution of additional genetic factors to GA lesion growth, we genotyped 
nine common AMD associated variants at 5 loci in FAM - discovery (Table 12 and 
Supplementary Table S7). The frequencies of the variants in FAM - discovery were 
comparable to those observed in AMD cases in other studies which have been shown to 
significantly and independently influence the risk for AMD [58]. In addition, we calculated a 
genetic risk score (GRS) to summarize the genetic risk of the individual participants. The 
average GRS in the discovery study was 1.96 (S.D. = 1.37) and thus slightly higher than the 
observed values for GA patients in a previous study [58]. 
 
In the discovery study, neither the genetic risk score nor most single genetic variants analyzed 
revealed a significant influence on GA growth rate (Praw > 0.05, Table 12) with the exception 
of variant C3_rs2230199 (Praw< 0.05). Interestingly, the risk increasing allele (C) at 
C3_rs2230199 reduced the growth rate with a slope of -0.262 (95% CI: -0.455 - -0.070). 
Thus, individuals who have an increased risk to develop AMD due to the risk increasing allele 
at C3_rs2230199 show a reduced rate of GA lesion growth when compared to individuals 
who do not carry risk increasing alleles. To further validate this finding, we replicated this 
correlation in FAM - replication and AREDS - replication. We found similar negative slopes 
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in both replication cohorts and pooled the findings in a mixed effects model (Figure 7). The 
random effects model had a slope of -0.236 (95% CI: -0.358 - -0.114) and demonstrated a 
highly significant correlation of the number of C3_rs2230199 risk alleles with GA growth 
(Praw = 1.5x10
-4
), which remained statistically significant after adjustment for multiple testing 
(Pcorrected = 0.0024). Additionally, we found no significant evidence for heterogeneity between 
the studies (Phet = 0.4186).  
 
Correlation of clinical and demographic factors with GA growth 
After root transforming the measured area prior to the calculation of the growth rates, a 
significant correlation between the initial lesion size (in [mm²]) or the root transformed initial 
lesion size (in [mm]) and the growth rate of the lesion was not observed (Table 12). We also 
found no significant correlation to gender, age or the number of examinations to determine the 
GA growth rate. However, we found a strong correlation between the presence of GA in the 
fellow eye (bilateral GA) and GA growth (Table 12), in agreement with a previous report 
[137]. The findings indicate a significant increase in GA growth in cases where GA is present 
in both eyes of an individual. The slope of the regression model was estimated to be 0.322 
(95% CI: 0.054 – 0.590) in the discovery study. To validate this finding, the effect of bilateral 
GA was investigated in the two replication cohorts. In each replication study, we found 
similar effect sizes in the same direction as observed in the discovery study. The findings 
were summarized in a meta-analysis of slopes and standard errors obtained from the 
individual studies (Figure 7). The random effects model showed a highly significant 
correlation (slope: 0.317, 95% CI: 0.148-0.485) of the presence of bilateral GA with GA 
growth (Praw = 0.00023), which remained significant after adjustment for multiple testing 
(Pcorrected= 0.0037, Table 12). Again, no significant evidence for heterogeneity between the 
studies was found (Phet = 0.9704). The growth rates for each individual were stratified 
according to the presence or absence of bilateral GA and were visualized in a jitterplot 
(Figure 8).  
 
Multivariate linear regression models 
After correlating risk alleles at ARMS2_rs10490924 and presence of bilateral GA with GA 
lesion growth and identification of a novel genetic variant (C3_rs2230199) in the univariate 
regression analysis, we further evaluated the possibility that one of these factors influences or 
confounds the correlation with the other factors. We therefore fitted a multivariate linear 
regression model for each of the three studies and all three studies combined with the three 
identified factors in the same model (Table 13).  
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Table 13.  Multivariate linear regression analysis of factors significantly correlated to 
GA growth 
 Factors included in multivariate linear regression models  
 ARMS2_rs10490924 C3_rs2230199 bilateral GA P
1
 
FAM  
discovery 
0.131 
(-0.033 - 0.295) 
-0.239  
(-0.429 - -0.049) 
0.341  
(0.084 - 0.598) 
0.0014 
FAM 
replication 
0.200  
(-0.008 - 0.407) 
-0.401  
(-0.708 - -0.094) 
0.244  
(-0.097 - 0.585) 
0.0089 
ARED  
replication 
0.205  
(0.031 - 0.380) 
-0.168  
(-0.363 - 0.028) 
0.362  
(0.087 -0.639) 
0.0039 
All  
combined² 
0.174  
(0.072 - 0.276) 
-0.232  
(-0.355 - -0.109) 
0.326  
(0.163 - 0.488) 
5.83e-08 
 
1
 P value of linear regression model vs. null model 
2 
combined effect sizes were estimated from random effects model (meta-analysis) 
 
 
No significant evidence for a confounding effect of these factors on the correlation of the 
other factors was found (Pcorrected< 0.05). The adjusted slopes in the multivariate analyses 
differed on average by 0.048 (S.D. = 0.086) for ARMS2_rs10490924, 0.0946 (S.D. = 0.0913) 
for C3_rs2230199 and 0.034 (S.D. = 0.027) for bilateral GA when compared to the slopes in 
the univariate analysis. The combined regression model showed a highly significant fit (Praw = 
5.83x10
-8
) and an adjusted R² of 0.072, thus explaining up to 7.2% of the variation in the GA 
growth rate.  
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4.3 Discussion 
Here, we aimed to further elucidate the contribution of genetic as well as clinical and 
demographic factors on the rate of AMD GA lesion enlargement. We extended previous 
efforts [115,139,140] and now provide data on the largest available dataset on GA lesion 
progression so far. If both eyes were affected, the previous studies either included only one 
eye at random [115,140] or pooled the data for both eyes [139]. Here, we chose to combine 
the growth rates observed for the two eyes of an individual to a single variable under the 
assumption that a germline genetic variant should influence lesion growth in a similar fashion 
in both eyes. And indeed, we and others report a high degree of concordance between GA 
growth rate in the two affected eyes of the patient [135–137,143,144]. Of noted, the ARED 
study reveals a lower occurence of bilateral GA which can be explained mainly by two 
findings. Firstly, the ascertainment strategy was different for AREDS and FAM. While the 
ARED study specifically recruited patients with unilateral late stage AMD at baseline, the 
FAM study protocol included both uni- and bilateral patients. Secondly, we observed a 
significantly lower mean age in the ARED study compared to the FAM study. As individuals 
with unilateral GA are much more likely to progress to advanced stages in the fellow eye than 
individuals without late AMD manifestations [145,146], we expect the number of bilateral 
GA cases to increase in the ARED study over time.  
 
A number of earlier studies have not reported a significant influence of genetic factors on GA 
lesion growth after adjustment for multiple testing [115,139,140]. Nevertheless, the 
correlation for C3_rs2230199 and ARMS2_rs10490924 presented in this report, was also 
suggested in a previous study which was based on a subsample of the present patient cohort 
[139]. However, the correlation in the previous work was not statistically significant after 
adjustment for multiple testing. Furthermore, in the FAM study several eyes were excluded 
from the current anaylsis which exhibited FAF phenotypes reminiscent of monogenetic 
diseases (e.g. GPS-FAF pattern [31] or CACD-FAF phenotypes [147]). In addition, we note 
that previous studies usually did not account for the large influence of the initial size of the 
lesion on the rate of progression possibly confounding the analyses. By root transforming the 
measured GA areas, we eliminated this problem. Furthermore, the present study included 
more than twice the number of participants than each single previous study and, thus, had a 
much higher power to detect significant correlations.  
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Our data confirm a significant correlation between GA lesion size and the number of risk 
alleles at ARMS2_rs10490924, a variant which represents the AMD risk haplotype at the 
ARMS2/HTRA1 locus [148]. As the functional gene at this locus has not yet been identified 
[149], it is inappropriate to speculate about the mechanisms involved by which this locus may 
contribute to both the development as well as the progression of the disease.  
 
At the C3 locus, the risk increasing allele at C3_rs2230199 reduced the growth rate of GA 
lesions. As the risk increasing allele at C3 results in reduced levels of CFH binding and thus 
in overly active complement [150], the observed statistical correlation between lesion size and 
C3 risk variant is inverse to findings for AMD risk and C3 risk variant and thus rather 
counter-intuitive. Complement activation is generally thought to be associated with increased 
inflammation due to priming [151] and activation of microglia [152] and as such would be 
expected to be associated with faster disease progression. On the other hand, several studies 
demonstrated low levels of inflammation to be beneficial: (i) C3 knockout mice (C3
-/-
) 
implicated the complement system in neurogenesis [153] by showing that increased levels of 
complement activation promoted neurogenesis in healthy and diseased neuronal tissue; (ii) in 
the presence of immune cells low levels of complement activation revealed neuroprotective 
properties [154] and (iii) properdin, the only positive regulator of the alternative complement 
pathway, was found to be a protective factor in inflammatory diseases, thus shedding new 
light on the complement activation in neurodegenerative and inflammatory diseases [155]. 
Taking these findings into account, active neurogenesis and neuroprotection due to increased 
complement activation could counteract neurodegenerative activities in GA and thus could 
reduce lesion growth [156,157]. 
 
Our study replicated an earlier report on the influence of disease status of the fellow eye on 
GA lesion growth [137]. We demonstrate that (i) the slope, and thus the effect size, for 
bilateral GA is virtually the same in all cohorts analyzed in this study and (ii) that this 
correlation is independent of C3_rs2230199 and ARMS2_rs10490924. The 
ARMS2_rs10490924 variant increases the risk of progression from early to late AMD [158] as 
well as the growth rate of GA lesions. Thus, this variant may explain the increased growth in 
bilateral GA patients by (i) promoting the onset of GA in the fellow eye and (ii) increasing the 
growth rate of the lesion. However, in the multivariate model, both variables (ARMS2 variant 
and bilateral GA) show an independent correlation with GA growth. Additionally, no 
significant association of ARMS_rs10490924 is detected with the presence of bilateral GA in 
the combined dataset (ORAllele: 0.810, 95% CI: 0.606 – 1.078) or in any individual study 
 58 
 
analyzed. Furthermore, the risk increasing alleles at C3_rs2230199 are independently 
correlated with a decreased progression rate.  This finding argues strongly against a 
confounding effect of risk increasing genetic factors on the increased growth rate observed in 
bilateral GA patients, specifically, as risk increasing alleles at C3_rs2230199 reduce GA 
lesion growth. As no significant association is observed between C3_rs2230199 risk alleles 
and the presence of bilateral GA (ORAllele = 1.087, 95% CI: 0.788 – 1.498), other factors must 
influence the onset of GA in the fellow eye and explain the increased growth rate in bilateral 
GA. 
 
In summary, our findings reveal a significant and independent contribution of at least two 
genetic factors and the presence of GA in the fellow eye to GA lesion growth. Our studies 
have an impact on design and evaluation of future clinical trials aimed at testing novel 
treatment approaches for GA. These factors can greatly confound the outcome, particularly 
when GA growth rate is the main outcome parameter. As the area and growth rate of GA 
lesions do not necessarily correlate with visual acuity due to the frequently observed 
phenomenon of foveal sparing over a long period of time [138], it is difficult to draw any 
conclusion from our data on how long the patient’s vision can be retained. Future studies will 
be needed to evaluate the impact of genetic and clinical factors on visual perception. 
 
4.4 Material and Methods 
Ethics Statement  
The study followed the tenets of the Declaration of Helsinki and was approved by the local 
Ethics Review Board at the University of Bonn (ID: 082/04) and the NIH (IRB operates under 
FWA00005897 and the IRB Blue Panel, IRB00005894). Informed written consent was 
obtained from each patient after explanation of the nature and possible consequences of the 
study. 
 
Study characteristics 
The study characteristics are summarized in Table 11. For screening (FAM - discovery) and 
initial validation (FAM - replication), we included a total of 201 eyes from 134 patients from 
the Fundus Autofluorescence in Age-Related Macular Degeneration (FAM) study 
(www.clinicaltrials.gov: NCT00393692) [139]. To validate the findings (AREDS - 
replication), we included 328 eyes from 254 patients from the Age-Related Eye Disease Study 
(AREDS) [115]. 
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Classification of geographic atrophy 
From the FAM-study, eyes with central (within a 500 µm radius of the foveal center) and 
non-central GA were included into the analysis and were classified as ‘GA’ eyes. In general, 
GA is funduscopically defined as one or more well-circumscribed, usually more or less 
circular patch of partial or complete depigmentation of the RPE, typically with exposure of 
underlying large choroidal blood vessels [135]. GA due to AMD is further defined as sharply 
demarcated lesion with clearly reduced FAF of an extend of ≥ 0.05 mm² (approximately 
178µm in diameter) that does not correspond to exudative retinal changes (e.g. bleeding, 
exudates, fibrous scar) in an eye with funduscopically visible soft drusen and/or retinal 
pigment abnormalities consistent with AMD [137]. 
 
For the AREDS Study, GA associated with AMD was defined on stereoscopic color fundus 
photographs as sharply circumscribed areas of RPE depigmentation occurring in the macular 
area, generally considered to be circular in shape, with obvious visualization of the underlying 
choroidal blood vessels. The size must be as large as 1/8 disk diameter. An area of RPE 
atrophy within or adjacent to fibrosis or other features of neovascularization is not considered 
GA. Central GA is defined as the involvement of the center of the fovea, which was 
deteremined by retinal vascular configuration and pigment change. The digitized images were 
evaulated for GA area (mm
2
) using computerized planimetry [115]. 
 
Fundus autofluorescence (FAF) measurements and calculation of GA growth rate 
In the FAM study, FAF was measured and the lesion area was determined as previously 
reported [139] while AREDS analyzed the area of GA by color fundus photographs [115]. To 
eliminate the dependency of growth rates on baseline lesion size measurements, the individual 
area measurement was square root transformed (√area [mm]) [141]. We calculated lesion 
growth per examination interval by dividing the root transformed area by the time between 
examination points (in [years]), yielding a linear growth rate of the lesion (in [mm/year]). In 
case a growth rate was negative due to measurement imprecision, the growth rate for this 
interval was set at zero. The resulting growth rates per examination interval (√growth 
[mm/year]) were summarized for each individual by computing the mean of all growth rates 
for one individual. If data were available for both eyes of a patient, the mean of all computed 
growth rates from both eyes per individual were used. To generate normal distributed data and 
to reduce the bias from outliers, the growth rates per individual were log transformed with the 
natural logarithm (ln). This resulted in a single log-square-root growth rate variable per 
individual (ln(√growth [mm/year])), which was used for all subsequent analyses. 
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Clinical and demographic variables 
The age at first examination (in [years]), the gender and lesion sizes in one eye (unilateral 
GA) or both eyes (bilateral GA) at the last examination as well as the mean follow-up time of 
our patients and the mean interval between examinations (in [years], Table 11) were 
recorded. Additionally, we report the mean number of examinations each individual received 
(minimum: 2, maximum: 21) in order to exclude a confounding effect of the number of 
examinations on GA growth (Table 11). 
 
Genotyping and genetic risk score (GRS) 
Genotyping was performed as described [58,115]. Briefly, genomic DNA was extracted from 
peripheral blood leukocytes by established methods. Genotyping was performed by TaqMan 
SNP genotyping (Applied Biosystems, Foster City, USA) or by PCR followed by restriction 
enzyme digestion (New England Biolabs, Ipswich, USA) and subsequent restriction fragment 
length analysis (RFLP).The resulting genotypes were coded as the number of AMD risk 
increasing alleles (0, 1 or 2), i.e. alleles which are more frequent in cases than in controls 
(Supplementary Table S7) [58]. These variants were used to compute the genetic risk score 
according to Grassmann et al. 2012 with weights obtained from the parsimonious model 
based on 10 SNPs (Supplementary Table S7). 
 
Statistical analyses and visualization 
To visualize the raw data, we computed means and 95% confidence intervals of growth rates 
in different subgroups and used the ggplot function from the ggplot2 [159] package in R [97] 
for drawing jitterplots. Linear regression was done to evaluate correlations between clinical 
and genetic variables with GA growth and computed P-values and confidence intervals as 
implemented in R. Furthermore, obtained P-values were adjusted by a conservative 
Bonferroni correction multiplying the P-values with the number of (independent) tests 
performed. Since we conducted the study in a three stage setup, we subsequently combined 
the obtained slopes and standard errors from the three independent studies by using the 
function rma from the packages metafor  [160] and conducted the meta-analysis assuming a 
random effects model. This approach also allowed an assessment of heterogeneity between 
the estimates from each study. 
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5. A candidate gene association study identifies DAPL1 as a female-specific 
susceptibility locus for age-related macular degeneration (AMD). 
 
This chapter is identical to the following publication currently in press: 
Grassmann F, Friedrich U, Fauser S, Schick T, Milenkovic A, Schulz HL, von Strachwitz 
CN, Bettecken T, Lichtner P, Meitinger T, Arend N, Wolf A, Haritoglou C, Rudolph G, 
Chakravarthy U, Silvestri G, McKay GJ, Freitag-Wolf1 S, Krawczak M, Smith RT, Merriam 
JC, Merriam JE, Allikmets R, Heid IM, Weber BHF (2015) A candidate gene association 
study identifies DAPL1 as a female-specific susceptibility locus for age-related macular 
degeneration (AMD). Neuromolecular Medicine, in press 
 
Abstract 
Age-related macular degeneration (AMD) is the leading cause of blindness among white 
caucasians over the age of 50 years with a prevalence rate expected to increase markedly with 
an anticipated increase in the life span of the world population. To further expand our 
knowledge of the genetic architecture of the disease, we pursued a candidate gene approach 
assessing 25 genes and a total of 109 variants. Of these, synonymous single nucleotide 
polymorphism (SNP) rs17810398 located in DAPL1 (death associated protein-like 1) was 
found to be associated with AMD in a joint analysis of 3,229 cases and 2,835 controls from 
five studies (combined PADJ = 1.15×10
-6
, OR=1.332 [1.187-1.496]). This association was 
characterised by a highly significant sex difference (Pdiff = 0.0032) in that it was clearly 
confined to females with genome wide significance (PADJ = 2.62×10
-8
, OR = 1.541 [1.324-
1.796]; males: PADJ = 0.382, OR = 1.084 [0.905-1.298]). By targeted resequencing of risk and 
non-risk associated haplotypes in the DAPL1 locus, we identified additional potentially 
functional risk variants, namely a common 897bp deletion and a SNP predicted to affect a 
putative binding site of an exonic splicing enhancer. We show that the risk haplotype 
correlates with a reduced retinal transcript level of two, less frequent, non-canoncical DAPL1 
isoforms. DAPL1 plays a role in epithelial differentiation and may be involved in apoptotic 
processes thereby suggesting a possible novel pathway in AMD pathogenesis. 
 
5.1 Introduction 
Age-related macular degeneration (AMD) is a common condition of complex aetiology with 
major risk factors including age, gender, smoking, ethnicity and genetics [161]. While AMD 
ultimately represents the primary cause of blindness in developed countries [162], its early 
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form is less severe and characterized by the mere presence of drusen and pigmentary 
abnormalities in the macular area of the retina [163]. Late stage AMD manifests as choroidal 
neovascularization and/or geographic atrophy and is associated with irreversible central visual 
loss [59,161].  
 
Genetic predisposition plays an important role in AMD and is estimated to contribute up to 
70% of the disease risk [72]. To date, two major and several minor to moderate AMD 
susceptibility loci have been identified with per allele odds ratios ranging from 1.3 to 3.4 [33]. 
Of note, many of these loci suggest an involvement of inflammatory processes and impaired 
complement activation in AMD pathogenesis [34,47,75,78,80], a fact that has raised major 
interest in novel therapeutic approaches to address progression of the disease [164]. 
 
Genetic variants associated with complex diseases are usually identified by high-throughput 
genome-wide association studies of large numbers of cases and controls [165]. However, 
candidate gene studies with similar sample sizes normally have greater statistical power to 
detect genetic disease associations [166], especially for genes not covered efficiently by 
commercially available genotyping platforms [167]. 
 
In this study, we aimed to expand our current knowledge of the genetic architecture of AMD 
pathogenesis, following a candidate gene approach. In a well-powered case-control study, we 
screened 109 haplotype tagging variants in 25 genes for an association with late stage AMD. 
Attempts to replicate any positive findings in over 4,000 individuals from four previous 
studies revealed that variation in the DAPL1 gene is significantly associated with AMD. 
Importantly, this association is restricted to females and the variants of interest correlate with 
altered transcription levels of specific retinal isoforms of the DAPL1 gene. 
 
5.2 Results 
Association of 109 SNPs in 25 candidate genes with late stage AMD 
We first selected 25 genes and 109 haplotype tagging single-nucleotide polymorphisms 
(SNPs) for an initial analysis of 710 late stage AMD cases and 612 controls (GER1) (Table 
14 and Supplementary Table S8 and Supplementary Table S9). Criteria for candidate gene 
selection included one or a combination of the following: (i) causative involvement of the 
gene in phenotypically related retinopathies, (ii) known gene function compatible with 
suspected AMD pathogenesis, (iii) specific or predominant gene expression in cellular sites of 
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primary AMD pathology, i.e. the photoreceptor/retinal pigment epithelium (RPE)/choroid 
complex. All SNPs were tested for a significant deviation from Hardy-Weinberg equilibrium 
(p< 0.05) in all controls and in female and male controls separately. This identified three 
SNPs (RGR:rs2279227, rs4620343 and TRPM3:rs3812532) which were subsequently 
excluded from further analyses. Association tests adjusted for age and sex revealed a 
nominally significant association using logistic regression between AMD and three SNPs 
(DAPL1: rs17810398:C>T, P=0.016; RP1: rs9643828:T>C, P=0.037; CST3: rs2424577:C>T, 
P=0.028) (Supplementary Table S9). 
 
Replication of three nominally significant AMD associated candidate gene variants 
The three SNPs with a nominally significant AMD association were genotyped in an 
independent German replication sample of 996 late stage AMD cases and 645 controls 
(GER2). The disease association could be confirmed only for rs17810398 (P=0.0014), a 
synonymous SNP in the coding sequence of the death-associated protein-like 1 (DAPL1) gene 
(Table 15). Analysis of this SNP in three other studies (681/367 late stage cases/controls from 
US, 300/183 from UK and 542/1028 from Cologne, Table 14) yielded consistent results 
(Table 15). Combined analyses of the 3,229 cases and 2,835 controls yielded a P value of 
1.15 x 10
-6
 after adjustment for age, sex and study (Table 15). Given that 106 tests were 
performed, this result is significant at a significance level of 1.20 x 10
-4
 after Bonferroni 
correction. The risk allele frequencies were similar in all four studies (13.3-14.3 % in cases; 
10.3-12.4 % in controls) and the per-allele odds ratios (OR) was consistent in direction and 
magnitude (1.177 ≤ OR ≤ 1.530) with no indication for heterogeneity (I2 = 0).  
 
Imputation and replication of genetic variants at the DAPL1 locus 
We next imputed the genotypes of 20,422 additional SNPs around rs17810398 in GER1 study 
based on 8 tag SNPs in the DAPL1 locus. After quality control, 517 SNPs remained for 
analysis and we obtained association signals (Padj< 0.05) that were confined to a 154 kb 
region devoid of any gene other than DAPL1 (Figure 9 and Supplementary Table S10).  
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Table 14.  Summary characteristics of participating study populations 
 
 
 
 
 
 
 
 
 
1 
Geographic Atrophy 
2 
Neovascular AMD 
3
 Individuals with both GA and NV in either the same eye or in different eyes 
  
  
Number of individuals 
 
Mean age (SD) [years] in 
 
Stage Study Cases GA 
1
 NV 
2
 GA&NV 
3
 Controls Total Study type cases controls 
Fraction 
male [%] 
1 GER1 
710 161 423 126 612 1322 
Case/Control 78.81 (6.64) 78.21 (5.28) 36.99 
2 GER2 
996 216 535 245 646 1642 
Case/Control 
76.15 (7.32) 73.05 (8.34) 37.72 
2 US 
681 165 516 0 367 1048 
Case/Control 79.08 (8.48) 74.57 (7.10) 39.79 
2 UK 
300 38 252 10 183 483 
Case/Control 78.45 (9.75) 74.53 (8.91) 34.78 
2 COL 
542 55 459 28 1028 1570 
Population based 75.49 (7.11) 69.51 (5.82) 42.93 
1+2 ALL 
3229 635 2185 409 2835 6064 
mixed 77.68 (7.78) 73.14 (7.49) 39.36 
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Table 15. Association between AMD and rs17810398:C>T and rs17810816:A>G in five independent studies computed by logistic 
regression adjusted for covariates (N=3229 cases and 2835 controls) 
 
1
 minor allele frequency 
2
 odds ratio (OR) and 95% confidence intervals (95% CI) 
* adjusted for age and sex 
** adjusted for age 
*** analyses were additionally adjusted for study 
 
Number of individuals All Females Males 
 
(Females/Males) MAF1 
  
MAF1 
 
 
MAF1 
 
  
Sample Cases Controls Cases Controls PADJ 
* OR (95% CI) 2 * Cases Controls PADJ 
** OR (95% CI) 2 ** Cases Controls PADJ 
d OR (95% CI) 2 ** 
rs17810398                             
GER1 710(455/255) 612(378/234) 0.133 0.106 0.028 
1.311  
(1.031-1.673) 0.134 0.098 0.026 
1.415 
 (1.046-1.930) 0.131 0.118 0.501 
1.147 
 (0.770-1.714) 
GER2 996(670/326) 645(352/293) 0.143 0.109 1.39E-03 
1.448 
(1.157-1.823) 0.150 0.090 5.64E-05 
1.891 
 (1.396-2.598) 0.127 0.132 0.957 
1.010  
(0.714-1.433) 
US 681(428/253) 367(203/164) 0.141 0.109 0.037 
1.366  
(1.024-1.838) 0.149 0.094 3.58E-03 
1.838 
 (1.233-2.804) 0.127 0.128 0.869 
0.964 
 (0.626-1.497) 
UK 300(193/107) 183(122/61) 0.145 0.104 0.047 
1.530  
(1.013-2.352) 0.155 0.102 0.044 
1.701 
 (1.026-2.900) 0.126 0.107 0.560 
1.238  
(0.613-2.611) 
COL 542(314/228) 1028(582/446) 0.137 0.124 0.199 
1.177  
(0.917-1.508) 0.131 0.126 0.234 
1.235 
 (0.870-1.746) 0.145 0.122 0.472 
1.139 
 (0.796-1.623) 
ALL*** 3229(2060/1169) 2835(1637/1198) 0.140 0.113 1.15E-06 
1.332  
(1.187-1.496) 0.144 0.105 2.62E-08 
1.541 
 (1.324-1.796) 0.131 0.124 0.382 
1.084  
(0.905-1.298) 
rs17810816                             
GER1 710(455/255) 612(378/234) 0.184 0.134 8.49E-04 
1.435  
(1.163-1.778) 0.183 0.124 0.0021 
1.526 
 (1.169-2.008) 0.185 0.152 0.147 
1.292 
 (0.916-1.832) 
GER2 996(670/326) 645(352/293) 0.179 0.145 4.92E-03 
1.335  
(1.093-1.636) 0.184 0.122 1.47E-04 
1.704 
 (1.300-2.256) 0.170 0.172 0.854 
0.972 
 (0.716-1.322) 
US 681(428/253) 367(203/164) 0.180 0.144 0.021 
1.370  
(1.051-1.797) 0.187 0.132 0.0085 
1.622 
 (1.139-2.346) 0.167 0.159 0.683 
1.089  
(0.725-1.646) 
UK 300(193/107) 183(122/61) 0.166 0.149 0.497 
1.144  
(0.779-1.693) 0.168 0.145 0.390 
1.231 
 (0.770-1.998) 0.162 0.158 0.944 
0.976 
 (0.503-1.938) 
COL 542(314/228) 1028(582/446) 0.188 0.159 0.072 
1.223  
(0.981-1.522) 0.175 0.156 0.139 
1.257  
(0.926-1.701) 0.205 0.162 0.242 
1.209 
 (0.879-1.660) 
ALL*** 3229(2060/1169) 2835(1637/1198) 0.180 0.148 1.76E-07 
1.318  
(1.188-1.462) 0.181 0.137 2.68E-08 
1.471 
 (1.285-1.687) 0.179 0.162 0.141 
1.129 
 (0.961-1.326) 
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Figure 9. Association with AMD of imputed and typed variants at the DAPL1 locus. Association 
signals of markers are shown by the log-P value from a logistic regression model (additive model 
adjusted for age and sex; y-axis) and are plotted against their physical position (x-axis). Stage 1 results 
(GER1 sample) are marked by filled (genotyped) and open triangles (imputed). Association signals of 
rs17810398 and rs17810816 in the pooled samples (3053 cases and 2737 controls) are indicated by 
blue and green diamonds respectively. 
 
Forty-eight imputed SNPs revealed a more significant association than rs17810398 
(PADJ=0.027), with a minimum PADJ of 0.014 at rs74923781 and its perfect proxy 
rs17810816:A>G (r² = 1 based on 1000 Genomes CEU samples) in DAPL1 intron 4. De novo 
genotyping of rs17810816 gave consistent associations in terms of its direction in all four 
replication studies with a nominal significance (Padj≤0.05) attained in GER2, US and COL. 
There was no indication of heterogeneity (I
2 
= 0). The combined analysis yielded a Padj of 1.76 
× 10
-7
 after adjustment for age, sex and study (Table 15 and Figure 9). Linkage 
disequilibrium (LD) and haplotype analysis in the GER1 study revealed rs17810398 and 
rs17810816 to be in moderate LD in controls (r
2
 = 0.55, Supplementary Figure S5). 
 
Variants rs1710398 and rs17810816 show a female specific association 
Stratifying the combined analysis by phenotype, including AMD subtype and age-group, 
revealed no subgroup-specific association for rs17810398 or rs17810816 (Figure 10). 
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However, stratification by sex revealed that the association signals of both SNPs were 
confined to females with genome-wide significance (rs1710398: PADJ= 2.62 × 10
-8
, 
rs17810816: PADJ= 2.68 × 10
-8
). No AMD association was evident in males (rs1710398: 
PADJ= 0.382, rs17810816: PADJ= 0.141; Figure 10, Supplementary Figure S6, Table 15). 
The difference between sex-specific ORs was statistically significant (rs17810398: Pdiff = 
0.0034, rs17810816: Pdiff = 0.014) at the 5% level and was observed in all studies analyzed 
(Supplementary Figure S6, Table 15). In the combined study, the minor allele frequency 
(MAF) of rs17810398 was lower in female controls than in male controls and higher in 
female cases than in male cases. A similar, albeit less pronounced effect was seen for variant 
rs17810816. 
 
 
 
Figure 10. Subgroup analysis in the combined study of candidate SNPs rs17810398 and 
rs17810816 in the DAPL1 gene. Odds ratios and corresponding 95% confidence intervals are given 
with the size of each rectangles representing the respective number of cases. AMD phenotypic 
subgroups comprise patients with geographic atrophy (GA), and neovascular AMD (NV) and both 
latestage forms (GA&NV). 
 
DAPL1 encodes four isoforms in retina/RPE 
For expression analysis of the DAPL1 locus, we scrutinized expressed sequence tags (EST) 
and identified three entries (GenBank accession numbers: DA417123 [thalamus], BG818506 
[oligodendroglioma], BI016096 [lung tumor]) that suggested alternative splicing of DAPl1 
gene products. A potential correlation between rs1710398 and rs17810816 genotype and the 
occurrence of DAPL1 isoforms was investigated by 3’-RACE experiments on four unrelated 
RPE/retina tissue samples, two of which were homozygous (ID_16 and ID_17 ) for the non-
risk alleles and two of which were heterozygous (ID_13 and ID_14) for the risk alleles. After 
plasmid cloning of PCR products, we sequenced 1,200 cDNA clones and identified a total of 
24 specific DAPL1 isoforms four of which (referred to as isoforms 1 to 4, Supplementary 
Figure S7) were consistently found in all samples. The most abundant isoform 1 (65–77 % 
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over all samples) corresponded to the DAPL1 reference sequence (NM_001017920). Isoform 
2 (6–12 %) and 3 (3–6 %) had not been reported before, whereas isoform 4 (3–6 %) matched 
EST BG818506 (Figure 11A and Figure 11B). Sequences corresponding to DA417123 and 
BI016096 were not detected in the RPE/retina RNA samples. RT-PCR analysis confirmed the 
expression of isoforms 1 to 4 in human tissues with isoform 4 likely being specific for 
RPE/retina (Supplementary Figure S8). 
 
 
Figure 11. Functional consequences for isoform expression of DAPL1 variants. A. Exon/intron 
structure of four frequent DAPL1 isoforms (gene orientation is from left to right). SNP positions are 
marked by vertical dotted lines. B. Frequency of the four isoforms as determined from sequencing 
1,200 cDNA clones that were obtained after 3’-RACE of four unrelated RPE/retina tissue samples 
either homozygous (ID_16, ID_17) or heterozygous (ID_13, ID_14) for the non-risk alleles of 
rs17810398 and rs17810816. C. Distribution of rs17810398 alleles in heterozygous RPE/retina tissue 
samples ID_13 and ID_14 (Supplementary Table S11). Statistically significant deviations from the 
reference transcript (i.e. isoform 1) are indicated by asterisks (P<0.0001). 
 
Resequencing of candidate regions at the DAPL1 locus 
In a search for additional risk variants at the extended DAPL1 locus, we re-sequenced over 10 
kb of intronic/exonic sequences in each of 12 probands homozygous for AMD risk alleles 
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rs17810398:T and rs17810816:G and eight probands homozygous for AMD non-risk alleles 
rs17810398:C and rs17810816:A (Supplementary Figure S7). Due to its extensive 
saturation with repeat structures, resequencing of the genomic region around DAPL1exon 4 of 
HQ179937 (isoform 4) was carried out for three individuals following sub-cloning of PCR 
fragments. In total, we detected 33 sequence variants (Supplementary Table S12, 
Supplementary Table S13), three of which (rs75277023:G>A, rs6146986, and 
rs144087548:A>T) were in strong LD with rs17810398 and rs17810816 (r
2
 in controls > 0.9, 
Supplementary Figure S5). Variants rs6146986 and rs144087548 were of particular interest 
because the minor allele of the former represents a common 878 bp deletion in DAPL1 intron 
2 and the latter was predicted to affect a putative binding site of an exonic splicing enhancer 
(serine/arginine-rich splicing factor 1, SRSF1), 24-bp upstream of the most 3’ exon shared by 
isoforms 3 and 4 (Supplementary Figure S7).Genotyping of rs6146986 and rs144087548 in 
the GER1 study confirmed their strong LD with rs17810398 (rs6146986: r² = 0.93) and 
rs17810816 (rs144087548: r² = 0.77) (Supplementary Figure S5, Table 16). Additional 
cDNA resequencing of eight RPE/retina tissues heterozygous for rs17810398 did not reveal 
additional coding variants (Supplementary Table S14). 
 
Table 16. Association results in the GER1 study for four functional candidate SNPs in 
DAPL1. 
SNP 
Position on 
chr 2 [bp / 
hg19] 
Major 
allele 
Minor 
allele 
MAF² Odds Ratio 
(95% CI) 
P
1
 R2³ 
Cases Controls 
rs17810398 159,660,870 C T 13.3% 10.5% 
1.314 
(1.033-1.680) 
0.027 Ref. 
rs6146986 
159,661,997-
159,662,874 
- 
878 bp 
deletio
n 
13.5% 10.7% 
1.310 
(1.033-1.667) 
0.027 NA 
rs17810816 159,671,992 A G 18.4% 13.4% 
1.435 
(1.163-1.778) 
8.49 × 10
-4
 0.866 
rs144087548 159,718,894 A T 17.4% 13.8% 
1.296 
(1.047-1.609) 
0.018 0.735 
 
1
P from logistic regression adjusted for age and sex.  
² MAF: minor allele frequency calculated in 710 cases or 612 controls 
³ R² to top variant based on CEU samples from the 1000 genomes project 
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AMD associated variants are correlated to a differential expression of DAPL1 isoforms 
Samples heterozygous for rs17810398 (ID_13 and ID_14) were characterized by a 
significantly different abundance of non-risk and risk isoforms 3 and 4 (P < 10
-4
). This was 
not the case for isoforms 1 and 2 (Figure 11C, Supplementary Table S11). DAPL1 isoform 
expression in RPE/retina was further evaluated in vivo by semi-quantitative cDNA 
sequencing (Figure 12). Of 39 unrelated RPE/retina tissues available, seven were 
heterozygous for AMD associated variants rs17810398, rs6146986, rs17810816, and 
rs144087548. In agreement with our 3’-RACE data, these samples revealed differential 
expression of isoforms 3 and 4 but not isoforms 1 and 2 (Figure 12). Interestingly, sample 
ID_11 was heterozygous for rs17810398, but homozygous for the non-risk alleles of 
rs6146986, rs17810816, and rs144087548. In this sample, expression intensities of isoform 3 
and 4 alleles were equal excluding rs17810398 as a functional variant involved in the 
differential expression of isoforms 3 and 4. This leaves rs6146986, rs17810816, rs144087548 
or an as yet unknown but correlated variant as the truly functional risk variant at the DAPL1 
locus. 
 
 
Figure 12. Semi-quantitative cDNA sequencing of eight RPE/retina tissue samples heterozygous 
for synonymous coding SNP rs17810398:C>T. The chromatograms of the variant nucleotide at 
rs17810398 flanked by +/- 3 bp are shown for isoforms 1&2, 3, and 4. Isoforms were specifically 
amplified by three different exon-spanning primer combinations. Genotypes of the four candidate 
variants are given above the chromatograms. The sample heterozygous for rs17810398 but 
homozygous for the non-risk alleles of rs6416986, rs17810816, and rs144087548 is highlighted in red. 
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5.3 Discussion 
Here, we provide evidence that DAPL1 is an AMD-associated gene and that its disease 
association is female-specific. To our knowledge, this is a first study reporting a sex-specific 
genetic association with AMD at a genome wide significance level. Although lead SNPs 
rs17810398 and rs17810816 have been imputed into large GWAS data sets, neither variant 
has been identified before as AMD-associated [33]. This is likely due to the female specificity 
of the association as male/female ratios in multi-center GWAS tend to differ greatly between 
cohorts thereby potentially leading to reduced power. Behrens et al. [168] have 
methodologically shown that gender-stratified analyses greatly increase power to detect 
gender-specific effects. Additionally, we have also observed the female specific association in 
our population-based sample (COL study) only by adjusting the analysis for age. This further 
indicates that different study types increase the heterogeneity and therefore may lead to 
decreased power to detect this association.  
 
We also considered the possibility that age is a confounding factor in our study since (i) 
females are slightly older than males and (ii) cases are older than controls. If any of the 
variants would be correlated with longevity, this could potentially confound our analysis. 
However, we found no evidence for a correlation between either SNP or age, neither in cases, 
controls, females or males separately or analyzed jointly (P > 0.05). Additionally, we note that 
logistic regression analyses were adjusted for age in our analyses. Furthermore, two SNPs at 
the DAPL1 locus (rs9869 and rs10497199) were investigated in a recent study by [169]. For 
these two variants, the authors found no association with longevity (P > 0.5). Variant rs9869 
is weakly linked to markers rs17810398 (r² = 0.13) and rs17810816 (r² = 0.1) while 
rs10497199 is independent of either variant (r² < 0.1). Taken together, these findings have led 
us to exclude a confounding effect of age in our analysis. 
 
The observed association in the present study could eventually be explained by a population 
substructure in our cases or controls from the UK or US. Although we cannot definitely 
exclude such a possibility, it is of note that frequency and effect sizes of the two DAPL1 risk 
variants rs17810398 and rs17810816 (in males, females and jointly) observed in the UK and 
US study are similar to the frequencies observed in the combined German cohort (Table 15). 
The German samples derive from a genetically homogenous population from a small area in 
southern Germany. Homogeneity was estimated previously from genome-wide data available 
for a subset of cases [33]. From these data, we conclude that the US and UK study primarily 
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consists of Caucasians which are genetically similar to the German cohort and, if at all, 
population substructure may only exert a minor effect on study outcome. 
 
Although DAPL1 is evolutionarily conserved, only little is known about its function. It has 
been shown to be abundantly expressed in the retina/RPE transcriptome [170] as well as in 
epidermis, oesophageal epithelium, and tongue epithelium where it appears to be involved in 
the early stages of stratified epithelial differentiation [171]. Based upon strong amino acid 
sequence similarities, DAPL1 has also been connected to the death-associated protein (DAP), 
a basic, proline-rich protein of 15-kD molecular weight that acts as a positive mediator of 
programmed cell death upon induction by interferon-gamma [172]. Clarification of the 
cellular function of DAPL1 in the RPE/retina is required to allow more detailed insight into 
this novel pathway of AMD pathogenesis. 
 
We have shown that DAPL1 is present in a multitude of correctly spliced isoforms, two of 
which, isoforms 3 and 4, were specifically down-regulated in the presence of AMD associated 
alleles. Although we could not identify the causative variant at the DAPL1 locus, we excluded 
lead SNP rs17810398 as the presence of the T-risk allele in one patient (ID_11) had no 
influence on the transcript levels of isoform 3 or 4. Notably, the unique C-terminus of isoform 
4 encodes two potential transmembrane domains with significant homology to the rhodopsin-
like G-protein coupled receptor (GPCR) family. Another member of the GPCR family, the G 
protein-coupled estrogen receptor 1 (GPER), plays a role in intracellular signaling following 
estrogen binding and could provide a useful lead when searching for factors involved in sex-
dependent AMD risk. While at present we cannot explain the gender-specificity of the 
association with DAPL1, our results provide a starting point at a molecular level to investigate 
why AMD is more frequent in women than in men [173]. 
 
Taken together, we investigated 25 gene loci of interest to AMD pathology and excluded all 
but one from being disease-associated. Our data implicate DAPL1 as a novel gene involved in 
AMD pathology although the cellular functions of this gene and of its various differentially 
spliced transcripts remain elusive. Our study revealed a correlation between risk variants at 
rs17810398 and rs17810816 on the one hand and expression levels of DAPL1 isoforms 3 and 
4 on the other, the latter being specifically expressed in RPE/retina tissue. We also reported a 
significant sex difference of the effect of DAPL1 where only females showed an association 
signal at this locus. Although speculative at present, this sex difference may be explained by a 
role of DAPL1 variants in sex-specific signaling processes. Our findings add another piece to 
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the puzzle of the genetic architecture of AMD, which, once completed, should allow refined 
identification of individuals at risk for this disease. 
 
5.4 Materials and Methods 
Subjects 
Five independent studies were included in our study comprising a total of 3,229 unrelated 
Caucasian patients with clinically documented AMD (cases) and 2,835 unrelated individuals 
with comparable age range and ethnicity without signs of macular disease (controls) (Table 
14). All data were available for analysis at the analysis center in Regensburg.  
Discovery study GER1 (stage 1) included 710 AMD patients and 612 controls from the 
University Eye Clinic of Würzburg (Germany). The four replication studies (Stage 2) 
comprised (i) 996 AMD patients and 645 controls from the University Eye Clinics in 
München, Tübingen and Würzburg (Germany) (GER2); (ii) 681 AMD patients and 367 
controls from Columbia University (New York, USA) (US); (iii) 300 AMD patients and 183 
controls from the Royal Victoria Hospital (Belfast, UK) (UK); and (iv) 542 AMD patients 
and 1,028 controls from the Department of Ophthalmology at the University Hospital 
Cologne, Germany (COL). Cases and controls were examined by trained ophthalmologists. 
Stereo fundus photographs were graded according to standardized classification systems as 
described previously [58]. The study was conducted at all sites in strict adherence to the tenets 
of the Declaration of Helsinki and was approved by the respective Ethics Committees at the 
University Eye Clinics of Würzburg, München and Tübingen, by the Institutional Review 
Board at Columbia University, by the Research Ethics Committee of Queen's University 
Belfast and by the local Ethics Committee in Cologne. 
 
Genotyping 
Genomic DNA was extracted from peripheral blood leukocytes according to established 
protocols. Genotyping of SNPs was carried out by direct sequencing, TaqMan SNP 
genotyping (Applied Biosystems, Foster City, USA) or by primer extension of multiplex PCR 
products and subsequent allele detection by matrix-assisted laser desorption/ionization time of 
flight (MALDI-TOF; Sequenom, San Diego, USA). Direct sequencing was performed with 
the Big Dye Terminator Cycle sequencing kit version 1.1 (Applied Biosystems, Foster City, 
U.S.A.) according to the manufacturer’s instructions. Reactions were analyzed with an ABI 
Prism 3130xl sequencer (Applied Biosystems). TaqMan pre-designed SNP genotyping assays 
(Applied Biosystems) were used according to the manufacturer’s instructions. The 
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rs144087548 variant was genotyped by polymerase chain reaction (forward primer: 5’-CGC 
AGA CAT GAT GCT GGG GGT-3’; reverse primer: 5’-ACA TGC AAG ACG GGG AAT 
TGA-3’) followed by HpyCH4III digestion (New England Biolabs, Ipswich, USA) and 
restriction fragment length analysis. All SNPs showed high genotyping quality with an 
average call rate > 98% in each of the five case-control samples. 
 
Statistical methods 
Discovery study: We excluded three SNPs (rs2279227 [RGR], rs4620343 and rs3812532 
[TRPM3]), each with significant deviation from Hardy-Weinberg equilibrium (HWE, P ≤ 
0.05) in the control group of the discovery sample. SNP association analysis was carried out 
by logistic regression adjusted for age and sex. All analyses modeled an additive genetic 
effect and the genotype was coded as the number of alleles present at a given variant (i.e. 0, 1 
or 2). 
 
Replication studies and combined analysis. All SNPs were in HWE (P> 0.05). We used the 
same tests for SNP association analysis as in the discovery study. We also combined the 
individual data from all five studies and also adjusted the respective analyses by study center 
(coded as factors). The I
2 
measure was computed to measure between-study heterogeneity. 
We also conducted sex-stratified analyses for each study separately and for all study samples 
combined. Sex differences were asses for statistical significance using a t-test derived from 
sex-specific beta estimates and corresponding standard errors.  
 
All reported P values were two-sided except where noted otherwise. All SNP association 
analyses were carried out with R (v3.0.1, http://R-Forge.R-project.org/). To allow a more 
detailed inspection of the genomic region of interest, measures of linkage disequilibrium (LD) 
were calculated using R package snp.plotter [174].  
 
Imputation of SNPs 
Prior to imputation, 8 tag SNPs in DAPL1 were phased in the GER1 study individuals using 
SHAPEIT2 [175]. Then, untyped SNPs were imputed with IMPUTE2 [176] using the 1000 
Genomes Phase I integrated haplotypes (release 20110521) as reference panel. After the 
exclusion of SNPs with imputation quality (“info”) < 0.5, the genotype probabilities (dosages) 
of the remaining SNPs were also analyzed by logistic regression in R, using an additive model 
adjusted for age and sex.  
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Genomic resequencing 
Genomic resequencing was done for regions of interest defined by the presence of certain 
gene elements (putative promoter, coding exons of transcripts NM_001017920.2, HQ179935, 
HQ179936, and HQ179937) or conserved elements based upon the “46-Way Most Cons” 
track of the UCSC genome browser, NCBI Build 37/hg19]. Regions within extensive repeat 
structures were excluded (Supplementary Figure S7). Resequencing primers are listed in 
Supplementary Table S11. 
 
Prediction of functional impact of risk variants 
The functional impact AMD associated SNPs (with known dbSNP ID) on RNA processing as 
well as protein sequence, structure and function was predicted using the web-based “SNP 
Function Prediction” tool implemented in the “SNPinfo Web Server” 
(http://snpinfo.niehs.nih.gov/index.html) [177]. For newly identified SNPs, we used 
ESEfinder 3.0 to predict the effect of a given SNP allele on putative exonic splicing enhancers 
(http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi) [178].  
 
Characterization of major splice variants of DAPL1 in human retina/RPE 
To determine major splice variants and functional polyadenylation sites, 3’ rapid 
amplification of cDNA ends (3’-RACE) experiments were conducted. RNAs from RPE/retina 
tissues that were either heterozygous (ID_13 and ID_14) or homozygous (ID_16 and ID_17) 
for the non-risk rs17810398:C allele were isolated by RNeasy Mini Kit followed by DNAseI 
treatment (QIAGEN, Hilden, Germany). 3’-RACE was conducted with the FirstChoice RLM-
RACE Kit (Applied Biosystems/Ambion, Austin, USA) according to the manufacturer’s 
instructions. Forward primers for first and second (nested) PCR were 5’-GCA CTG GCA 
CACG CTA TG-3’ and 5’-TTG GCA CCT TGG AAA GAC ATA CC-3’, respectively. 
Amplified RACE products were ligated into the pGEM-T vector (Promega, Madison, USA). 
PCR products were obtained with M13 forward and M13 reverse primers from a total of 
1,200 clones. Of these, 597 clones were sequenced; the remaining 603 could unequivocally be 
assigned to DAPL1 isoform 1 (NM_001017920.2, HQ179934) by visual gel inspection. The 
sequences of isoforms 2 to 6 were submitted to GenBank (HQ179935, HQ179936, 
HQ179937, HQ179938, HQ179939). 
 
Expression analysis and semi-quantitative resequencing 
Eight RPE/retina tissues with risk variant genotypes as given in Figure 11 and 
Supplementary Table S13 were used as templates to amplify isoform-specific PCR products 
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with forward primer 5’-GCA CTG GCA CAC GCT ATG-3’ and the isoform-specific reverse 
primers 5’-CGA GGC TGC TGA ATA ATG TAG-3’ (isoform 1 & 2), 5’-TCT GGA TCC 
TCT GAG CTT CTT CTC-3’ (isoform 3) or 5’-CTG GAT CCT CTG AGC TTC TTG TGT-
3’ (isoform 4), followed by sequencing with the forward primer. Primers for the GUSB gene 
were 5’-ACT ATC GCC ATC AAC AAC ACA CTC ACC-3’ and 5’-GTG ACG GTG ATG 
TCA TCG AT-3’. For tissue samples, sex was determined with fluorescence-based PCR 
analysis of the homologous, X- and Y-linked genes AMELX and AMELY as described in 
Sullivan et al. [179].  
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6. General Discussion 
Tables and figures in the discussion are based on the following review articles: 
1. Grassmann F, Ach T, Brandl C, Heid IM & Weber BHF (2015) What does genetics tell us 
about AMD? Ann Rev Vis Sci, in revision. 
2. Grassmann F, Fauser S & Weber BHF (2015) The genetics of age-related macular 
degeneration (AMD) and its usability for designing treatment options Eur J Pharm 
Biopharm., in revision 
 
The main aim of this thesis was to investigate genetic as well as non-genetic markers involved 
in AMD pathogenesis. Specifically, this thesis focused  on a number of questions related to 
AMD pathogenesis: 
(i) is it possible to quantify the cummulative genetic risk for AMD of an individual and 
project absolute risk estimates based on a genetic risk score (GRS) calculated from common 
and previously published genetic variants? Are there additional features in AMD pathogenesis 
that can be evaluated based on such a genetic risk score? 
(ii) are (circulating) microRNAs involved in neovascular AMD pathogenesis and can they be 
used as a specific biomarker for this late stage disease? What pathways are regulated by 
identified circulating microRNAs and how do these microRNAs influence angiogenesis? Are 
other forms of late stage disease such as atrophic AMD also associated with neovascular 
AMD related cmiRNAs? 
(iii) are genetic variants or non-genetic factors correlated with progression of geographic 
atrophy lesions and are these correlations independent of each other? 
(iv) are there additional common genetic variants associated with AMD, which have not been 
detected by meta analyses of individual study data in the AMD Genetics Consortium [33]? 
 
6.1 Genetic variants are among the strongest factors influencing AMD risk  
The heritability of late stage AMD is estimated to be between 45% to 71% [72] and therefore 
comparable to the estimated heritabilities of other complex diseases e.g. Alzheimer's disease 
[180] or Psoriasis [181]. However, the genetics of AMD is unique among complex diseases as 
several loci with strong effect sizes of common variants have been identified (e.g. variants in 
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ARMS2/HTRA1, CFH, C3 or CFB  Figure 13). These variants exceed the expectation of 
effect size vs. their respective effect allele frequency usually observed on complex diseases 
(Figure 13) [33,182]. 
 
 
Figure 13. Plot of effect size versus effect-allele frequency of AMD, Psioriasis and Alzheimer’s 
disease (AD) risk variants. For complex diseases, the observed effect sizes are usually dependent on 
the frequency of the variant. Common variants have generally low effect sizes while rare variants have 
increased effect sizes. For AMD associated variants, several loci exceed this expectation 
(ARMS2/HTRA1, CFH, CFB and C3). Data based on Fritsche et al. 2013, Lambert et al. 2013, Tsoi et 
al. 2012 [33,181,182]. Figure taken from Grassmann et al. 2015, Ann Rev Vis Sci.  
 
The cumulative impact of known variants on disease risk can also be expressed as the fraction 
of disease variance being explained by known factors. This estimate usually varies between 
1% and 20% for most complex diseases [183]. However, these fractions are still considered 
minor by recent reports on genomics and genetic studies in popular media, which have 
proclaimed a “failure of the human genome” [184]. While the explained fraction of disease 
variance of known genetic factors for diseases with a heritability smaller than 30%, like type 
2 diabetes [185], is indeed low (around 2%), they can still account for a higher disease 
variabilty than individual environmental risk factors. For instance, smoking explains about 
1% of disease variance in type 2 diabetes, while the body mass index explains around 9% 
[186]. In diseases with a stronger genetic contribution, known genetic risk factors account for 
a higher explained disease variance. For Crohn’s disease, variations identified in genome-
wide association studies explain up to 12% of the disease variance [187], while the strongest 
measurable non-genetic predictor (smoking) only accounts for 3% of the variance [188]. 
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Depending on the overall prevalence assumed for late stage AMD, the variance jointly 
explained by 19 disease associated variants was estimated to be between 10% and 30% [33], 
further highlighting the unique properties of AMD genetics among complex diseases. 
Although we can not explain a large proportion of the variance in most complex diseases, it is 
not essential to fully explain all of the disease variance to provide valuable insights into 
disease mechanisms. Even small effects can implicate important pathways, e.g. the previously 
underappreciated importance of the autophagy pathway in Crohn’s disease pathology [189]. 
 
6.2 Novel genetic factors associated with AMD risk 
In order to advance our understanding of genes and pathways involved in AMD beyond 
GWAS-related approaches, we conducted a candidate gene based association study including 
more than 109 candidate variants in 25 candidate genes (see chapter 5) and found a significant 
association for variants in the DAPL1 gene. This association was primarily confined to 
females. By adding both associated top variants (rs17810398 and rs17810816) to the genetic 
risk score model proposed in reference [58], the resulting AUC of the model increased by 
0.01 to 0.83, thus slightly increasing classification accuracy. This increase in the AUC value, 
may, however, be inflated. Due to the “winner’s curse”, the odds ratio estimates of the risk 
variants are larger in the study that identified the variant. Since all individuals contributing to 
the calculation of the risk model were also part of the study identifying the DAPL1 risk 
variants, the impact of those variants is likely overestimated. The rather small contribution to 
the risk prediction is, however, not surpising and was predicted previously [42]. Even variants 
with large odds ratios above 2.00 can only be expected to increase the prediction accuracies 
by small margins, because the genetic risk for cases and controls overlaps significantly. For 
instance, a risk allele that increases the odds for the disease by two fold (i.e. has an odds ratio 
of 2.00) and an allele frequency frequency of 20% in cases, would have an allele frequency of 
11% in controls. Consequently, more than 20% of all controls would carry at least one risk 
allele. Therefore, it is difficult to distinguish cases and controls from such associated variants 
reliably, unless the effects of several variants are analysed jointly. Even then, a substantial 
overlap of the genetic risk between cases and controls is evident (see Figure 4). 
By performing statistical power analyses, we estimated that our candidate gene approach 
allowed us to find a significant association with AMD (p < 0.05) in the discovery study in 
case the risk variant is associated with AMD with an odds ratio greater than 1.40. Therefore, 
we cannot entirely exclude the tested variants and consequently the analyzed genes from 
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being relevant for AMD, since our study may have missed  weakly associated variants (OR < 
1.40). Hence, large scale studies with more participants are necessary to provide a definite 
answer on the involvement of the remaining candidate genes in AMD.  
 
6.3 Genetics of AMD and implications for treatment options  
Several studies estimated the contribution of known risk variants to treatment response in 
anti-VEGFA treatment for neovascular AMD. Variants in CFH, ARMS2 and VEGFA have 
been implicated with moderate effect sizes to be involved in treatment success, although there 
are conflicting data [190–194]. Even though neovascular AMD can be reliably treated and 
vision can be stabilized for some time, eventually patients with the neovascular form of AMD 
show a degeneration of the RPE and photoreceptors reminiscent of geographic atrophy [195]. 
Therefore, efforts are currently made to explore novel treatment options for neovascular AMD 
as well as for the so far untreatable atrophic form (GA) [16]. While 9 out of 10 clinical trials 
aimed at treating neovascular AMD are based on anti-VEGFA treatment and most of these 
report a successful impediment of neovascularisation and leakage, many different targets are  
currently being considered and tested in preclinical and clinical trials in an effort to treat 
atrophic AMD (Table 17) [16]. These latter trials either use neuroprotective agents, anti-
complement antibodies or anti-inflammatory substances, many of which are based on 
antibody approaches. So far, none of the studies treating atrophic AMD, however, report a 
significant treatment effect (Table 17) and this can, in part, be attributed to our limited 
knowledge on factors involved in disease progression and severity. Genetic association 
studies have a tremendous success to identify variants and thus genes involved in AMD. The 
identified genes are, however, per definition involved in disease risk (i.e. risk for incident 
AMD) and not necessarily in disease severity or progression and thus provide little insight 
into processess that can be targeted in AMD patients currently suffering from the disease (i.e. 
risk for prevalent AMD). Rather, they provide insight into processess involved before the 
onset of disease and as such are valuable targets for risk prediction before the onset of 
symptoms and consequently, for preventive treatment. In fact, little is known on the impact of 
genetic variants or non-genetic factors on disease severity, e.g. growth rates of GA lesions, 
area of neovascularisation or scarring, cummulative drusen area or similar measurements.   
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Table 17. Clinical trials for early AMD and geographic atrophy (adopted from Holz et al 2014), taken from Grassmann et al. 2015 Eur J 
Pharm Biopharm. in revision 
   
Clinical trial registration 
(sponsor) 
AMD 
type  Phase 
No. of 
patients Drug/Treatment Mechanism Current status primary end point Result 
NCT01802866 
(Acucela Inc.) GA 2/3 
about 
440 Emixustat (RPE65 inhibitor) vs. placebo Visual cycle inhibitor Recruiting Change in GA area Pending 
NCT00429936 
(Sirion Therapeutics Inc.) GA 2 246 Fenretinide (retinol analogon) vs. placebo Visual cycle inhibitor Completed Change in GA area 
No significant 
effect 
NCT00695318 
(Alimera Sciences) GA 2 40 
Fluocinolone acetonide (corticosteroid) vs. 
sham Suppresion of inflammation 
Ongoing, not 
recruiting Change in GA area Pending 
NCT00766649 
(NEI) GA 1/2 11 Rapamycin (mTor pathway inhibitor) 
Suppresion of inflammation/ 
Immunisuppresant Recruiting 
Change in GA area 
and visual acuity 
No significant 
effect 
NCT01229215 
(Genentech) GA 2 143 
Lampalizumab (antibody against CFD) vs. 
sham 
Suppression of complement 
activation Completed Change in GA area Pending 
NCT00935883 
(Alexion Pharmaceuticals) GA 2 30 
Eculizumab (antibody against C5) vs. 
sham 
Suppression of complement 
activation Completed Change in GA area 
No significant 
effect 
NCT01527500 
(Novartis) GA 2 
about 
120 LFG316 (antibody against C5) vs. sham 
Suppression of complement 
activation Recruiting Change in GA area Pending 
NCT00447954 
(Neurotech Pharmaceuticals) GA 2 48 CNTF (neural growth factor) vs. sham Neuroprotection Completed Visual acuity 
No significant 
effect 
NCT00890097 
(Alcon Research) GA 3 772 
Tandospirone (serotonin 1A receptor 
agonist) vs. placebo Neuroprotection Completed Change in GA area 
No significant 
effect 
NCT00658619 
(Allergan) GA 2 119 
Brimonidine tartrate (α-2 adrenergic 
receptor antagonist) vs. sham Neuroprotection Completed Change in GA area Pending 
NCT01344993 
(Advanced Cell Technology) GA 1/2 16 Stem cell derived human RPE Transplanation of RPE cells Recruiting Safety/tolerability Pending 
NCT01782989 (MEDARVA 
Foundation) GA 2/3 286 
Doxycyclin (antibiotic, inhibitor of 
metalloproteases) vs. placebo 
Inhibition of metalloproteases/ 
suppresion of inflammation Recruiting Change in GA area Pending 
ACTRN12612000704897 
(Ellex) early 2 360 Low-energy laser (2RT laser) Stimulating wound healing Recruiting 
Progression to 
advanced AMD Pending 
NCT00951288 
(Catholic University) early 1/2 30 
Saffron supplementation (contains 
antioxidant carotids) vs. placebo Neuroprotection Recruiting 
Visual acuity and 
function 
Improved visual 
function 
NCT01528605 
(Peking University) early 2 168 
Lutein and zeaxanthin (antioxidant 
carotids) supplementation vs. placebo Neuroprotection Completed 
Macular pigment 
optical density 
(MPOD) Improved MPOD 
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6.4 Factors associated with disease severity and prevelant AMD 
A recent study excluded AMD associated risk variants in CFH, ARMS2/HTRA1 and C3 from 
being associated with GA lesion growth [139], while others report a significant association for 
some of those variants [115,140]. By analyzing the largest dataset available on GA lesion 
growth, we showed a significant contribution of two genetic variants to GA growth 
(C3_rs2230199 and ARMS2_rs10490924). Noteworthy, GA in both eyes also significantly 
increased the rate of progression of GA lesions, with effect sizes comparable to the genetic 
variants. Taken together, the genetic variants explained about 4% of the inter-individual 
variability of GA lesion growth, while the addition of the disease status of the fellow eye 
(presence of GA or absence of GA in the fellow eye) increased the explained variance to 
7.2%. These findings have direct implications for the design and interpretation of the success 
of treatment trials. Although the risk increasing allele in C3_rs2330199 results in a more 
active form of complement component 3, thus increasing risk for AMD, we could show that 
the same risk increasing allele reduces GA growth significantly. Inhibition of the complement 
cascade with anti-complement antibodies might therefore not be promising venues since low 
levels of inflammation seem to be beneficial in neurodegenerative diseases [154,156,157]. 
We also explored non-genetic (epigenetic) markers which are associated with prevalent 
AMD. Circulating microRNAs in serum and plasma have been shown to be dysregulated in a 
variety of age related degenerative diseases. We therefore aimed to further our knowledge on 
dysregulated microRNAs in prevalent AMD and showed that, indeed, several microRNAs are 
associated with prevalent neovascular AMD. These microRNAs are predicted to regulate 
target genes in inflammatory as well as angiogenic pathways. The precise targets of these 
microRNAs can be best evaluated in vitro and in vivo with microRNA mimics and anti-
microRNAs. Such agents are potential treatment options in itself. Future studies tackling the 
role of circulating microRNAs in AMD pathology are underway (see Perspectives) 
 
6.5 Understanding genes and pathways involved in disease risk 
Although genome-wide association studies showed a huge success to identify disease 
associated variants for virtually all complex diseases [196], care has to be taken in the 
interpretation of these results. Currently, several pitfalls for the interpretation of GWAS data 
exist and are outlined below. 
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6.5.1 Clinical heterogeneity of AMD and implications for associated variants 
In AMD, most association studies investigated the association of variants with early AMD or 
late stage AMD, both of which are clinically highly heterogenous groups. Profound clinical 
heterogeneity exists for the early stages of the disease, and the late stage AMD is comprised 
of at least two major forms of the disease, atrophic and neovascular AMD [197]. The reasons 
for jointly investigating distinct disease manifestations are manifold: (i) the more patients a 
study includes, the more statistical power this study has to identify a significant assocation; 
(ii) both late stage forms are sometimes not easily distinguished, for instance in case where an 
individual is affected with GA and NV in the same eye; (iii) individuals suffering from GA 
may spontaneously develop NV AMD and vice versa, further increasing classification 
difficulties; (iv) in early AMD, various phenotypical manifestations of the disease exist (e.g. 
different drusen characteristics, changes in pigmentation), which often occur jointly in the 
same eye. It is therefore difficult to delineate distinct sub phenotypes of early AMD. Taken 
together, any association found so far is a genetic associations common to jointly investigated 
phenotypes (i.e. GA and NV or all stages or types of early AMD). Furthermore, clinical 
heterogeneity is probably one of several possible factors reponsible for the reduced effect 
sizes of late stage AMD associated risk variations in early AMD. Only recently, a sufficient 
amount of patients and controls have been recruited to further investigate the genetic basis of 
different AMD subtypes (see Perspectives). 
 
6.5.2 The search for the causative variant, affected gene and pathway 
More than 19 disease associated loci have been identified in a recent meta analysis [40] and 
an additional 16 loci are expected to be reported soon by the International AMD Genomics 
Consortium (IAMDGC) (Figure 1, Figure 14). In a first attempt to annotate and prioritize 
risk variants for further research, we have used the {FunciSNP} pipeline implemented in R to 
find variants correlated (R² > 0.7) with the SNP showing strongest association at each locus 
and created a circos plot of all annotated variants. For example, among the available data sets 
of the 19 loci [40], we found coding variants in six loci and several 3’-UTR variants in one 
locus. Additionally, in one locus we found variants annotated as expression quantitative trait 
loci (eQTLs), potentially altering the expression of a gene. In order to find tissue specific 
exons, we conducted next generation sequencing of RNA libraries (RNASeq) derived from 
several retinal cell types like photoreceptors, RPE and choroid cells [198]. In two loci, we 
found variants in novel (non-canonical) exons, representing the most likely candidates in 
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these loci. In the remaining nine loci, the most likely functional variant is still elusive (Figure 
14) and identification could be hindered by complex haplotype structures with long stretches 
of linkage disequilibrium, multiple signals at each locus, insufficient genotype information, 
particularly for copy number variants (e.g. deletions or insertions) and lack of affordable high-
throughput methods to characterize many candidate variants especially in the appropriate 
tissue and cell types [199].  
 
Figure 14. Functional annotation of AMD associated candidate variants. Top variants as well as 
correlated variants with R² > 0.7 to the top variant in nineteen AMD associated loci were annotated 
based on biofeatures implemented in package {FunciSNP} and a detailed map of the location and 
annotation of AMD associated candidate variants and regions in the genome was plotted. Candidate 
variants are color-coded by functional category. Transcripts expressed in the human retina, human 
RPE or human RPE derived from induced pluriponent stem cells (iPSC) are marked with an asterisk *. 
Several, previously published functional variants are not shown as their correlation with the top SNP is 
low (R² < 0.7), thus these variants are not detected by simple correlation analyses. Figure taken from 
Grassmann et al. 2015, Ann Rev Vis Sci  
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In order to explore novel ways to prevent or delay the onset of AMD, further molecular and 
statistical research is required to identify the responsible variants and affected genes and 
pathways [199].  
 
6.6 Perspectives 
Despite many efforts and huge successes of genome-wide association studies, the 
fundamental challenges in AMD and in other diseases still await to be addressed [200], 
namely finding appropriate animal models and treatment options based on the knowledge of 
genetic risk factors. For several diseases, findings of genome-wide association studies 
translated into identification of appropriate mouse models that mimic the genetic risk of the 
disease [201,202] and help to further shed light on processes involved in disease pathology. 
So far, no association study has led to the direct identifcation of a treatment option, although 
it is now possible for some diseases to adjust treatment recommendations according to the 
genotype of affected individuals [200]. 
In AMD, we have a good understanding of a large proportion of the disease genetics, yet there 
is still no suitable mouse model [203], nor is there a treatment option based on findings from 
genetic association studies [16]. This can be attributed to the possible pitfalls of current study 
designs discussed above, i.e. clinical heterogeneity of AMD subtypes and lack of knowledge 
on the true associated causal variant and the affected gene and pathway. 
Here, I want to highlight two approaches currently underway to further our knowledge on 
disease risk and factors involved in AMD pathogenesis. 
 
6.6.1 The International AMD Genomics Consortium 
The International AMD Genomics Consortium (IAMDGC), an association of more than 26 
research groups worldwide, has collected over 50,000 samples comprising healthy and 
diseased individuals. Traditionally, individual participating study data are pooled by 
combining the effect size estimates from each separate study group. In IAMDGC, all of the 
samples were genotyped on the same genotyping platform in the same genotyping center, thus 
greatly reducing inter-study variability which should increase the number of loci significantly 
implicated in AMD. Furthermore, in the IAMDGC all genotypes are fully accessible for 
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analysis, thus facilitating dissection of complex haplotype structures and identification of 
additional, independent signals. In addition, the large number of individuals now allows 
investigations into genetic factors associated with AMD sub-phenotypes like pure geographic 
atrophy or distinct manifestations of early AMD. First results of genome-wide association 
analyses are expected to be published in 2015. 
 
6.6.2 Circulating microRNAs  
The identification of significantly disregulated microRNAs in AMD patients compared to 
controls points to genes and pathways involved in prevalent AMD. In order to find the targets 
(genes) influenced by the significantly associated circulating microRNAs, several methods 
have been proposed [204,205]. The most straightforward methods include the modulation of 
those microRNAs in a variety of cell types e.g. RPE cells or endothelial cells. After 
knockdown or overexpression of a microRNA species, the expression profile of all genes can 
readily be evaluated with next generation sequencing. In addition, several in vitro assays can 
be used to assess the influence of these microRNAs on cells (e.g. tube formation assay [128], 
cell migration assay [109], measuring oxidative stress or immune responses [151]). Another 
promising approach is to modulate multiple microRNAs at the same time, thus mimicing the 
disease associated microRNA profile.  
We could show that a specific microRNA profile is associated specifically with neovascular 
AMD. Consequently, the next step is to find a microRNA profile for geographic atrophy. The 
current study included 59 cases with (pure) geographic atrophy. Unless the effect sizes for 
dysregulated candidate microRNAs are larger, we would need more cases affected with GA to 
identify a microRNA profile. The recruitment of these cases is currently in progress at the 
Department of Ophthalmology at the University of Bonn. 
Further studies also include the evaluation of circulating microRNAs in mouse models of 
AMD. We are currently working on a mouse model mimicing disease progression of 
geographic atrophy by inducing atrophic lesions in the RPE with oxidized lipid metabolites 
[203]. In addition, we are collaborating with Prof. Langmann from the Department of 
Experimental Immunology of the Eye from the Eye Clinic Cologne to evaluate cmiRNAs in a 
laser induced mouse model of neovascular AMD [206]. These experiments will be 
supplemented by in vitro analyses of identified microRNAs. 
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8. Zusammenfassung 
Die altersabhängige Makuladegeneration (AMD) ist eine degenerative Erkrankung der 
zentralen Retina und eine der Hauptursachen von Erblindungen in höherem Alter. AMD ist 
eine komplexe Krankheit ausgelöst durch genetische und umweltbedingte Faktoren. Die 
Frühform der AMD führt in der Regel nicht zu Einschränkungen der Sehfähigkeit. Im 
Gegensatz dazu kann die Spätform der AMD zu einem starken Verlust der Sehschärfe und 
schließlich zur Erblindung führen. In der Literatur werden zwei verschiedene 
Erscheinungsformen der Spätform unterschieden: Geographische Atrophie (GA) und 
neovaskuläre AMD (NV). 
In der vorliegenden Arbeit wurden vier Hauptprojekte zusammengefaßt: 
(i) Im ersten Projekt sollte ein genetisches Risikomodell für AMD berechnet und bewertet 
werden. Das Risikomodell basiert auf einem genetischen Risiko Score (GRS), welcher in 
einer großen Fall-Kontroll Studie aus den Genotypen häufig vorkommender, AMD 
assoziierter Risikovarianten berechnet wurde. Für das Risikomodell wurde ein AUC Wert 
(area under the receiver operating characteristics curve Wert) von 0.82 berechnet, welcher 
als ausreichend angesehen wird um Personen in Hochrisiko- bzw. Niedrigrisikogruppen 
einzuteilen. Zudem haben wir die absoluten Risiken verschiedener Risikogruppen berechnet 
und konnten so das Krankheitsrisiko von Personen in diesen Gruppen innerhalb der nächsten 
5 Jahre vorhersagen. Desweiteren zeigten unsere Analysen, dass AMD Patienten vor dem 75. 
Lebensjahr einen statistisch signifikanten höheren genetischen Risiko Score haben als 
Patienten, die nach dem 75. Lebensjahr erkrankten. 
(ii) Um die Klassifikationseffizienz des Risikomodells eventuell zu verbessern, wurden 
zirkulierende microRNAs als mögliche Biomarker für AMD untersucht. Wir konnten zeigen, 
dass sowohl drei zirkulierende microRNAs individuell (hsa-mir-301a-3p, hsa-mir-424-5p and 
hsa-mir-361-5p), sowie auch ein, auf den drei microRNAs gemeinsam basierendes Profil, 
signifikant mit neovaskulärer AMD assoziiert sind. Mit verschiedenen 
Vorhersageprogrammen wurden für diese microRNAs mögliche Zielgene berechnet. Die so 
identifizierten Zielgene lassen sich hauptsächlich inflammatorischen und angiogenetischen 
Signalwegen zuordnen. Zudem konnten wir für die microRNA hsa-mir-361-5p in einer in 
vitro Angiogeneseuntersuchung zeigen, dass diese microRNA das Wachstum von neuen 
Blutgefäßen beeinflusst. 
. 
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(iii) Im dritten Projekt untersuchten wir den Einfluss von einzelnen genetischen Varianten, 
den daraus berechneten genetischen Risiko Score (GRS), sowie klinischen Variablen auf die 
Wachstumsrate der geographischen Atrophie. Wir konnten diese Untersuchungen in dem 
bisher größten Patientenkollektiv dieser Art durchführen und zeigen, dass zwei genetische 
Risikovarianten (C3_rs2230199 and ARMS2_rs10490924) signifikant mit der Progression der 
geographischen Atrophie korreliert sind. Zudem fanden wir, dass Patienten mit bilateral 
auftretender geographischer Atrophie eine signifikant größere Wachstumsrate aufwiesen als 
Patienten, die nur in einem Auge an GA erkrankt waren. Um mögliche Korrelationen 
zwischen den identifzierten Variablen auszuschließen, wurden multivariate lineare 
Regressionsmodelle erstellt. Damit konnten wir zeigen, dass die Variablen sowohl 
unabhängig voneinander mit der Progression von GA korreliert waren, als auch dass sie etwa 
7% der Wachstumsratenvariabilität erklären. 
(iv) Um neue AMD Risikovarianten zu identifizieren, die aufgrund von Überlegungen zur 
statistischen Power eher nicht über GWAS Ansätze zu entdecken sind, wurde eine 
Kandidatengen-Assoziationsstudie durchgeführt. In dieser Studie fanden wir eine statisch 
signifikante Assoziation von zwei häufigen Varianten im DAPL1 Gen mit der Spätform der 
AMD. Interessanterweise zeigte sich diese Assoziation nur in weiblichen Fällen und 
Kontrollen und nicht in männlichen Individuen. Der DAPL1 Lokus ist daher der erste 
Genlokus für AMD, für den eine geschlechterspezifische Assoziation beschrieben wurde. 
Durch weitere in vitro Untersuchungen der Risikovarianten und deren Effekten auf die 
Expression von DAPL1 konnten wir zeigen, dass die Risikoallele der Varianten mit einer 
reduzierten Expression von Retina- und RPE spezifischen Transkripten korrelieren 
Zusammenfassend konnte ich im rahmen meiner Dissertationsarbeit den Einfluss neuer 
Faktoren auf die Pathologie der AMD nachweisen aufgrund folgender Beobachtungen: (i) Die 
Identifzierung neuer genetischer Varianten, die mit dem Risiko an AMD zu erkranken 
assoziiert sind; (ii) Die Berechnung eines genetischen Risikomodells für AMD, das es erlaubt 
das genetische Risiko einer Person an AMD zu berechnen; (iii) Die Identifizierung 
genetischer und klinischer Variablen, die mit dem Wachstum der geographischen Atrophie 
und damit der Schwere der Krankheit korrelieren; (iv) Und zuletzt durch die Identifzierung 
und Charakterisierung eines Biomarkers basierend auf zirkulierenden microRNAs für die 
neovaskuläre AMD. 
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9. Summary 
Age-related macular degeneration (AMD) is a degenerative disease of the central retina and a 
leading cause of severe vision impairment in industrialized countries. AMD is a complex 
disease caused by genetic predisposition and environmental factors. Early stages of the 
disease usually do not lead to visual impairment. In contrast, the late stage forms of AMD can 
result in profound vision loss, eventually leading to blindness. Two distinct forms of late stage 
AMD have been described: geographic atrophy (GA) and neovascular AMD (NV).  
In this thesis, four main projects were pursued:  
(i) In the first project, a genetic risk model for AMD should be computed and evaluated. This 
model was based on a genetic risk score (GRS) calculated from twelve known, common 
genetic risk factors in a large cohort of late stage AMD cases and AMD-free controls. The 
computed model presented to have a decent classification accuracy with an area under the 
receiver operating characteristics curve (AUC) value of 0.82, which is sufficient to classify 
individuals as having a high or low risk for AMD. Furthermore, we computed absolute risk 
estimates for several risk groups to develop AMD in the next five years. In addition, we 
showed that individuals that were affected with AMD before the age of 75 had a statistically 
significantly higher genetic risk score than those individuals that got AMD after the age of 75. 
(ii) In order to improve the classification scheme, circulating microRNAs were investigated as 
potential biomarkers for AMD. We showed that three circulating microRNAs (hsa-mir-301a-
3p, hsa-mir-424-5p and hsa-mir-361-5p) as well as a combined profile are significantly 
associated with neovascular AMD. With pathway enrichment analyses performed on 
predicted target genes of these microRNAs, inflammatory as well as angiogenc pathways 
were implicated in AMD. In addition, hsa-mir-361-5p was shown to influence the rate of 
neovascularization in an in vitro angiogenesis assay. 
(iii) The third project investigated a potential involvement of the genetic risk score and single 
genetic variants as well as clinical factors on the growth rate of geographic atrophy lesions. 
By analyzing the largest dataset available on geographic atrophy lesion growth, we showed 
that two genetic risk variants (C3_rs2230199 and ARMS2_rs10490924) are significanlty 
correlated with the growth rate of GA lesions. Furthermore, the presence of GA in the fellow 
eye (bilateral GA) was shown to be significantly correlated with increased GA growth. We 
computed multivariate linear regression models and showed that these factors are 
independently correlated with GA growth and jointly explain around 7% of the disease 
variability. 
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(iv) In a candidate gene approach, novel genetic risk variants associated with AMD risk were 
investigated. We found a statistically significant association of two variants in the DAPL1 
gene with late stage AMD. Interestingly, the observed associations were confined to females, 
thus identifying the first gender specific locus associated with AMD. By further functional 
characterization of these risk variants and DAPL1 transcript levels, we showed that the 
presence of risk alleles correlated with reduced levels of retinal and RPE specific isoforms of 
DAPL1. 
In conclusion, this thesis provided further insights into AMD pathology by:  (i) implicating 
novel genetic factors associated with AMD risk; (ii) computing a genetic risk model, 
effectively summarizing the genetic risk for AMD of an individual; (iii) implicating factors 
correlated with geographic atrophy lesion growth and thus disease severity and (iv) 
identification of a biomarker for neovascular AMD based on circulating microRNAs. 
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10.2 Supplementary Figures 
 
 
Supplementary Figure S1. Risk estimates for 16 AMD associated variants by disease subtypes. 
Logistic regression models were fitted with all patients (N=986), GA cases only (N=229), NV cases 
only (N=581) or mixed GA+NV cases (N=176) versus controls (N=796). Odds ratio estimates (OR) 
are given per risk allele; horizontal bars indicate 95% confidence intervals and the arrow indicates that 
the boundary extends below 1 or above 6.  
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Supplementary Figure S2. Venn diagram of target genes predicted 
by microT-CDS. Target genes were predicted with microT-CDS with a 
microT threshold of 0.7. In total, 3,516 target genes were predicted. 
 
 
 
Supplementary Figure S3. Knockdown of candidate miRNAs in 
human endothelial cells. Mean relative reduction in miRNA levels 
compared to control antagomir (mock). Whiskers represent the standard 
error of the mean. 
 104 
 
 
Supplementary Figure S4. Representative images of in vitro tube formation assays in human 
endothelial cells. The measured cumulative tube length in each image was close to the mean 
cumulative tube length measured in all images of the respective treatment. 
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Supplementary Figure S5. Linkage disequilibrium (LD) map of the DAPL1 gene locus. SNP 
positions are indicated by vertical/diagonal lines. A. Values of r² are indicated by coloring (white, low 
r²; black, high r²). B. Values of D’ are indicated by coloring (white, low D’; black, high D’). 
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Supplementary Figure S6. Sex-specific analysis in the combined study of candidate SNPs 
rs17810398 and rs17810816 in the DAPL1 gene. Odds ratios and corresponding 95% confidence 
intervals are given with the size of each rectangle representing the respective number of cases. Late 
stage sub-phenotypes were combined. 
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Supplementary Figure S7. Re-sequencing strategy of the DAPL1 locus. A screenshot of the UCSC 
genome browser with default and custom tracks at position hg19:chr2: 159,650,435-159,721,003 is 
shown (http://genome.ucsc.edu). Track names are given above each track. From top to bottom, tracks 
are as follows: (1) Identified risk variants based upon discovery study (green), imputation analysis 
(blue; Supplementary Table S10) or resequencing (purple; Supplementary Table S13); (2) RefSeq 
sequence of DAPL1 (NM_001017920.2); (3) Common DAPL1 transcripts as identified in four 
RPE/retina tissue samples (isoform 1: HQ179934/NM001017920.2, isoform 2: HQ179935, isoform 3: 
HQ179936, isoform 4: HQ179937); (4) Exons identified in common and rare isoforms of DAPL1; (5) 
Resequenced PCR fragments (Supplementary Table S11); (6) Regions of interest based upon exon 
structure and conservation; (7) “46-Way Most Cons” track of the UCSC genome browser(14.03.2014); 
(8) UCSC RepeatMasker track (14.03.2014). 
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Supplementary Figure S8. RT-PCR expression analysis of 
DAPL1 isoforms. All forward and reverse primers used were 
exon-spanning to avoid amplification of traces of genomic 
contamination in the mRNA preparations. Expected and 
observed fragment sizes were as follows: 329 bp (isoform 1), 
448 bp (isoform2), 340 bp (isoform 3) and 331 bp (isoform 4). 
Expression analysis of housekeeping gene β-glucuronidase 
(GUSB; 197 bp) served as a control for first-strand cDNA 
integrity. 
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10.3 Supplementary Tables 
 
Supplementary Table S1. Published genetic variations associated with AMD 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Variant Gene Year Ref. 
rs1061170 CFH 2005 [34] 
rs2274700 (proxy: rs1410996) CFH 2006 [74] 
rs800292 CFH 2005 [37] 
∆CFHR3/CFHR1 (proxy: rs6677604) CFH/CFHR 2007 [75] 
rs10490924 ARMS2 2005 [73] 
c.del443ins54 ARMS2 2008 [148] 
rs11200638 HTRA1 2006 [207] 
rs4151667 CFB 2006 [47] 
rs547154 (proxy: rs438999) CFB 2006 [47] 
rs2230199 C3 2008 [38] 
rs7412 APOE 1998 [32] 
rs429358 APOE 1998 [32] 
rs2285714 CFI/PLA2G12A 2009 [80] 
rs493258 LIPC 2010 [81] 
rs10468017 LIPC 2010 [82] 
rs9621532 SYN3/TIMP3 2010 [81] 
  
 
1
1
0
 
Supplementary Table S2. Cross validated absolute risks for late stage AMD in different risk groups in the modeled population 
 
 
 
 
 
 
 
 
 
1
 Approximate age groups corresponding to prevalences according to [17,19] for prevalences between 65 and 79 years and [90] for prevalences above 80 years 
2 
Averaged fractions of controls and cases observed in 2000 test sets in each risk group 
 
 
 
 
 
 
  
 Modeled 
prevalence (age 
group in yrs)
1
 
Positive predictive value in risk group [%] 
  1 (low) 2 3 4 5 (high) 
Fraction of cases in the modeled 
general population (absolute risk) [%]  
      
 1% (65-69 yrs) 0.13 0.22 0.91 4.22 46.8 
 2.5% (70-74) 0.35 0.56 2.26 10.0 58.1 
 5% (75-79) 0.70 1.13 4.54 18.5 68.4 
 10% (80-84) 1.46 2.39 9.13 32.4 80.0 
 15% (>85) 2.20 3.72 13.7 42.7 85.6 
Fraction of cases and controls in our 
study
2
 
 
     
Cases [%]  1.00 8.50 38.7 40.8 11.0 
Controls [%]  7.90 38.2 43.5 10.2 0.40 
  
 
1
1
1
 
 Supplementary Table S3. Primers and methods used for genotyping 
 
1
 Restriction enzyme used for RFLP assay 
2
 PCR with these primers yielded two distinct PCR products of different lengths corresponding to each allele. 
3 
SNPs were found in primer binding site  
Nearby gene(s) Marker Method Forward primer (5‘-3‘) Rreverse primer (5‘-3‘) Universal Extension primer (MALDI-TOF) 
CFH rs1061170 Sequencing TTGCACACAAGATGGATGGT GCATCTGGGAGTAGGAGACC  
  RFLP (Tsp509I)1 CCTTTGTTAGTAACTTTAGTTCGTCTT CCAAAAACTAAATAGGTCCATTGGT  
 rs1410996 MALDI-TOF ACGTTGGATGCCGTCAATGAGATTTACGTC ACGTTGGATGCCTCTACATCAGTGGTATAG ACGCAGTCCCTGACTACCTCATG 
 rs800292 Taqman (C___2530382_10)    
  MALDI-TOF ACGTTGGATGAAATGCCGCCCTGGATATAG ACGTTGGATGTAAGAGCAACCCATTCTCCC CCTGGATATAGATCTCTTGGAAAT 
 rs6677604 Sequencing TTGCTTGAGGAAAGTTGTGC TTCCCATCTCCTGTCACAAA  
  MALDI-TOF ACGTTGGATGCCACCAAAGCACAATACCTC ACGTTGGATGCATGACTTACATAGTTGCCC TAGCTGTGAGTCCTTTCC 
ARMS2/HTRA rs10490924 Sequencing GCCTGAGATGGCAAGTCTGT TGTAGCAGGTGCATTGGAAG  
 del443ins54 PCR² ACTCATCACGTCATCACCAAT CTCTCTGCAGCCCTCATTTG3  
 rs11200638 RFLP (EagI)1 ATGCCACCCACAACAACTTT GGTTCTCTCGCTGAGATTCG  
CFB rs4151667 Sequencing GGTCTGGAGTTTCAGCTTGG TCTTGGAGAAGTCGGAAGGA  
  MALDI-TOF ACGTTGGATGCTTCTCTCCTGCCTTCCAAC ACGTTGGATGCAAGAGGCCCAAGATAAAGG ATCTCAGCCCCCAAC 
 rs438999 Sequencing GAGGTCAGGGGTCATGAGAA AGACAGGGATTCATGGGATG  
  MALDI-TOF ACGTTGGATGACAACCTCCTTGTCTCTTCG ACGTTGGATGAAGAGTCACCTGGCCAGAAG GGGGACTTATGGGGAAATCCAACTC 
C3 rs2230199 RFLP (HhaI)1 GTGGTTGACGGTGAAGATCC CAAGATCCGGAAGCTGGAC  
  MALDI-TOF ACGTTGGATGCAACAGGGAGTTCAAGTCAG ACGTTGGATGTCCACCACTTGGGTCCCGAA AGTGAGTTCAAGTCAGAAAAGGGG 
APOE rs7412 Sequencing GATGGACGAGACCATGAAGG CTCGAACCAGCTCTTGAGG  
 rs429358 Sequencing GATGGACGAGACCATGAAGG CTCGAACCAGCTCTTGAGG  
PLA2G12A rs2285714 Sequencing CAAGCCACCAGATCATCCTT CAAATGCCTTTTGCAGCTTA  
  MALDI-TOF ACGTTGGATGCCTGACAAAGTGTTGCAACC ACGTTGGATGCAGTCATTCTTGCTTTTGCC GGGTGACACGACAGGTGCTATGA 
SYN3 rs9621532 RFLP (EcoO109I) GGTTCTACTGGCTGGGTGAA TACCCCCACTACCCCTAGTT  
  MALDI-TOF ACGTTGGATGTGAAAGGGATTGAAAGCAGG ACGTTGGATGTCTGGGCAGCCTGAAAACTC GGGATTGAAAGCAGGTCATTA 
LIPC rs10468017 RFLP (SspI) TTTACGGTCTCCAAGACTGCT CCAAGTTCATTCACAGGGACT  
 rs493258 Taqman ( C___1929355_10)    
  Sequencing AGACCAGCAGGCATCACC CCAGAAACAAACAAGTGGAGTG  
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Supplementary Table S4. Mean and 95% confidence intervals of log transformed fold changes of cmiRNA levels in the combined study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
NV cases GA cases controls 
Number of individuals 129 59 147 
hsa-mir-301a-3p -0.318 (-0.416 - -0.220) 0.030 (-0.110 - 0.170) 0.055 (-0.025 - 0.134) 
hsa-mir-361-5p -0.373 (-0.500 - -0.245) -0.069 (-0.203 -  0.065) -0.002 (-0.076 - 0.072) 
hsa-mir-424-5p -0.338 (-0.437 - -0.240) 0.077 (-0.068 - 0.223) -0.071 (-0.152 - 0.011) 
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Supplementary Table S5. Previously published associated variations used to calculate the genetic risk score 
 
 
 
 
 
 
 
 
 
 
1
 95% confidence intervals 
2
 Risk allele refers to AMD risk increasing allele 
 
 
 
 
  
         
Frequency of risk allele in 
Nearby gene(s) Marker ID 
Impact/effect of 
variant 
Odds ratio 95% CI1 P-value Non risk allele Risk allele2 Cases (N=72) Controls (N=77) 
CFH rs1061170 1 p.Y402H 2.18 1.33-3.68 0.001762 T C 0.59 0.36 
 
rs800292 2 p.I62V 1.76 0.79-4.06 0.1662 A G 0.89 0.83 
 
rs6677604 3 
proxy for 
∆CFHR3/CFHR1 1.96 
0.94-4.28 
0.0742 
A G 
0.87 0.79 
ARMS2 rs10490924 4 p.A69S 5.62 2.90-12.01 2.63E-08 G T 0.55 0.19 
CFB rs4151667 5 p.L9H 8.47 1.48-160.00 0.01319 A T 0.99 0.93 
 
rs438999 6 
proxy for rs641153 
(p.R32Q) 2.29 
0.77-7.73 
0.1374 
C T 
0.95 0.91 
C3 rs2230199 7 p.R102G 1.73 0.95-3.25 0.07395 G C 0.28 0.18 
APOE rs7412 8 p.R158C 0.70 0.30-1.57 0.3924 C T 0.08 0.12 
 
rs429358 9 p.C112R 1.80 0.76-4.54 0.1829 C T 0.92 0.86 
PLA2G12A rs2285714 10 
synonymous exonic, 
unknown 1.19 
0.72-1.99 
0.492 
C T 
0.45 0.40 
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Supplementary Table S6. Primers and mature microRNA sequences 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
primer name mature miRNA sequence primer sequence 
hsa-miR-142-RT CAUAAAGUAGAAAGCACUACU CATAAAGTAGAAAGCACTACT 
hsa-miR-361-RT UUAUCAGAAUCUCCAGGGGUAC TTATCAGAATCTCCAGGGGTA 
hsa-miR-424-RT CAGCAGCAAUUCAUGUUUUGAA CAGCAGCAATTCATGTTTTGAA 
hsa-miR-4732-5p_RT UGUAGAGCAGGGAGCAGGAAGCU TGTAGAGCAGGGAGCAGGAAGCT 
hsa-miR-451a_RT AAACCGUUACCAUUACUGAGUU AAACCGTTACCATTACTGAGTT 
hsa-miR-192-RT CUGACCUAUGAAUUGACAGCC CTGACCTATGAATTGACAGCC 
hsa-miR-26a-RT UUCAAGUAAUCCAGGAUAGGCU TTCAAGTAATCCAGGATAGGCT 
hsa-miR-505-RT GGGAGCCAGGAAGUAUUGAUGU GGGAGCCAGGAAGTATTGAT 
hsa-miR-335-5p_RT UCAAGAGCAAUAACGAAAAAUGU TCAAGAGCAATAACGAAAAATGT 
hsa-miR-301a-3p_RT CAGUGCAAUAGUAUUGUCAAAGC CAGTGCAATAGTATTGTCAAAGC 
hsa-miR-30b-5p_RT UGUAAACAUCCUACACUCAGCU TGTAAACATCCTACACTCAGCT 
hsa-miR-194-5p_RT UGUAACAGCAACUCCAUGUGGA TGTAACAGCAACTCCATGTGGA 
hsa-miR-4732-5p_RT UGUAGAGCAGGGAGCAGGAAGCU TGTAGAGCAGGGAGCAGGAAGCT 
Univeral_PCR_Primer - AACGAGACGACGACAGACTTT 
URT_Primer - AACGAGACGACGACAGACTTTTTTTTTTTTTTTV 
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Supplementary Table S7. Allele frequencies of evaluated genetic variants in this study 
   
FAM study - discovery FAM study - replication ARED study combined 
Variant Risk allele* Weight** Allele frequency Allele frequency Allele frequency Allele frequency 
CFH_rs1061170 C 0.629 0.669 - - - 
CFH_rs6677604 G 0.702 0.930 - - - 
CFH_rs800292 G 0.932 0.913 - - - 
C3_rs2230199 C 0.377 0.326 0.229 0.305 0.300 
ARMS2_rs10490924 T 1.301 0.483 0.479 0.451 0.461 
CFB_rs438999 T 1.026 0.965 - - - 
CFB_rs4151667 T 1.406 0.988 - - - 
APOE_rs7412 T 0.397 0.093 - - - 
APOE_rs429358 T 0.335 0.901 - - - 
CFI_rs2285714 T 0.169 0.413 - - - 
 
* Risk allele refers to the risk increasing allele, i.e. the allele that is more frequent in cases than in controls 
** Weights were obtained from the multiple logistic regression model in Grassmann et al. 2012 and used to calculate the genetic risk score (GRS) 
 
 
 
  
  
 
1
1
6
 
Supplementary Table S8. Candidate gene based analyses of 106 SNPs. Table spans more than one page 
Gene name Symbol 
Selection criteria
*
 
Chromosome 
band 
# SNPs 
analyzed 
Discovery Sample 
GER1 
Replication 
Sample 
GER2 Protein 
Function 
Retinal / RPE 
expression Pmin
**
 P
***
 
SH3-domain GRB2-like (endophilin) interacting protein 1 SGIP1 - X 1p31.3 3 0.696 … 
Retinal pigment epithelium-specific protein 65kDa RPE65 X X 1p31 4 0.059 … 
ATP-binding cassette, sub-family A (ABC1), member 4 ABCA4 X X 1p22 17 0.183 … 
Cathepsin S CTSS X - 1q21 2 0.742 … 
G protein-coupled receptor 75 GPR75 - X 2p16 2 0.780 … 
c-mer proto-oncogene tyrosine kinase MERTK X X 2q14.1 3 0.342 … 
Death associated protein-like 1 DAPL1 - X 2q24 8 0.016 0.002 
Membrane protein, palmitoylated 4 MPP4 - X 2q33.2 5 0.430 … 
Retinol binding protein 1, cellular RBP1 - X 3q21-q23 4 0.444 … 
Succinate receptor 1 SUCNR1 X - 3q25.1 6 0.067 … 
WD repeat domain 17 WDR17 - X 4q34 3 0.356 … 
Neuropeptide VF precursor NPVF - X 7p21-p15 2 0.164 … 
Retinitis pigmentosa 1 (autosomal dominant) RP1 X X 8q12.1 3 0.037 0.44 
Transient receptor potential cation channel, subfamily M, member 3 TRPM3 - X 9q21.11 10 0.141 … 
Cadherin-related family member 1 CDHR1 X X 10q23.1 6 0.197 … 
Retinal G protein coupled receptor RGR X X 10q23 2 0.096 … 
Cathepsin D CTSD - X 11p15.5 5 0.355 … 
Fatty acid desaturase 3 FADS3 X - 11q12-q13.1 3 0.496 … 
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Supplementary Table S8. continued 
Bestrophin 1 BEST1 X X 11q12 3 0.070 … 
Chromosome 11 open reading frame 48 C11orf48 - X 11q12.3 2 0.149 … 
Retinol dehydrogenase 12 (all-trans/9-cis/11-cis) RDH12 X X 14q24.1 1 0.247 … 
Retinaldehyde binding protein 1 RLBP1 X X 15q26.1 2 0.488 … 
ATPase, Na+/K+ transporting, beta 2 polypeptide ATP1B2 - X 17p13.1 2 0.212 … 
Neuropilin (NRP) and tolloid (TLL)-like 1 NETO1 - X 18q22.2 6 0.256 … 
Cystatin C CST3 X X 20p11.2 2 0.028 1.00 
*
 X: present; -: not present
 
**  
Pmin: minimum Pvaluefrom logistic regression model adjusted for age and gender for all SNPs analyzed in this region 
*** 
Pvalue from logistic regression model adjusted for age and gender 
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Supplementary Table S9. Association results for the 106 SNPs analyzed in the discovery sample. Table spans more than one page 
        
Minor Allele 
Frequency in 
Number of 
non-missing 
genotypes in 
 
Gene 
SNP (dbSNP-
ID) Chr. 
Position 
[hg19] 
Major 
allele 
Minor 
allele 
Odds 
ratio 
95% 
Confidence 
Intervals Controls Cases Controls Cases 
P-
Value* 
SGIP1 rs1373909 1 67040875 A G 1.018 0.872-1.188 0.420 0.424 611 710 0.821 
SGIP1 rs1536112 1 67107225 A G 1.019 0.869-1.194 0.435 0.438 608 707 0.817 
SGIP1 rs6588216 1 67145847 A G 1.010 0.850-1.200 0.277 0.280 610 708 0.910 
RPE65 rs3118415 1 68894296 A G 1.041 0.850-1.276 0.171 0.176 588 696 0.696 
RPE65 rs3125895 1 68901735 G T 1.002 0.860-1.167 0.410 0.410 608 702 0.980 
RPE65 rs3790472 1 68910999 G T 1.160 0.995-1.354 0.441 0.478 608 703 0.059 
RPE65 rs436070 1 68918895 G A 0.866 0.716-1.048 0.209 0.186 608 706 0.139 
ABCA4 rs1800555 1 94463617 G A 0.872 0.397-1.915 0.011 0.009 612 710 0.729 
ABCA4 rs7537325 1 94469631 A G 1.007 0.840-1.207 0.225 0.227 604 704 0.939 
ABCA4 rs1800553 1 94473807 G A 1.559 0.534-5.107 0.004 0.006 612 710 0.429 
ABCA4 rs2275033 1 94480037 G A 0.937 0.804-1.092 0.434 0.418 604 687 0.404 
ABCA4 rs1932014 1 94488497 T C 1.014 0.872-1.180 0.453 0.457 606 708 0.853 
ABCA4 rs3789395 1 94501594 G T 0.990 0.849-1.154 0.461 0.459 609 704 0.894 
ABCA4 rs11165069 1 94504545 G A 0.972 0.807-1.172 0.212 0.206 604 703 0.768 
ABCA4 rs497511 1 94523113 T C 1.063 0.910-1.242 0.471 0.485 611 705 0.438 
ABCA4 rs549114 1 94534354 C T 1.055 0.893-1.248 0.321 0.332 605 698 0.529 
ABCA4 rs4147827 1 94548080 G C 0.920 0.762-1.112 0.209 0.195 609 704 0.390 
ABCA4 rs952499 1 94558425 A G 0.964 0.825-1.127 0.498 0.488 611 702 0.647 
ABCA4 rs950283 1 94567223 A G 1.049 0.896-1.227 0.360 0.373 612 710 0.555 
ABCA4 rs1209515 1 94571335 G A 1.091 0.920-1.295 0.268 0.284 607 704 0.318 
ABCA4 rs4147815 1 94574808 C T 0.944 0.780-1.141 0.223 0.213 611 692 0.550 
ABCA4 rs2297634 1 94576968 A G 1.103 0.944-1.290 0.469 0.491 611 706 0.219 
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Supplementary Table S9. continued 
ABCA4 rs2184339 1 94585331 A G 0.891 0.752-1.056 0.307 0.286 608 704 0.183 
ABCA4 rs3761911 1 94588754 A T 1.044 0.890-1.226 0.376 0.385 605 703 0.597 
CTSS rs1136774 1 150738197 A G 1.001 0.858-1.167 0.471 0.472 611 708 0.991 
CTSS rs3754212 1 150738200 T C 1.028 0.874-1.208 0.360 0.366 607 707 0.742 
GPR75 rs805368 2 54083420 C T 1.025 0.861-1.221 0.272 0.276 612 708 0.780 
GPR75 rs805373 2 54086595 T C 0.983 0.840-1.150 0.452 0.446 612 708 0.829 
MERTK rs7604639 2 112751928 A G 0.930 0.792-1.092 0.395 0.378 611 709 0.373 
MERTK rs3811634 2 112754943 C T 1.036 0.877-1.224 0.300 0.308 612 710 0.677 
MERTK rs55812028 2 112780969 A G 0.915 0.760-1.100 0.234 0.219 612 708 0.342 
DAPL1 rs2280184 2 159652231 T G 0.924 0.790-1.081 0.416 0.399 607 706 0.322 
DAPL1 rs17810398 2 159660870 C T 1.348 1.058-1.722 0.103 0.133 611 710 0.016 
DAPL1 rs2271663 2 159661077 C T 0.983 0.843-1.147 0.465 0.460 611 695 0.832 
DAPL1 rs17810428 2 159661451 G A 0.951 0.808-1.119 0.321 0.312 611 703 0.544 
DAPL1 rs9869 2 159663599 T C 0.912 0.782-1.063 0.444 0.419 608 706 0.240 
DAPL1 rs6716178 2 159667328 G A 0.894 0.757-1.056 0.327 0.302 608 707 0.187 
DAPL1 rs10016 2 159672442 A G 0.937 0.800-1.096 0.370 0.353 610 706 0.414 
DAPL1 rs11673825 2 159672626 T C 0.921 0.782-1.085 0.300 0.284 609 707 0.327 
MPP4 rs3754932 2 202509814 G A 1.064 0.913-1.240 0.488 0.502 608 708 0.430 
MPP4 rs2597900 2 202523347 G A 1.036 0.888-1.208 0.428 0.437 608 702 0.655 
MPP4 rs1208083 2 202532447 C T 1.006 0.837-1.211 0.223 0.224 611 708 0.947 
MPP4 rs1914267 2 202542836 G A 0.954 0.816-1.115 0.435 0.424 607 707 0.554 
MPP4 rs888012 2 202561571 C T 0.958 0.808-1.137 0.294 0.286 608 704 0.625 
RBP1 rs211585 3 139235564 G A 1.021 0.876-1.189 0.476 0.481 610 708 0.792 
RBP1 rs2071388 3 139236683 A G 0.947 0.808-1.109 0.390 0.378 604 708 0.499 
RBP1 rs10935331 3 139256732 G C 1.062 0.911-1.237 0.416 0.430 611 708 0.444 
RBP1 rs9862672 3 139262793 G A 1.045 0.875-1.249 0.236 0.244 609 707 0.625 
SUCNR1 rs6763405 3 151589418 G A 1.034 0.775-1.382 0.076 0.079 594 699 0.821 
SUCNR1 rs1402012 3 151589783 T C 0.949 0.763-1.181 0.151 0.146 598 694 0.639 
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Supplementary Table S9. continued 
SUCNR1 rs1445359 3 151591741 T C 1.261 0.985-1.618 0.102 0.124 596 691 0.067 
SUCNR1 rs1445358 3 151593218 C T 1.105 0.897-1.365 0.155 0.169 590 680 0.350 
SUCNR1 rs13315275 3 151597310 G A 1.031 0.877-1.212 0.418 0.426 596 684 0.712 
SUCNR1 rs13079080 3 151599393 C T 1.133 0.972-1.321 0.461 0.494 590 681 0.111 
WDR17 rs17062505 4 177019413 T C 0.961 0.814-1.136 0.307 0.300 610 704 0.643 
WDR17 rs17625943 4 177098285 G A 0.952 0.792-1.144 0.254 0.245 601 678 0.599 
WDR17 rs11736872 4 177100644 G A 0.924 0.782-1.092 0.292 0.276 610 708 0.356 
NPVF rs739749 7 25262594 A G 1.026 0.880-1.196 0.482 0.489 601 689 0.743 
NPVF rs2074423 7 25263948 C T 1.149 0.945-1.400 0.182 0.203 601 688 0.164 
RP1 rs9643828 8 55529073 T C 0.835 0.704-0.989 0.295 0.260 612 710 0.037 
RP1 rs2293869 8 55539395 A T 1.060 0.91-1.2340 0.426 0.439 605 702 0.458 
RP1 rs446227 8 55541450 G A 1.133 0.949-1.354 0.248 0.272 612 710 0.168 
TRPM3 rs1889915 9 73164712 G A 1.069 0.916-1.247 0.474 0.489 609 708 0.398 
TRPM3 rs11142497 9 73198353 G A 0.953 0.815-1.116 0.443 0.431 609 709 0.552 
TRPM3 rs11142503 9 73218892 G A 0.923 0.784-1.087 0.350 0.333 611 707 0.336 
TRPM3 rs1538670 9 73255337 G T 0.953 0.817-1.111 0.421 0.409 607 704 0.538 
TRPM3 rs10123161 9 73296400 G A 0.966 0.822-1.135 0.328 0.320 612 710 0.670 
TRPM3 rs7031754 9 73311986 T C 0.902 0.772-1.054 0.442 0.417 611 707 0.194 
TRPM3 rs564929 9 73434585 G A 1.079 0.922-1.263 0.361 0.378 612 707 0.342 
TRPM3 rs579587 9 73438011 G A 0.910 0.779-1.064 0.439 0.416 612 708 0.237 
TRPM3 rs1337029 9 73459960 T C 1.050 0.886-1.246 0.263 0.272 611 707 0.573 
TRPM3 rs2152757 9 73478555 G A 0.868 0.719-1.048 0.213 0.190 609 707 0.141 
CDHR1 rs7099098 10 85950406 C T 0.959 0.815-1.129 0.346 0.337 612 701 0.615 
CDHR1 rs11200915 10 85957681 A C 0.994 0.839-1.177 0.295 0.292 607 706 0.939 
CDHR1 rs11200920 10 85960274 A C 1.092 0.908-1.315 0.224 0.238 612 710 0.350 
CDHR1 rs4933975 10 85960395 G C 0.955 0.819-1.113 0.467 0.454 602 706 0.553 
CDHR1 rs4933978 10 85971347 G A 0.893 0.752-1.060 0.281 0.257 612 703 0.197 
CDHR1 rs3814213 10 85974236 C T 1.052 0.903-1.225 0.471 0.485 612 702 0.518 
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Supplementary Table S9. continued 
RGR rs1042454 10 86012713 C T 1.054 0.896-1.240 0.345 0.360 612 710 0.524 
RGR rs11200947 10 86020637 A G 1.179 0.972-1.432 0.193 0.220 611 710 0.096 
CTSD rs2334411 11 1773477 A C 0.944 0.789-1.129 0.260 0.247 603 699 0.528 
CTSD rs8839 11 1774136 A C 1.071 0.867-1.324 0.152 0.161 610 706 0.528 
CTSD rs55923455 11 1777866 A G 0.955 0.807-1.130 0.325 0.315 599 696 0.593 
CTSD rs1317356 11 1779138 G A 1.076 0.921-1.257 0.489 0.508 609 707 0.355 
CTSD rs7122341 11 1781790 A G 0.949 0.792-1.136 0.240 0.229 608 709 0.568 
FADS3 rs174626 11 61637057 T C 1.054 0.907-1.224 0.453 0.466 604 710 0.496 
FADS3 rs174634 11 61647387 G C 1.044 0.873-1.249 0.243 0.251 612 710 0.638 
FADS3 rs174468 11 61663691 C T 0.969 0.828-1.134 0.412 0.405 611 707 0.697 
BEST1 rs149698 11 61730036 G A 0.936 0.795-1.101 0.317 0.302 609 704 0.424 
BEST1 rs1800008 11 61730183 C T 1.105 0.920-1.328 0.234 0.250 610 705 0.288 
BEST1 rs1800009 11 61730234 T C 1.163 0.988-1.371 0.334 0.366 609 707 0.070 
C11orf48 rs7386 11 62430335 C T 0.908 0.782-1.053 0.482 0.455 611 708 0.201 
C11orf48 rs17637597 11 62438750 A G 1.135 0.956-1.348 0.257 0.283 611 709 0.149 
RDH12 rs718212 14 68196636 T C 0.910 0.776-1.067 0.400 0.381 608 704 0.247 
RLBP1 rs2710 15 89753220 G A 1.021 0.874-1.193 0.399 0.403 602 703 0.791 
RLBP1 rs3825991 15 89761664 G T 1.055 0.908-1.225 0.489 0.503 601 701 0.488 
ATP1B2 rs1642764 17 7557834 T C 1.032 0.884-1.205 0.456 0.462 608 707 0.688 
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Supplementary Table S9. continued 
ATP1B2 rs55831773 17 7559037 C T 1.132 0.932-1.375 0.182 0.201 611 708 0.212 
NETO1 rs11872857 18 70416119 A G 1.020 0.809-1.288 0.119 0.122 611 710 0.868 
NETO1 rs2000809 18 70435137 T C 1.063 0.892-1.266 0.254 0.265 601 684 0.496 
NETO1 rs1032102 18 70453405 G A 1.035 0.876-1.224 0.299 0.305 612 704 0.683 
NETO1 rs753147 18 70461059 G A 0.912 0.779-1.069 0.425 0.405 612 708 0.256 
NETO1 rs753744 18 70527649 G A 0.915 0.766-1.094 0.274 0.256 612 708 0.331 
NETO1 rs10164255 18 70532840 C A 1.089 0.933-1.271 0.400 0.423 611 710 0.282 
CST3 rs2424577 20 23613750 C T 1.246 1.025-1.517 0.181 0.215 611 707 0.028 
CST3 rs3787499 20 23616807 T C 1.153 0.983-1.354 0.377 0.410 612 710 0.081 
 
*from logistic regression model adjusted for age and gender 
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Supplementary Table S10. Association results for imputed SNPs with significant association (p < 0.05) in the discovery sample (710 late 
stage AMD patients/612 controls). Table spans more than one page 
    
Minor Allele 
Frequency in 
   
SNP (dbSNP-ID) 
Odds 
ratio 
95% Confidence 
Intervals 
P-
Value* Cases Controls 
Minor 
allele 
Position 
[hg19] 
imputation 
quality 
rs74923781 1.399 1.072-1.835 0.014 0.135 0.107 G 159670440 0.722 
rs17810816 1.3801 1.064-1.799 0.016 0.140 0.112 G 159671992 0.765 
rs59737258 1.3398 1.05-1.716 0.019 0.183 0.154 A 159710981 0.717 
rs17810918 1.338 1.049-1.712 0.020 0.151 0.122 A 159674084 0.832 
rs79029713 1.4177 1.058-1.909 0.020 0.144 0.120 T 159608659 0.609 
rs76276633 1.4136 1.058-1.899 0.020 0.144 0.120 T 159613499 0.617 
rs16843331 1.4102 1.056-1.892 0.021 0.146 0.122 G 159625777 0.621 
rs80284529 1.4092 1.055-1.892 0.021 0.142 0.118 T 159625985 0.633 
rs60864902 1.4101 1.055-1.894 0.021 0.147 0.123 C 159618280 0.614 
rs75962772 1.4073 1.054-1.887 0.021 0.148 0.124 G 159615755 0.61 
rs80335441 1.4071 1.054-1.887 0.021 0.148 0.124 A 159617834 0.611 
rs10497202 1.407 1.054-1.887 0.021 0.148 0.124 C 159616934 0.611 
rs76502338 1.407 1.054-1.887 0.021 0.148 0.124 A 159612450 0.611 
rs10497200 1.408 1.054-1.89 0.021 0.148 0.125 A 159610120 0.606 
rs60324897 1.4079 1.054-1.89 0.021 0.148 0.125 A 159608966 0.606 
rs76719581 1.4065 1.054-1.886 0.022 0.144 0.120 T 159628604 0.633 
rs76721474 1.4 1.053-1.871 0.022 0.112 0.088 C 159638393 0.818 
rs76686128 1.4056 1.052-1.886 0.022 0.145 0.121 A 159622055 0.626 
rs139858290 1.406 1.052-1.887 0.022 0.144 0.121 A 159619820 0.625 
rs148057425 1.4059 1.052-1.887 0.022 0.144 0.121 A 159621470 0.625 
rs56894726 1.4054 1.052-1.886 0.022 0.145 0.121 C 159619146 0.625 
rs142646819 1.4025 1.051-1.88 0.022 0.147 0.123 C 159611690 0.617 
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Supplementary Table S10. continued 
rs77664069 1.4014 1.05-1.878 0.023 0.142 0.118 T 159628595 0.643 
rs149884088 1.3406 1.043-1.729 0.023 0.153 0.126 G 159706790 0.774 
rs145657727 1.4164 1.051-1.917 0.023 0.141 0.118 T 159623085 0.604 
rs113143827 1.3574 1.044-1.772 0.023 0.146 0.120 C 159724896 0.733 
rs113131637 1.3416 1.042-1.733 0.023 0.159 0.131 T 159710656 0.732 
rs112605456 1.3592 1.044-1.777 0.024 0.145 0.119 A 159728893 0.729 
rs190418388 1.3592 1.044-1.777 0.024 0.145 0.119 C 159729290 0.729 
rs62185469 1.4572 1.052-2.026 0.024 0.130 0.110 C 159735154 0.525 
rs35901244 1.3429 1.041-1.74 0.024 0.152 0.125 T 159723905 0.752 
rs6737129 1.338 1.04-1.728 0.025 0.152 0.125 A 159712710 0.769 
rs139700769 1.3379 1.04-1.728 0.025 0.152 0.125 T 159716306 0.769 
rs113383584 1.338 1.04-1.728 0.025 0.152 0.125 G 159719907 0.769 
rs112202751 1.338 1.04-1.728 0.025 0.152 0.125 G 159722218 0.769 
rs113711908 1.338 1.04-1.728 0.025 0.152 0.125 T 159721786 0.769 
rs113340479 1.3379 1.04-1.728 0.025 0.152 0.125 T 159721099 0.769 
rs150158829 1.3377 1.039-1.728 0.025 0.151 0.124 A 159707210 0.774 
rs113361777 1.3377 1.039-1.728 0.025 0.151 0.124 T 159707249 0.774 
rs144087548 1.3393 1.04-1.732 0.025 0.151 0.125 T 159718894 0.765 
rs149121711 1.33 1.038-1.709 0.025 0.176 0.149 C 159709248 0.651 
rs140328043 1.339 1.039-1.732 0.025 0.151 0.124 T 159708160 0.767 
rs7562293 1.339 1.039-1.732 0.025 0.151 0.124 T 159707998 0.767 
rs6729542 1.3507 1.04-1.762 0.025 0.125 0.099 C 159648421 0.885 
rs111494772 1.34 1.039-1.735 0.025 0.152 0.125 T 159711036 0.757 
rs62185474 1.4558 1.049-2.029 0.026 0.134 0.114 C 159739588 0.503 
rs148268005 1.348 1.039-1.757 0.026 0.127 0.102 C 159648405 0.875 
rs61482440 1.3199 1.034-1.691 0.027 0.171 0.144 A 159676470 0.742 
rs17810398 1.3135 1.033-1.676 0.027 0.133 0.105 T 159660870 1 
rs72997145 1.3273 1.034-1.71 0.027 0.170 0.143 T 159695064 0.717 
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Supplementary Table S10. continued 
rs72997107 1.319 1.033-1.69 0.027 0.171 0.144 T 159676285 0.741 
rs72997111 1.319 1.033-1.69 0.027 0.170 0.143 T 159677635 0.743 
rs75277023 1.3081 1.028-1.67 0.030 0.132 0.105 A 159660494 0.999 
rs78765308 1.307 1.027-1.669 0.031 0.132 0.105 A 159659291 0.998 
rs55989586 1.3745 1.031-1.84 0.031 0.158 0.136 C 159624664 0.581 
esv2676504 1.3093 1.025-1.678 0.032 0.134 0.108 T 159661994 0.951 
rs140343416 1.3348 1.026-1.742 0.032 0.201 0.176 A 159707144 0.542 
rs79632155 1.3612 1.026-1.813 0.033 0.139 0.116 A 159630744 0.679 
rs9751590 1.3172 1.022-1.703 0.034 0.180 0.155 C 159720291 0.664 
rs4561615 1.2987 1.021-1.658 0.035 0.136 0.109 C 159650386 0.963 
rs79614044 1.319 1.019-1.713 0.036 0.124 0.100 A 159641297 0.91 
rs17204323 1.3181 1.019-1.712 0.037 0.123 0.099 G 159645078 0.918 
rs147441846 1.3181 1.019-1.712 0.037 0.123 0.099 A 159643141 0.918 
rs79281718 1.3181 1.019-1.712 0.037 0.123 0.099 A 159643742 0.918 
rs11422552 1.3543 1.016-1.812 0.040 0.183 0.162 TA 159620245 0.519 
rs146948267 1.339 1.013-1.777 0.041 0.122 0.100 A 159717629 0.755 
rs17810584 1.294 1.009-1.666 0.044 0.132 0.108 T 159664703 0.918 
rs10188387 1.2867 1.002-1.658 0.049 0.145 0.121 T 159664713 0.825 
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Supplementary Table S11. Isoform-specific allele frequencies of SNP rs17810398 in 351 resequenced cDNA clones from two 
heterozygous RPE/retina tissue samples (ID_13, ID_14). 
 
rs17810398 alleles 
P
*
 
C T 
Isoform 1 107 103 Reference 
Isoform 2 36 41 0.60 
Isoform 3 22 1 1.2×10
-5
 
Isoform 4 24 2 3.3×10
-5
 
*
 obtained from Fisher’s exact test to test for deviations from the distribution of the reference transcript (i.e. isoform 1)  
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Supplementary Table S12. Analyzed genomic regions and corresponding primers for product amplification with PCR. 
Fragment 
Position on chromosome 2 
[hg19] 
Fragment size [bp] Forward primer (5' -> 3') Reverse Primer (5' -> 3') 
Promoter 159,651,088-159,651,537 450 CAATAATGGCTAAGCTTAAAGTTGT GTGCACCTGCAATGTAACAG 
Exon 1 159,651,457-159,652,045 589 AGATGTCCTGAAGCAAAGAGC GGTAGACAGAGAAGCTTCCGT 
Intron 1.1 159,652,693-159,653,272 580 CTTCCAACTGCCTTCCTTCTT TCATTCGAACTTTCATTTGGTT 
Intron 1.2 159,653,108-159,653,867 760 AGGCTCCTTACATAGACAAAGACA TACCGGGCCTGCATTTTA 
Intron 1.3 159,655,462-159,656,171 710 TGCAGGCTTATGTTTATCTTCACT GAAGCGGAAGATAATATCCCTAGA 
Intron 1.4 159,659,652-159,660,267 616 ATGTGTAGAATAACTGTGGATGA ATACCCACCTTCCATCCAGA 
Exon 2 159,660,178-159,660,965 788 GGCAGGATTATTAATGCAGTTT GCCTTGGTTTGTCCTAAAATAACT 
Intron 2.1 159,660,875-159,661,384 510 AAACAAGGTAGGGACTCTTAATTTT CTCGGTACCTATGTGTTTCTGG 
Intron 2.2* 159,661,876-159,662,944 
1069 (deletion absent)  
191 (deletion present) 
CATGACAAAAGGGAAGCTGTGC GCTATCCTCATTTATAGCCCCAAAGA 
Exon 3  159,663,504-159,664,070 567 ATGTGGCCTTTTCAGTGGGA TTCCTCCAACCCTAGACCAT 
Exon 3b 159,664,059-159,664,411 353 GGGTTGGAGGAAGGCTGGGTACC TCGAGGTGGCCGGATGGCCTG 
Intron 3.1 159,667,434-159,668,027 594 CTGGGATTTGTGCTCGTTCA TTATGACTAGAGAGCCCTGAAAT 
Intron 3.2 159,667,947-159,668,395 449 ATACTACCCAACTTCAGGCTCTAA CAGCTTTCCAGAGTATAAGCTACA 
Intron 3.3 159,670,892-159,671,351 460 GTTGGCAGAGATAATCCTTGG GGCCAGCAAGGAAGGAAT 
Intron 3.4 159,671,834-159,672,072 239 TGAGGAGTTTTTCGTCCCCACTCT TTTCTAGCCCTAAACCCATGGGAGT 
Exon 4 159,672,011-159,672,594 584 AAGGACAGTAAATGAGAGAAGAC AGGTATTCTGGATGCTTCACTT 
Exon 4b 159,682,865-159,682,995 537 CCCTTTCCTTCCTTAGACCTTCC TTGGAAGAAGATTCCTCAACTACAC 
Exon rare_5 159,710,049-159,710,318 272 CCAGCATTAAGGGCTGGTTTT GGTTGGAGAGGAAGAAGTACACG 
Exon 5b 159,718,792-159,719,425 634 CGCAGACATGATGCTGGGGGT ACATGCAAGACGGGGAATTGA 
*
 Fragment was not resequenced but visually inspected by gel electrophoresis 
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Supplementary Table S13. Resequencing results of selected genomic regions (see Supplementary Table S12 and Supplementary Figure S7).  
dbSNP ID / GeneBank ID (Position) 
Position on chromosome 
2 [hg19] 
Allele 1 Allele 2 
Individuals homozygous for non-risk 
alleles 
Individuals homozygous for  
either risk allele 
N(Allele 2) / N(chromosomes) 
N(Allele 2) / 
N(chromosomes) 
rs925781 159,651,734 G A 10 / 16 0 / 24 
rs1356173 159,651,973 G A 4 / 16 0 / 24 
rs12463934 159,652,852 C T 4 / 16 0 / 24 
rs7578195 159,653,250 T C 1 / 16 0 / 24 
rs71421092 159,653,626 A G 0 / 16 5 / 22 
rs12996550 159,653,721 C G 3 / 16 0 / 22 
rs6437202 159,656,114 G C 8 / 14 0 / 16 
rs6756488 159,660,277 T A 4 / 16 0 / 24 
rs75277023 159,660,494 G A 0 / 16 24 / 24 
rs11297084 159,660,646 - A 6 / 16 0 / 24 
rs17810398 159,660,870 C T 0 / 16 24 / 24 
rs2271663 159,661,077 C T 6 / 16 0 / 24 
rs147412692 159,661,111 A G 0 / 16 9 / 24 
rs11684616 159,661,318 A G 0 / 14 0 / 22 
rs6146986 159,661,997-159,662,874 - 878 bp deletion 0 / 16 24 / 24 
rs9869 159,663,599 T C 4 / 14 2 / 24 
rs10497199 159,663,616 G A 4 / 14 0 / 24 
rs75859613 159,664,016 T C 1 / 16 0 / 24 
rs62183691 159,664,285 G A 6 / 16 0 / 24 
NM_001017920.2_c.207+3984 / HQ220184 (77) 159,667,611 G A 1 / 16 0 / 24 
rs908402 159,667,731 G A 6 / 16 0 / 24 
rs71421093 159,668,241 A G 4 / 16 0 / 24 
rs11693126 159,670,945 T C 0 / 16 0 / 22 
NM_001017920.2_c.208-1029 / HQ220186 (225) 159,671,188 C T 0 / 16 1 / 22 
rs17810816 159,671,992 A G 0 / 16 24 / 24 
rs1515922 159,672,168 G A 1 / 16 0 / 24 
rs61740878 159,672,252 G A 1 / 14 0 / 24 
rs10016 159,672,442 A G 9 / 14 0 / 24 
rs35919361 159,683,271 C A 2-4 / 4* 1-2 / 2* 
rs9750235 159,710,189 A T 11 / 16 1 / 24 
rs144087548 159,718,894 A T 0 / 16 23 / 24 
rs34995873 159,719,031 A G 1 / 16 0 / 24 
* Due to an extensively long AT/T-stretch, only three individuals could be resequenced after subcloning the obtained stutter bands. 
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Supplementary Table S14. Variants detected by cDNA re-sequencing of eight RPE/retina tissue samples heterozygous for rs17810398. 
Alleles are given for the + strand. 
dbSNP ID 
RPE/retina tissue sample 
ID_A ID_B ID_C ID_E ID_2 ID_11 ID_13 ID_14 
Gender Female Male Male Male Male Female Male Male 
rs17810398 C/T C/T C/T C/T C/T C/T C/T C/T 
rs9869 C/T T/T T/T T/T T/T C/T C/T C/T 
rs10497199 G/G A/G A/G G/G A/G A/G G/G G/G 
rs34995873 A/A A/A A/A A/A A/A A/A A/A A/G 
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